XXI World Congress on Parkinson`s Disease and Related Disorders

Transcription

XXI World Congress on
Parkinson’s Disease and
Related Disorders
Milan, Italy
6-9 December 2015
PROGRAM
www.oic.it/iaprd2015
XXI World Congress on Parkinson’s Disease and Related Disorders
TABLE OF CONTENTS
Welcome Letter ............................................................................. page 3
About IAPRD ................................................................................. page 4
Committees................................................................................... page 6
Travel Awards ............................................................................... page 8
CME Accreditation ........................................................................ page 10
Scientific Information ................................................................... page 11
Program at a glance ..................................................................... page 14
Scientific Program
Sunday, 6 December .................................................................. page
Monday, 7 December ................................................................. page
Tuesday, 8 December ................................................................ page
Wednesday, 9 December ........................................................... page
18
24
33
40
Poster Sessions
Monday, 7 December ................................................................. page 45
Tuesday, 8 December ................................................................ page 56
Wednesday, 9 December ........................................................... page 69
Name Index ................................................................................... page 81
General Information ..................................................................... page 91
Social Events ................................................................................. page 94
Sponsored Symposia .................................................................... page 96
Congress Venue Layout ................................................................ page 98
Acknowledgements ...................................................................... page 101
Company Profiles .......................................................................... page 102
2
WELCOME LETTER
Dear Colleagues,
on behalf of the board of the International Association of Parkinsonism
and Related Disorders, it is our pleasure to welcome all of you to the
XXI World Congress on Parkinson’s Disease and Related Disorders,
taking place in exciting Milan, Italy.
The motto of this Congress is “Sharing Richness”, and indeed, it is the
ultimate goal of our Association to share the overwhelming amount of
new developments in not only the understanding of the etiology and
pathophysiology of the multitude of motor and behavioural disorders,
but also the therapeutic strategies, essential to further increase quality
of life of world-wide patients suffering those debilitating diseases. This
Congress will reach this goal by bringing together a, traditionally equigender, large faculty of distinguished younger scientists, clinicians and
allied health experts.
The Congress includes plenary lectures, cutting edge scientific symposia,
interactive forum discussions and educational workshops, and offers
numerous slots for oral presentation of ongoing research and ‘selected
topics.’
Milan, the undisputed international center for fashion and modern design,
and cultural capital of Northern Italy, home of ‘the last supper’, offers a
challenging venue to make your visit a pinnacle of your scientific tourism
so far.
Erik Ch. Wolters
IAPRD President
Angelo Antonini
Congress Chair
3
ABOUT IAPRD
ABOUT THE INTERNATIONAL ASSOCIATION OF
PARKINSONISM AND RELATED DISORDERS
Established over fifty years ago by the World Federation of Neurology,
the International Association of Parkinsonism and Related Disorders
(IAPRD) is an international, professional association of clinicians,
scientists and other healthcare professionals who are interested in
neurodegenerative disorders including Parkinson’s disease, secondary
parkinsonism, hyperkinetic and hypokinetic movement disorders,
and other disorders affecting muscle tone and motor coordination.
The International Association of Parkinsonism and Related Disorders
is a fully independent, charitable institution under Dutch law aiming to
conduct research into and advance knowledge of Parkinson’s disease and
other movement disorders, as well as to advise the World Federation of
Neurology in matters related to Parkinson’s disease and other movement
disorders. The Association is having its registered seat in the Municipality
of Amsterdam, The Netherlands, and is registered in the Trade Register
of the Amsterdam Chamber of Commerce and Industries.
MEETINGS
The IAPRD organizes regularly meetings and educational activities, and
every two years, a World Congress on Parkinson’s disease and Related
Disorders is organized, which evaluates progress and identifies promising
areas for research in these fields. At various intervals, also workshops on
current issues in Parkinson’s disease, designed to produce consensus
reports, are organized. The Committee is especially committed to
developing educational programs for physicians in not fully westernized
countries.
4
ABOUT IAPRD
PUBLICATIONS
In order to fulfil its mission statements, IAPRD not only develops
educational activities such as symposia and congresses (including the
World Congress of Parkinson’s Disease and Related Disorders), but also
promotes publications, among them its official journal, Parkinsonism
& Related Disorders, as well as textbooks. To optimally channel
communication between basic research and clinical communities, and
in order to promote optimal diagnosis and treatment for the various
movement disorders, Parkinsonism & Related Disorders is supplied free
of charge to all IAPRD members, and listed books can be ordered by all
members at reduced prices via the Amsterdam - Free University Press.
To learn more about IAPRD, please visit the association website:
http://www.iaprd.org/
5
COMMITTEES
COMMITTEES
Angelo Antonini, Italy (Chair)
Alberto Albanese, Italy (Co-Chair)
Erik Ch. Wolters, The Netherlands (President, Int. Association of
Parkinsonism and Related Disorders)
EXECUTIVE SCIENTIFIC BOARD
Erik Ch. Wolters, The Netherlands (Chair)
Alberto Albanese, Italy
Angelo Antonini, Italy
Christian Baumann, Switzerland
Peter Riederer, Germany
Moussa Youdim, Israel
SCIENTIFIC PROGRAM COMMITTEE
Alberto Albanese, Italy
Jean-Philippe Azulay, France
Christian Baumann, Switzerland
Vincenzo Bonifati, The Netherlands
David Brooks, United Kingdom
M. Angela Cenci, Sweden
Alberto J. Espay, USA
Victor Fung, Australia
Nobutaka Hattori, Japan
Beom S. Jeon, Korea
Per Odin, Sweden
Ronald F. Pfeiffer, USA
K. Ray Chaudhuri, United Kingdom
Irena Rektorova, Czech Republik
Fabrizio Stocchi, Italy
Jon Stoessl, Canada
Eng King Tan, Singapore
Francesc Valldeoriola, Spain
Jens Volkmann, Germany
Gregor K. Wenning, Austria
Zbigniew K. Wszolek, USA
6
COMMITTEES
INDUSTRY LIAISON COMMITTEE
Fabrizio Stocchi, Italy (Chair)
Roongroj Bhidayasiri, Thailand
K. Ray Chaudhuri, United Kingdom
Dirk Dressler, Germany
Heinz Reichmann, Germany
Daniel Truong, USA
Erik Ch. Wolters, The Netherlands
Moussa Youdim, Israel
PROCEEDINGS COMMITTEE
Zbigniew K. Wszolek, USA (Chair)
Vincenzo Bonifati, The Netherlands
Susan Calne, Canada
Jonathan Carr, South Africa
Ronald F. Pfeiffer, USA
Robert Rodnitzky, USA
Eng Kin Tan, Singapore
Erik Ch. Wolters, The Netherlands
ABSTRACT COMMITTEE
Peter Riederer, Germany
TRAVEL AWARDS COMMITTEE
Alessandro Di Rocco, USA
7
TRAVEL AWARDS
8
TRAVEL AWARDS
Congress Travel Awards are sponsored by the Melvin Yahr International
Parkinson’s Disease Foundation (Chaired by Dr. Alessandro Di Rocco) and
the International Association of Parkinsonism and Related Disorders.
The awards are aimed to promote participation at the Congress by young
researchers under the age of 35.
Congratulations to all awardees.
Abdellatif Abbaoui, Morocco
Chahidi Abderrahmane, Morocco
Ikbol Abdukadirova, Uzbekistan
Assiya Akanova, Kazakhstan
Karthick Kumar Alagamuthu, India
Cristina Alcacer, Spain
Vivian Altmann, Brasil
Tania Álvarez Avellón, Spain
Nilesh Ambhore, India
Sina Asaadi, Iran
Dilorom Ayupova, Uzbekistan
Anvar Azimov, Uzbekistan
Sneha Banavara, India
Ela Barcelon, Philippines
Melinda Barkhuizen, South Africa
Rui Duarte Barreto, Portugal
Sarvar Bebitov, Uzbekistan
Seti Belay, Ethiopia
Alice Biosa, Italy
Lalit Pratap Chandravanshi, India
Nargiza Chekeeva, Kyrgyz Republic
Maria Chondrogiorgi, Greece
Chi-Jing Choong, Malaysia
Alin Ciobica, Romania
Ilaria Cova, Italy
Maria Diez Cirarda, Spain
Vidyadhara Dj, India
Sojida Djalilova, Uzbekistan
Farangisbonu Doniyorova, Uzbekistan
Maria Magdalena Dumitru, Romania
Roberto Erro, Italy
Zhangqiuzi Fan, China
Monika Figura, Poland
Ndiaga Matar Gaye, Senegal
Hanneke Geut, The Netherlands
Elvina Giyazitdinova, Uzbekistan
Daniela Gonçalves, Portugal
Alicia González Martínez, Spain
Deepali Gupta, India
Richa Gupta, India
Ron Terry Gurel, Israel
Sabrina Guzzetti, Italy
Kristina Harutyunyan, Armenia
Stephanie Hirschbichler, Austria
Ekaterina Ilicheva, Russia
Elena Ivanova, Russia
Mahalakshmi Iyer, India
Shyam Jaiswal, India
Joy Jibin, India
Mirzo Juraev, Uzbekistan
Stefania Kalampokini, Greece
Kovendan Kalimuthu, India
Kunduz Karbozova, Kyrgyz Republic
Sofiya Khachaturyan, Armenia
Mukhlisa Khanova, Uzbekistan
Kamola Khasanova, Uzbekistan
Nino Khizanishvili, Georgia
Nataliia Kozhemiako, Ukraine
Gokul Krishna, India
Akanksha Kulshreshtha, India
Nitin Kumar, India
Pardeep Kumar, India
Oybek Kurbanov, Uzbekistan
Magdalena Kurnik, Poland
Wafaa Laabbar, Morocco
Navya Lakkappa, India
Abhishenk Lenka, India
Jia Liu, China
Mahmoud Loftinia, Iran
Olaia Lucas Jimenez, Spain
Mustaq Ahamed Shafi, India
Sarvi Sharifi, The Netherlands
Anuradha Sharma, India
Vinod Kumar Sharma, India
Vikas Sharma, India
Neha Sharma, India
Sorabh Sharma, India
Ranjit Singh, India
Enda Cindylosa Sitepu, Indonesia
Nodirjon Sokhibnazarov, Uzbekistan
Pranay Srivastava, India
Anna Strasz, Poland
Albert Stezin Sunny, India
Natalia Szejko, Poland
Marat Tadjenov, Uzbekistan
Joy Lynn Tan, Singapore
Lokesh Thangamani, India
Dilshod Tolibov, Uzbekistan
Oybek Turgunkhujaev, Uzbekistan
Djahangir Tursunov, Uzbekistan
Anahit Voskanyan, Armenia
Amha Meshesha Weldehana, Ethiopia
Rajesh Singh Yadav, India
Farkhod Yunusov, Uzbekistan
TRAVEL AWARDS
Elena Lyashenko, Russia
Antonella Macerollo, Italy
Manjunath Mahadevappa, India
Irina Miliukhina, Russia
Sanjarbek Mirdedayev, Uzbekistan
Mari Anne Kristin Moll, Philippines
Tim Moors, The Netherlands
Elisavet Moti, Greece
Bakhrom Muinjonov, Uzbekistan
Somnath Mukherjee, India
Rajini Naduthota, India
Nodir Nurmetov, Uzbekistan
Simone Olgiati, Italy
Manuela Padurariu, Romania
Pankaj Pandey, India
Fawaz Pullishery, India
Marialuisa Quadri, Italy
Sumit Rajput, India
Jayalakshmi Ramalingam, India
Gretchen Reynolds, USA
Anna Sauerbier, Germany
Emma Scelzo, Italy
Alice Serafin, Italy
Irina Serbanoiu, Romania
Agostino Seresini, Italy
9
CME ACCREDITATION
10
CME ACCREDITATION
The XXI World Congress on Parkinson’s Disease and Related Disorders is
accredited by the European Accreditation Council for Continuing Medical
Education (EACCME) to provide the following CME activity for medical
specialists. The EACCME is an institution of the European Union of
Medical Specialists (UEMS), www.uems.net.
The XXI World Congress on Parkinson’s Disease and Related Disorders is
designated for a maximum of 20 hours of European external CME credits.
Each medical specialist should claim only those hours of credit that he/
she actually spent in the educational activity.
Through an agreement between the European Union of Medical Specialists
and the American Medical Association, physicians may convert EACCME
credits to an equivalent number of AMA PRA Category 1 Credits™.
Information on the process to convert EACCME credit to AMA credit can
be found at www.ama-assn.org/go/internationalcme.
Live educational activities, occurring outside of Canada, recognized by
the UEMS-EACCME for ECMEC credits are deemed to be Accredited
Group Learning Activities (Section 1) as defined by the Maintenance of
Certification Program of The Royal College of Physicians and Surgeons
of Canada.
The CME questionnaire and certificate will be available on the Congress
website www.oic.it/iaprd2015 from 10 December 2015 to 6 January
2016.
Please note that the registration code, printed on your badge is necessary
to access the CME questionnaire and to print out your certificate.
THIS IS NO ORDINARY MEETING
One of the most interesting aspects of the XXI World Congress on
Parkinson’s Disease and Related Disorders is the diversity of approaches
presented. This allows for original solutions to be discussed for a wide
range of problems, both on research and clinical management.
Needless to say, the contact between neurologists working in different
countries is vital for such an exchange to take place.
Presentations are geared to various levels of skills, so that participants
from a variety of backgrounds will have the chance to enrich their
knowledge and enjoy the networking opportunities.
Delegates will find that there is an exciting range of subjects in main
lectures, parallel sessions, interactive and educational sessions,
symposia and poster sessions.
The emphasis is on discussion and on a positive critical attitude. Language
difficulties and hierarchical divisions may have hindered scientific
discussion in other meetings, however IAPRD congresses have managed
to rise above both barriers.
We now look forward to the involvement of all participants, be it in open
forums during all the sessions, or at a more personal “one to one” level.
SCIENTIFIC INFORMATION
THE XXI IAPRD CONGRESS – HIGHLIGHTS
The wide range of topics included in the program will be presented by
international experts. Lectures, symposia, session summaries, and
discussions will be led by experienced moderators while educational
sessions and updates will summarize on the newest aspects. As
customary, a considerable amount of platform time will be given over
to discussion. A further opportunity is the Technical Exhibition, where
novelties may be explored and where delegates will have the chance to
liaise with industry representatives.
The Congress will address all aspects of movement disorders including
basic science, genetics, differential diagnosis and therapeutic interventions.
OFFICIAL LANGUAGE
The official language of the International Association Parkinsonism and
Related Disorders is English. All participants are encouraged to join
discussions, independently of their fluency in English as the exchange of
ideas and critical evaluation of presentations is the main purpose of the
entire Congress.
11
PLENARY SESSIONS
There will be seven Plenary Sessions, covering the main topics of the
Congress, delivered by leading clinical experts, basic scientists and other
health care professionals.
PARALLEL SESSIONS
They will focus on specific topics, regarding clinical and/or basic science
aspects in the field of movement disorders, representing several points
of view.
INTERACTIVE SESSIONS
They are planned on Monday and Tuesday program. Debates will offer a
lively and hopefully fruitful discussion on controversial issues.
EDUCATIONAL SESSIONS
They will cover all aspects of Parkinson’s disease and other movement
disorders, and will serve the educational mission of the IAPRD.
SPECIAL SESSION “PAST, PRESENT AND FUTURE OF TECHNOLOGY
FOR PARKINSON DISEASE”
On Tuesday 8 December from 13.00 to 15.00 in Yellow Hall 3 the World
Federation of Neurology (WFN) program “Past, Present and Future of
Technology for Parkinson Disease” will take place. It is a session to
educate clinicians and researchers about some of the technologies
available for assessing and monitoring different aspects of Parkinson’s
disease and related disorders. The program will provide a framework
to categorize the many technological options that are quickly becoming
available in both clinical and research environments. There will be a
discussion of the role of non-profit entities in the development of tools
as well as how to integrate others into decision-making (including the
role of the patient). Potential shortcomings, unmet needs and possible
opportunities will also be highlighted.
ORAL POSTER PRESENTATIONS
97 selected posters have been given the opportunity to present a
6-minutes short oral presentation of their abstract. And another 12 have
been selected to present their data in a 12-minutes presentation during
the Selected Topics Sessions.
12
SLIDE CENTRE
The Slide Centre is situated on level +1. All meeting rooms are equipped
with a computer slide projector alone, and no traditional slide or overhead
projectors for transparencies are available.
It will be not possible to use personal laptops in the meeting rooms.
Speakers are kindly requested to use “PowerPoint” (Windows or
Macintosh/Apple) for their presentations. The dimensions of PowerPoint
presentation should not exceed 300 MB, videos included.
Please use “.gif ” and “.jpg” extensions for images. Other types of extensions
will be accepted provided they can be recognized by PowerPoint.
The use of CD-Rom, pens or memory stick is advisable to ease downloading
of presentations, and same should be handed to technicians at the Slide
Centre in good time. Please remember to collect your CD or memory pen
from the Slide Centre at the end of the session.
Speakers with PowerPoint presentation on CD Rom or memory pen:
please report to the Slide Centre at least one hour before your presentation
or the day before if you are scheduled to speak in the morning.
Speakers with presentation on personal laptops: please report to the
Slide Centre at least four hours before your presentation or the day
before, if scheduled in the morning.
This timing will allow your presentation to be downloaded onto the main
computer.
POSTERS
Authors are required to attach their posters to the appropriate poster
board. Posters will be displayed with a daily rotation on Monday 7, Tuesday
8 and Wednesday 9 December. Poster boards will be duly numbered and
set up material will be provided by the Organizing Secretariat.
Dates and times of Poster Session discussions are indicated in the
program at a glance and in the scientific program. Authors are expected
to be present at their poster board during discussion.
13
PROGRAM AT A GLANCE
SUNDAY, 6 DECEMBER 2015
Silver Hall
Red Hall 2
10.30
12.00
12.30
Red Hall 1
Yellow Hall 3
Diagnosis of
Parkinson’s disease
Oral Poster Session
(1.30.01-1.30.12)
Pre-Congress Symposium
Recognition of life-long
curiosity in Parkinson’s
disease etiopathogenesis
Break
Genetics
What is new in
synucleinopathies
14.00
Break
14.30 Update on other degenerative What is new in tauopathies
Mental dysfunction in
movement disorders
16.00
Break
16.30 PD pharmacotherapeutical
interventions
18.00
18.30
Oral Poster Session
(1.30.13-1.30.24)
Break
Opening Ceremony
20.00
Welcome Reception (Exhibition Area)
MONDAY, 7 DECEMBER 2015
Silver Hall
Red Hall 2
8.30 Behavioural disorders
Advances in
in parkinsonism
imaging (1)
10.00
10.15 Parkinson’s disease
non-pharmacological
interventions
11.45
12.00-13.30 (Exhibition Area)
Visit Exhibition
POSTER SESSION I (1.001-2.036)
12.45
SELECTED TOPIC SESSION (2.60.01-2.60.06)
13.00-13.30 Lunch (Exhibition Area)
13.45 What exactly do the
basal ganglia do?
15.15
15.30
17.00
17.15
14
18.45
Iatrogenic motor
disorders
Update on sleep
disorders
Blue Hall
Red Hall 1
Yellow Hall 3
Unusual movement
disorders (1)
Genetics
Oral Poster Session
(2.50.01-2.50.12)
Short break
Industry Sponsored
Symposium 1
Industry Sponsored
Symposium 2
Short break
Interactive discussion
Management of
clinical-geneticParkinson’s disease
pathological cases
complications
Oral Poster Session
(2.50.13-2.50.24)
Short break
Neurorehabilitation for
Device-aided
Management of
Oral Poster Session
Parkinson’s disease: Parkinson’s disease autonomic dysfunction (2.50.25-2.50.37)
future perspectives
treatments:
in parkinsonism
practical issues
8.30
Red Hall 2
Blue Hall
Red Hall 1
Yellow Hall 3
Interventions in
parkinsonism (MSA/
PSP/CBD)
Advances in
Parkinson’s
disease imaging (2)
Unusual movement
disorders (2)
Update on tremor
Oral Poster Session
(3.50.01-3.50.10)
10.00
10.15
Short break
Biomarkers in
11.45
Short break
12.00 Industry Sponsored
Symposium 3
Visit Exhibition
POSTER SESSION II (2.037-3.087) (Exhibition Area)
SELECTED TOPIC SESSION (3.60.01-3.60.06) (Exhibition Area)
13.00-13.30 Lunch (Exhibition Area)
13.30
13.45
Short break
Dystonia revisited
15.15
Short break
15.30 Non-motor symptoms
in movement
disorders
17.00
Neurodegeneration
Hands on dystonia:
botulinum toxin
workshop
PROGRAM AT A GLANCE
TUESDAY, 8 DECEMBER 2015
Silver Hall
Dystonia
Short break
17.15 Deep brain stimulation
18.45
Animal models in Diagnostic challenges
movement disorders
Oral Poster Session
3.50.11-3.50.22
WEDNESDAY, 9 DECEMBER 2015
8.30
Silver Hall
Red Hall 2
Red Hall 1
Yellow Hall 3
MD developments
2014-2015:
Best PRD Articles
Sensor and sleep deficits in
Diagnosis of uncommon
movement disorders
Oral Poster Session
(4.50.01-4.50.12)
10.00
Short break
10.15
Cognitive impairment in
11.45
Psychogenic movement
disorders
13.15
Visit Exhibition
POSTER SESSION III (3.088-6.070) (Exhibition Area)
13.45
Disease associations in
movement disorders:
controversies
15.15
Closing Ceremony
DIRECTORY
Plenary
Sessions
Sponsored
Symposia
Recent advances in
essential tremor
Clinical
Parallel
Sessions
Instrumental hallmarks of
parkinsonism
Translational
Interactive
Parallel
Sessions
Sessions
Oral Poster Session
(4.50.13-4.50.23)
Educational Oral Poster
Sessions
Sessions
Exhibition
Area
15
UNDER THE PATRONAGE OF
SCIENTIFIC
PROGRAM
SUNDAY, 6 DECEMBER
10.30-12.00
PRE-CONGRESS SYMPOSIUM
RECOGNITION OF LIFE-LONG CURIOSITY IN PARKINSON’S DISEASE
ETIOPATHOGENESIS
Chairmen: T. Brücke (Austria), P. Riederer (Germany),
E.Ch. Wolters (The Netherlands)
Committee: T. Brücke (Austria), R. Horowski (Germany),
P. Riederer (Germany), M.B.H. Youdim (Israel),
10.30
Japanese pioneers in Parkinson’s disease (introduction by P. Riederer)
N. Hattori (Japan)
11.00
Senator-Doktor-Franz-Burda Award: 20 years of gene-hunting in
Parkinson’s disease (introduction by T. Brücke)
A. Zimprich (Austria)
11.30
The impact of genetic research in movement disorders (introduction by
E.Ch. Wolters)
Z.K. Wszolek (USA)
12.00
Break
12.30-14.00
CLINICAL PARALLEL SESSION
1.10 GENETICS
Chairmen: S. Goldwurm (Italy), E.K. Tan (Singapore)
18
RED HALL 2
12.30
Autosomal dominant Parkinsonism
Z.K. Wszolek (USA)
13.00
Autosomal recessive Parkinsonism
V. Bonifati (The Netherlands)
13.30
Common and rare risk variants for Parkinsonism
O. Ross (USA)
SILVER HALL
RED HALL 2
TRANSLATIONAL PARALLEL SESSION
1.20 WHAT IS NEW IN SYNUCLEINOPATHIES
Chairmen: P. Riederer (Germany), G.K. Wenning (Austria)
12.30
Alpha-synuclein propagation
N.L. Rey (USA)
13.00
Phenotypic spectrum of alpha-synuclein mutations
E.M. Valente (Italy)
13.30
Multiple system atrophy-mimics and boundary issues in multiple
system atrophy
H.-J. Kim (South Korea)
12.30-14.00
SUNDAY, 6 DECEMBER
12.30-14.00
RED HALL 1
EDUCATIONAL PARALLEL SESSION
1.40 DIAGNOSIS OF PARKINSON’S DISEASE
Chairmen: E. Melamed (Israel) †, E.Ch. Wolters (The Netherlands)
12.30
Clinical definition
13.00
Pre-motor manifestations
A. Iranzo (Spain)
13.30
Non motor manifestations
K. Ray Chaudhuri (United Kingdom)
19
SUNDAY, 6 DECEMBER
12.30-14.00
YELLOW HALL 3
ORAL POSTER SESSION (1.30.01-1.30.12)
Chairmen: A. Elia (Italy), E. Fiorenzato (Italy)
OP 1.30.01 An unexpected higher prevalence of Parkinson’s disease in females than males in the province of
Trento (Italy): a clues for the etiopathogenesis?
M.C. Malaguti, N. Vanacore, S. Ferrari, S. Piffer, R. Pertile, R. Roni, A. Polverino, M. Gentilini,
F. Cembrani, V. Bertozzi, M. Pellegrini, D. Orrico (Italy)
OP 1.30.02 Parkinson’s disease in Senegal: epidemiologic, clinical and therapeutic aspects
N.M. Gaye, L.B. Seck, N.S. Diagne, A.D. Sow, A.M. Diop, O. Cisse, A.B. Faye, M.S. Diop, K. Toure,
M. Ndiaye, A.G. Diop, M.M. Ndiaye (Senegal)
OP 1.30.03 A step forward to the future: UPDRS kinematic measures for telemedicine
G. Albani, C. Azzaro, F. Parisi, C. Ferraris, M. Giuberti, L. Contin, D. Pianu, L.G. Pradotto,
V. Cimolin, M. Galli, R. Nerino, G. Ferrari, A. Mauro (Italy)
OP 1.30.05 Longer duration of Parkinson’s disease is associated with reduced prevalence of hypertension
V. Brandi, D. Vetrano, M.S. Pisciotta, M.R. Lo Monaco, A. Laudisio, G. Onder, R. Bernabei,
G. Zuccalà (Italy)
OP 1.30.06 Gastroesophageal dysmotility in advanced Parkinson’s disease
F. Mancini, L. Manfredi, M. Lacerenza, C. Colombo A. Bestetti (Italy)
OP 1.30.07 Speech disorders and Parkinson’s disease
M. Pettorino, E. Pellegrino, M.G. Busà (Italy)
OP 1.30.08 An alternative perspective on interpretation of the secondary motor symptoms of Parkinson’s
disease
L. Vucolova (USA)
OP 1.30.09 An alternative perspective on interpretation of the cardinal motor symptoms of Parkinson’s disease
L. Vucolova (USA)
OP 1.30.10 Falling direction is important predictors for mechanism of falls in patients with Parkinson’s disease
J. Youn, M. Hwang, D. Kim, J.W. Cho (South Korea)
OP 1.30.11 Frequency and risk of falls in Parkinson’s disease in Ibadan
T. Farombi, M. Owolabi, A. Ogunniyi (Nigeria)
OP 1.30.12 Falls in Parkinson’s disease: effects on health related quality of life
T. Farombi, J. Yaria, M. Owolabi, A. Ogunniyi (Nigeria)
14.00
20
Break
SILVER HALL
1.11 UPDATE ON OTHER DEGENERATIVE MOVEMENT DISORDERS
Chairmen: F. Cardoso (Brazil), G.B. Landwehrmeyer (Germany)
14.30
Huntington disease
G.B. Landwehrmeyer (Germany)
15.00
Spino-cerebellar ataxia
A. Dürr (France)
15.30
Neurodegenerations with brain iron accumulation
S.A. Schneider (Germany)
14.30-16.00
RED HALL 2
SUNDAY, 6 DECEMBER
14.30-16.00
1.21 WHAT IS NEW IN TAUOPATHIES
Chairmen: C. Colosimo (Italy), B.S. Jeon (South Korea)
14.30
Phenotypic spectrum
G. Höglinger (Germany)
15.00
Neuropathology
D. Irwin (USA)
15.30
Imaging biomarkers
D.J. Brooks (Denmark)
14.30-16.00
RED HALL 1
1.41 MENTAL DYSFUNCTION IN PARKINSON’S DISEASE
Chairman: J. Kulisevsky (Spain)
14.30
Cognitive deterioration
J. Kulisevsky (Spain)
15.00
Depression
P. Barone (Italy)
15.30
Psychosis
T. van Laar (The Netherlands)
21
SUNDAY, 6 DECEMBER
14.30-16.00
YELLOW HALL 3
Chairmen: A. Elia (Italy), F. Mancini (Italy)
OP 1.30.13 A prospective study of cumulative incidence and course of RLS in de novo PD patients during
chronic dopaminergic therapy
S. Calzetti, E. Marchesi, M. Goldoni, A. Negrotti (Italy)
OP 1.30.14 Semantic and phonemic verbal fluency in patients with Parkinson’s disease (PD)
A.D. Roesch, A. Meyer, K. Nowak, U. Gschwandtner, P. Fuhr (Switzerland)
OP 1.30.15 Emotion recognition and emotion expression in Parkinson’s disease: an unifying emotional mirror
mechanism?
L. Ricciardi, F. Visco-Comandini, R. Erro, F. Morgante*, M. Bologna*, A. Fasano**,
D. Ricciardi*, M. Edwards, J. Kilner (United Kingdom, *Italy, **Canada)
OP 1.30.16 Association of depressive symptoms with circadian blood pressure alterations in Parkinson’s
disease
M.S. Pisciotta, D.L. Vetrano, V. Brandi, M.R. Lo Monaco, A. Laudisio, D. Fusco, G. Onder,
R. Bernabei, G. Zuccalà (Italy)
OP 1.30.17 Blood biomarkers associated with cognitive decline in early stage and drug-naive Parkinson’s
disease patients
J. Santiago, J. Potashkin (USA)
OP 1.30.18 Impact of gender on impulse control disorders and other non-motor symptoms among Parkinson’s
disease patients
N. Kovács, G. Deli, Z. Aschermann, A. Makkos, J. Janszky, M. Kovács (Hungary)
OP 1.30.19 Effects of Parkinson’s disease on cognitive action control: insights on impulsive response
tendencies using an oclomotor Simon task
J. Duprez, J. Houvenaghel, S. Argaud, M. Vérin, P. Sauleau (France)
OP 1.30.20 Sensory attenuation and Parkinson’s disease: a new pathophysiological framework of bradykinesia
A. Macerollo, J. Chen, P. Korlipara, T. Foltynie, J. Rothwell, M. Edwards, J. Kilner (United
Kingdom)
OP 1.30.21 Fine motor function skills in patients with Parkinson’s disease (PD) with and without mild cognitive
impairment (MCI)
P. Dahdal, A. Meyer, M. Chaturvedi, K. Nowak, A.D. Roesch, U. Gschwandtner, P. Fuhr
(Switzerland)
OP 1.30.24 Continuous monitoring of PD with an affordable novel computerised motor test based on a tablet
M. Da Lio, M. De Cecco, P. Bosetti, M. Malaguti (Italy)
16.00
22
Break
SILVER HALL
PLENARY SESSION
1.1 PARKINSON’S DISEASE PHARMACOTHERAPEUTICAL
INTERVENTIONS
Chairman: E.Ch. Wolters (The Netherlands)
16.30
Parkinson’s disease-related non-motor symptoms
K. Ray Chaudhuri (United Kingdom)
17.00
Levodopa based strategies
P.A. LeWitt (USA)
17.30
Enzyme-based strategies
F. Stocchi (Italy)
18.30-20.00
SUNDAY, 6 DECEMBER
16.30-18.00
SILVER HALL
PLENARY SESSION
OPENING CEREMONY
Welcoming words by the IAPRD President and the Congress Chair
E.Ch. Wolters (The Netherlands), A. Antonini (Italy)
Welcoming words
L. Battistin (Italy)
A. Berardelli (Italy)
Transplantation in Parkinson’s disease
A. Bjorklund (Sweden)
23
MONDAY, 7 DECEMBER
8.30-10.00
SILVER HALL
2.10 BEHAVIOURAL DISORDERS IN PARKINSONISM
Chairmen: D. Aarsland (Sweden), J. Kulisevsky (Spain)
8.30
Impulsivity and compulsivity in Parkinson’s disease
M. Samuel (United Kingdom)
9.00
Psychosis
M. Onofrj (Italy)
9.30
Deep brain stimulation-effect on emotions and behaviour
E. Moro (France)
8.30-10.00
RED HALL 2
2.20 ADVANCES IN PARKINSON’S DISEASE IMAGING (1)
Chairmen: U. Bonuccelli (Italy), A. Strafella (Canada)
8.30
Optimizing diagnosis in Parkinson’s disease
A.J. Stoessl (Canada)
9.00
Structural connectivity
A. Tessitore (Italy)
9.30
Functional connectivity
I. Rektorova (Czech Republic)
8.30-10.00
BLUE HALL
INTERACTIVE PARALLEL SESSION
2.30 UNUSUAL MOVEMENT DISORDERS (1) - video session
Coordinator: F. Morgante (Italy)
Speakers: F. Morgante (Italy), F. Cardoso (Brazil), M. Stamelou (Greece)
24
RED HALL 1
2.40 GENETICS
Chairmen: V. Bonifati (The Netherlands), E. Melamed (Israel) †
8.30
Genetics of Parkinson’s disease - Genotypes
V. Bonifati (The Netherlands)
9.00
Genetics of Parkinson’s disease - Phenotypes
Z.K. Wszolek (USA)
9.30
Genetic entities mimicking Parkinson’s Disease
O. Ross (USA)
8.30-10.00
YELLOW HALL 3
MONDAY, 7 DECEMBER
8.30-10.00
Chairmen: A. Elia (Italy), I. Isaias (Germany)
OP 2.50.01 Relationship between stay-at-home patients’ understanding of nformation regarding their
Parkinson’s disease and the burden of spouse caregivers
H. Takamoto, M. Hori (Japan)
OP 2.50.02 Restoration of tensegrity equilibrium can lead to beneficial modification of Parkinson disease’s
motor symptoms
L. Vucolova (USA)
OP 2.50.03 Use of three-dimensional gait analysis to assess the effectiveness of conventional rehabilitation
protocols in people with Parkinson’s disease
M. Pau, F. Corona, C. Casula, R. Pili, M. Murgia, M. Guicciardi (Italy)
OP 2.50.04 The worse is the clinical status of the patient with Parkinson, the higher is the stride length
percentage of improvement after automated mechanical peripheral stimulation
A. Kleiner, M. Galli, M. Gaglione, D. Hildebrand*, P. Sale, G. Albertini, F. Stocchi, M.F. De Pandis
(Italy, *Brazil)
OP 2.50.05 Stress Reduction Training in PD Patients - Influence on neuropsychiatric symptoms?
A. Meyer, A. Hadinia, K. Nowak, U. Gschwandtner, P. Fuhr (Switzerland)
OP 2.50.06 Cognitive Behavioral Group Therapy (CBT) for stress reduction in patients with Parkinson’s disease.
A randomized control trial
A. Hadinia, A. Meyer, K. Nowak, U. Gschwandtner, P. Fuhr (Switzerland)
OP 2.50.07 Quality of life measured by PDQ39 and SEIQoL during anti-stress training for Parkinson’s disease
(PD) patients
K. Nowak, A. Meyer, M. Chaturvedi, A. Hadinia, U. Gschwandtner, P. Fuhr (Switzerland)
25
MONDAY, 7 DECEMBER
OP 2.50.08 Cortisol measurements as a laboratory biomarker for stress reduction in Parkinson’s disease (PD)
patients
K. Nowak, A. Meyer, A. Hadinia, M. Chaturvedi, A.D. Roesch, U. Gschwandtner, P. Fuhr
(Switzerland)
OP 2.50.09 Effects of cognitive loading on standing balance and postural stability in Parkinson’s disease
patients with freezing of gait
W. Buated, P. Lolekha*, T. Fujinami, S. Hidaka, N. Kashyap (Japan, *Thailand)
OP 2.50.10 Theatre is a valid complementary therapeutic interventions for emotional rehabilitation of
Parkinson’s patients
G. Mirabella, P. De Vita, S. Rampelli, F. Lena, F. Dilettuso, M. Iacopini, R. D’Avella,
M.C. Borghese, S. Mazzotta, D. Lanni, M. Grano, S. Lubrani, N. Modugno (Italy)
OP 2.50.11 Pharmaceutical design in Parkinson’s disease: what do patients prefer?
K. Lefteri, F. Liu, M. Brown (United Kingdom)
OP 2.50.12 Unlocking Alzheimers and Parkinsonism - Do you dream for cure?
J. Joy (India)
10.00
Short break
10.15-11.45
SILVER HALL
PLENARY SESSION
2.1 PARKINSON’S DISEASE NON-PHARMACOLOGICAL
INTERVENTIONS
Chairmen: A. Antonini (Italy), G. Pezzoli (Italy)
26
10.15
Rehabilitation
G. Abbruzzese (Italy)
10.45
Transcranial stimulation
A. Priori (Italy)
11.15
Genetic, dietary and pharmacological determinants of urate and their
impact on Parkinson’s disease
M.A. Schwarzschild (USA)
EXHIBITION AREA
Chairmen: A. Elia (Italy), I. Isaias (Germany)
OP 2.60.01 An explorative assessment of antioxidant and inflammatory biomarkers for identification of
prodromal Parkinson’s disease (PD)
J. Campolo, R. De Maria, L. Cozzi, M. Parolini, P. Proserpio, L. Nobili, G. Gelosa, I. Piccolo,
P. Marraccini (Italy)
OP 2.60.02 Autonomic dysfunction in Parkinson’s disease associated with common glucocerebrosidase gene
mutations
F. Del Sorbo, A.E. Elia, L.M. Romito, P. Soliveri, C. Barzaghi, B. Garavaglia, P. Cortelli,
A. Albanese (Italy)
OP 2.60.03 Impulsive-compulsive behaviors in Parkin-associated Parkinson’s disease: a case-control study
F. Morgante, A. Fasano*, M. Ginevrino, S. Petrucci, L. Ricciardi**, F. Bove, C. Criscuolo,
M. Moccia, A.R. Bentivoglio, M.T. Pellecchia, G. Di Michele**, P. Barone, E.M. Valente (Italy,
*Canada, **United Kingdom)
MONDAY, 7 DECEMBER
12.00-13.30
OP 2.60.04 Recognition of life-long curiosity in Parkinson’s disease treatment developments
P. Riederer (Germany)
OP 2.60.05 Effect of pharmacist-led interventions on motor symptoms in Parkinson’s patients: a pilot study
C. Stuijt, T. Van Laar (The Netherlands)
OP 2.60.06 Long-term effectiveness of NUPLAZID™ (pimavanserin) in PD psychosis: Data from 2 open-label
studies
R. Mills, S. Isaacson, J. Azulay*, J. Ferreira**, D. Kreitzman, T. Ilic***, K. Chi-Burris,
H. Williams (USA, *France, **Portugal, ***Serbia)
12.00-13.30
EXHIBITION AREA
POSTER SESSION I (1.001-2.036)
27
MONDAY, 7 DECEMBER
13.45-15.15
SILVER HALL
PLENARY SESSION
2.2 WHAT EXACTLY DO THE BASAL GANGLIA DO?
Chairmen: A. Berardelli (Italy), A.M. Cenci Nilsson (Sweden)
13.45
Volitional moving
M. Hallett (USA)
14.15
Role of (in)direct pathway in action control
R.M. Costa (Portugal)
14.45
Basal ganglia modulation of limbic circuits in learning and memory
processes
P. Calabresi (Italy)
15.15
Short break
15.30-17.00
SILVER HALL
2.11 IATROGENIC MOTOR DISORDERS
Chairmen: A.J. Espay (USA), M. Stamelou (Greece)
15.30
Clinical phenotype
A.J. Espay (USA)
16.00
Imaging characterization
M. Tinazzi (Italy)
16.30
Therapeutic approach
F. Morgante (Italy)
15.30-17.00
2.21 UPDATE ON SLEEP DISORDERS
Chairmen: P. Cortelli (Italy), A. Iranzo (Spain)
28
15.30
Restless eye movement behavior disorder
L. Ferini-Strambi (Italy)
16.00
Excessive daytime sleepiness and sleep attacks
C. Baumann (Switzerland)
16.30
Restless legs syndrome
C. Bassetti (Switzerland)
RED HALL 2
BLUE HALL
2.31 INTERACTIVE DISCUSSION CLINICAL-GENETIC-PATHOLOGICAL
CASES
Coordinator: C. Adler (USA)
Speakers: C. Adler (USA), N. Hattori (Japan),
W.D.J. van de Berg (The Netherlands)
15.30-17.00
RED HALL 1
2.41 MANAGEMENT OF PARKINSON’S DISEASE COMPLICATIONS
Chairman: P. Odin (Sweden)
15.30
Motor complications
P. Odin (Sweden)
16.00
Non-motor fluctuations
A. Storch (Germany)
16.30
Impulse control disorders
M.C. Rodriguez-Oroz (Spain)
15.30-17.00
MONDAY, 7 DECEMBER
15.30-17.00
YELLOW HALL 3
Chairman: R. Cilia (Italy)
OP 2.50.13 Pharmacogenetics of levodopa: an algorithm for dose prediction
V. Altmann, M. Rieck, A. Schumacher-Schuh, S. Callegari-Jacques, C. de Mello Rieder, M. Hutz
(Brazil)
OP 2.50.14 Treatment with l-dopa normalize learning as measured with CVLT-2 in drug naive patients with
Parkinsons`disease
H.T.J. Sari, O.B. Tysnes, J.P. Larsen, A. Gramstad, G.O. Skeie (Norway)
OP 2.50.16 Onset and duration of motor effects with IPX066, levodopa-carbidopa extended-release capsules:
comparison with immediate-release levodopa-carbidopa and with levodopa-carbidopa+entacapone
S. Gupta, S. Khanna, R. Rubens, N. Modi (USA)
OP 2.50.17 Outpatient levodopa-carbidopa intestinal gel titration in patients with advanced Parkinson’s disease
R. Rodriguez, M. Lobatz, J. Dubow, S. Eaton, C. Hall, K. Chatamra, J. Benesh (USA)
OP 2.50.18 Effects of levodopa-carbidopa intestinal gel on non-motor symptoms and safety of outpatient
titration: a new phase 3 study in patients with advanced Parkinson’s disease
D. Standaert, J. Slevin, C. Hall, J. Dubow, S. Eaton, K. Chatamra, J. Benesh (USA)
29
MONDAY, 7 DECEMBER
OP 2.50.19 Determination of minimal important difference thresholds for Parkinson’s Disease Questionnaire-39
in advanced Parkinson’s disease patients
A. Antonini, E. Dansie Bacci*, K. Sail*, Y.J. Jalundhwala*, P.L. Kandukuri*, T. Marshall*,
K. Chatamra*, I. Wiklund**, D. Revicki* (Italy, *USA, **United Kingdom)
OP 2.50.20 Gastrointestinal safety of levodopa-carbidopa intestinal gel in advanced Parkinson’s disease
patients: GLORIA long-term registry interim results
D. Domagk, S. Dam-Larsen*, **A. Antonini, L. Bergmann***, A. Yegin***, W. Poewe****
(Germany, *Denmark, **Italy, ***USA, ****Austria)
OP 2.50.21 Antiparkinsonian medication adjustments following deep brain stimulation of subthalamic nucleus
in patients with advanced Parkinson’s disease
A. Gamaleya, E. Bril, A. Tomskiy, N. Gubareva, A. Poddubskaya, N. Fedorova, V. Shabalov
(Russia)
OP 2.50.22 Comparison of the antiparkinsonian and antidyskinetic effects of hemantane and amantadine
E. Ivanova, I. Kapitsa, E. Valdman, T. Voronina (Russia)
OP 2.50.24 A study of real life tolerability of rotigotine transdermal patch in Parkinson’s disease across all
motor stages
R. Barreto, A. Sauerbier, A. Rizos, R. Chaudhuri (United Kingdom)
17.00
Short break
17.15-18.45
RED HALL 2
2.22 NEUROREHABILITATION FOR PARKINSON’S DISEASE: FUTURE
PERSPECTIVES
Chairmen: G. Abbruzzese (Italy), K.B. Bhattacharyya (India)
30
17.15
Gait and posture
J.-P. Azulay (France)
17.45
Behavioural adaptation
B.R. Bloem (The Netherlands)
18.15
Exercise
M. Hirsch (USA)
BLUE HALL
2.32 DEVICE-AIDED PARKINSON’S DISEASE TREATMENTS:
PRACTICAL ISSUES
Chairmen: E. Dietrichs (Norway), L. Lopiano (Italy)
17.15
Selecting the right patient
P. Odin (sweden)
17.45
Infusion therapies
T. van Laar (The Netherlands)
18.15
Deep brain stimulation
F. Valldeoriola (Spain)
17.15-18.45
MONDAY, 7 DECEMBER
17.15-18.45
RED HALL 1
2.42 MANAGEMENT OF AUTONOMIC DYSFUNCTION IN PARKINSONISM
Chairman: H. Kaufmann (USA)
17.15
Blood pressure
H. Kaufmann (USA)
17.45
Urogenital
P. Cortelli (Italy)
18.15
Gastrointestinal
F. Stocchi (Italy)
19.00-20.30
WHITE HALL 1
ANNUAL GENERAL MEETING
31
MONDAY, 7 DECEMBER
17.15-18.45
YELLOW HALL 3
Chairmen: R. Cilia (Italy), P. Martinez-Martin (Spain), G. Riboldazzi (Italy)
OP 2.50.25 Rotigotine efficacy on sleep disturbances in Parkinson’s Disease patients: evidence from a
polysomnographic study
C. Liguori, M. Pierantozzi, F. Placidi, A. Stefani (Italy)
OP 2.50.26 Efficacy of sublingual apomorphine (APL-130277) for the treatment of OFF episodes in patients with
A. Agro, J. Dubow, B. Dzyngel, T. Bilbault, A. Giovinazzo, H. Shill*, R. Hauser* (Canada, *USA)
OP 2.50.27 Baseline disease severity not predictive of sublingual apomorphine (APL-130277) dose needed to
convert a PD patient from the OFF to ON state
J. Dubow, B. Dzyngel, T. Bilbault, A. Giovinazzo, A. Agro (Canada)
OP 2.50.28 Minimum MDS-UPDRS part iii change needed to convert a Parkinson’s disease patient from the OFF
to full ON state with sublingual apomorphine (APL-130277)
OP 2.50.29 Differences between apomorphine (APO) and lisuride (LIS) in PD therapy
R. Horowski (Germany)
OP 2.50.30 The effect of bilateral sub-thalamic nucleus deep brain stimulation (STN-DBS) on prosody of speech
of Parkinson’s disease
F. Majdinasab, S.A.H. Habibi, E. Ghorbani, M. Khoddami (Iran)
OP 2.50.31 Can intraoperative clinical testing predict stimulation-induced effects of STN-DBS?
J. Blume, E. Rothenfußer-Korber, A. Janzen, U. Bogdahn, J. Schlaier, M. Lange (Germany)
OP 2.50.32 The impact of microelectrode recording on selecting the most optimal trajectories for electrode implantation
M. Nagy, N. Kovács, Z. Aschermann, G. Deli, I. Balás (Hungary)
OP 2.50.33 Reflex saccades evaluation can estimate long-term symptom progression in DBS STN vs only
medically treated Parkinson’s disease patients
S. Szlufik, A. Przybyszewski, J. Dutkiewicz, P. Habela, T. Mandat, D. Koziorowski (Poland)
OP 2.50.34 High frequency repetitive transcranial magnetic stimulation can improve the quality of life and
depression in Parkinson’s disease: a randomized, double-blind, placebo-controlled study
N. Kovács, G. Deli, Z. Aschermann, A. Makkos, M. Kovács, J. Janszky, E. Pál (Hungary)
OP 2.50.35 The impact of STN DBS on kinetic tremor in Parkinson’s disease patients
S. Szlufik, M. Szumilas, J. Dutkiewicz, D. Koziorowski, T. Mandat, E. Slubowska (Poland)
OP 2.50.36 The combined depletion of monoamines alters the effectiveness of subthalamic deep brain stimulation
E. Faggiani, C. Delaville, A. Benazzouz (France)
32
OP 2.50.37 Unilateral deep brain stimulation of subthalamic nuclei does not affect reactive inhibition in
G. Mirabella, G. Giannini, M. Fragola, M. Santilli, N. Modugno (Italy)
SILVER HALL
3.10 INTERVENTIONS IN PARKINSONISM (MULTIPLE SYSTEM
ATROPHY/PROGRESSIVE SUPRANUCLEAR PALSY/CORTICO BASAL
DEGENERATION)
Chairmen: C. Colosimo (Italy), G. Höglinger (Germany)
8.30
Multiple system atrophy
G.K. Wenning (Austria)
9.00
Progressive supranuclear palsy
M. Stamelou (Greece)
9.30
Cortico basal degeneration
C. Colosimo (Italy)
8.30-10.00
TUESDAY, 8 DECEMBER
8.30-10.00
RED HALL 2
3.20 ADVANCES IN PARKINSON’S DISEASE IMAGING (2)
Chairmen: I. Rektorova (Czech Republic), M. Samuel (United Kingdom)
8.30
Biomarkers of atypical Parkinsonism
A. Antonini (Italy)
9.00
Imaging correlates of Parkinson cognitive impairment
R. Biundo (Italy)
9.30
Molecular imaging and neural networks in impulse control disorders
A. Strafella (Canada)
8.30-10.00
BLUE HALL
3.30 UNUSUAL MOVEMENT DISORDERS (2) - Video Session
Coordinator: A.J. Espay (USA)
Speakers: K. Bhatia (United Kingdom), F. Cardoso (Brazil),
A.J. Espay (USA)
33
TUESDAY, 8 DECEMBER
8.30-10.00
RED HALL 1
3.40 UPDATE ON TREMOR
Chairmen: A. Friedman (Poland), R. Helmich (The Netherlands)
8.30
Tremor: Pathophysiology
R. Helmich (The Netherlands)
9.00
Tremor: Clinical aspects
E.D. Louis (USA)
9.30
Tremor: Treatment
F. Vingerhoets (Switzerland)
8.30-10.00
YELLOW HALL 3
Chairmen: R. Cilia (Italy), I. Isaias (Germany)
OP 3.50.01 Case study of sporadic multiple system atrophy at a young age
B. Muinjonov, E. Giyazitdinova (Uzbekistan)
OP 3.50.02 Vascular parkinsonism as a common manifestation of second stage of CADASIL syndrome
OP 3.50.03 Hyperkinesia in ancient China: perspectives and prescriptions
J. Liu, L. Wang (China)
OP 3.50.04 Cortical and subcortical neurodegeneration in chorea-acanthocytosis and Huntington’s disease:
more differences than similarities
J. Liu, H. Heinsen*, T. Arzberger*, B. Bader*, C. Schmitz*, M. Kiessling*, A. Danek*
(China, *Germany)
OP 3.50.05 Novel GNAL mutation with intra-familial clinical heterogeneity: expanding the phenotype
M. Carecchio, C. Panteghini, C. Reale, C. Barzaghi, V. Monti, L. Romito, F. Sasanelli,
B. Garavaglia (Italy)
OP 3.50.06 DYT16/PRKRA founder mutation causes childhood-onset generalized dystonia in a family from
Southern Italy
M. Quadri, S. Olgiati, M. Sensi*, F. Gualandi*, E. Groppo*, V. Rispoli*, J. Graafland,
G.J. Breedveld, G. Fabbrini*, V. Bonifati (The Netherlands, *Italy)
OP 3.50.07 Frequency of the pain and sleep problems at dystonia patients and influence of deep brain
stimulation
V. Vuletic (Croatia)
OP 3.50.08 Tobacco increases dystonia risk but may ameliorate symptoms
C. Hellberg, A. Puschmann (Sweden)
34
OP 3.50.10 Differential induction of dyskinesia and inflammatory responses by intermittent versus continuous
L-DOPA delivery in the 6-OHDA model of Parkinson’s disease
A.R. Carta, G. Mulas, S. Spiga, D. Lecca E. Pillai (Italy)
10.00
Short break
10.15-11.45
SILVER HALL
PLENARY SESSION
3.1 BIOMARKERS IN PARKINSON’S DISEASE
Chairmen: N. Hattori (Japan), H. Reichmann (Germany)
10.15
Biomarkers in Parkinson’s disease
R. Uitti (USA)
10.45
Plasma and cerebro spinal fluid biomarkers in Parkinson’s disease
S. Saiki (Japan)
11.15
In-life diagnostic accuracy
C. Adler (USA
11.45
Short break
12.00-13.30
TUESDAY, 8 DECEMBER
OP 3.50.09 Wilson disease: acute dystonia during treatment with SSRI or SNRI
L. Wictor, K. Wictorin, H. Widner, A. Puschmann (Sweden)
EXHIBITION AREA
Chairmen: D. Calandrella (Italy), A. Merola (Italy), L. Romito (Italy)
OP 3.60.01 PANDA: prolonged release oxycodone/naloxone (OXN PR) for severe Parkinson’s disease (PD)related pain
K.R. Chaudhuri, P. Martinez-Martin*, O. Rascol**, M. Lomax, J. Decesare, M. Hopp***
(United Kingdom, *Spain, **France, ***Germany)
OP 3.60.02 Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson’s disease: effects
on motor and non motor symptoms with brain metabolism correlations
M. Auffret, A. Maurus, M. Vérin, J. Houvenaghel, F. Le Jeune, S. Drapier (France)
OP 3.60.03 Clinical and neuropathological features of rapid progressive dementia with lewy bodies
A. Geut, D. Hepp, A. Ingrassia, Y. Galis, E. Foncke, A. Lemstra, A. Rozemuller, W. Van De Berg
(The Netherlands)
OP 3.60.04 Epigenome-wide DNA methylation analysis in brothers and monozygotic twins discordant for
O. Kaut, I. Schmitt, S. Witt, J. Tost*, U. Wüllner (Germany, *France)
35
TUESDAY, 8 DECEMBER
OP 3.60.05 Unprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as
observed in the 6-OHDA lesioned rat model of Parkinson’s disease
A. Michel, P. Downey, J. Nicolas, D. Scheller (Belgium)
OP 3.60.06 Understanding the differential regulation of GBA and GBAP1 expression
V. Rimoldi, G. Rovaris, L. Straniero, G. Pezzoli, S. Goldwurm, G. Soldà, R. Asselta, S. Duga (Italy)
12.00-13.30
EXHIBITION AREA
POSTER SESSION II (2.037-3.087)
13.45-15.15
SILVER HALL
PLENARY SESSION
3.2 DYSTONIA REVISITED
Chairmen: M. Hallett (USA), J. Jankovic (USA)
13.45
Dystonia revisited
A. Albanese (Italy)
14.15
Pharmacological interventions in dystonia
D. Truong (USA)
14.45
Surgical interventions in dystonia
J. Volkmann (Germany)
15.15
Short break
15.30-17.00
SILVER HALL
3.11 NON-MOTOR SYMPTOMS IN MOVEMENT DISORDERS
Chairmen: C. Adler (USA), E.D. Louis (USA)
36
15.30
Non-motor symptoms in Parkinson’s disease
R. Pfeiffer (USA)
16.00
Non-motor symptoms in essential tremor
E.D. Louis (USA)
16.30
Non-motor symptoms in dystonia
A. Berardelli (Italy)
RED HALL 2
3.21 NEURODEGENERATION
Chairmen: P. Riederer (Germany), M.C. Rodriguez-Oroz (Spain)
15.30
Mitochondrial function
A. Schapira (United Kingdom)
16.00
Role of iron
H. Reichmann (Germany)
16.30
Role of mitochondrial biogenesis
M.B.H. Youdim (Israel)
15.30-17.00
BLUE HALL
TUESDAY, 8 DECEMBER
15.30-17.00
3.31 HANDS ON DYSTONIA: BOTULINUM TOXIN WORKSHOP
Coordinator: C. Colosimo (Italy)
Speakers: C. Colosimo (Italy), D. Dressler (Germany), D. Truong (USA)
15.30-17.00
RED HALL 1
3.41 DYSTONIA
Chairman: A. Albanese (Italy)
15.30
Pathophysiology/Classification
A. Albanese (Italy)
16.00
Clinical aspects
J. Jankovic (USA)
16.30
Surgical interventions
A. Fasano (Canada)
17.00
Short break
37
TUESDAY, 8 DECEMBER
17.15-18.45
SILVER HALL
3.12 DEEP BRAIN STIMULATION
Chairmen: M.F. Contarino (The Netherlands), A. Fasano (Canada)
17.15
Indications of deep brain stimulation
E. Moro (France)
17.45
Sensing technology: rationale
P. Brown (United Kingdom)
18.15
Adaptive deep brain stimulation: state of the art and where are we
heading to
A. Priori (Italy)
17.15-18.45
BLUE HALL
3.32 ANIMAL MODELS IN MOVEMENT DISORDERS
Chairmen: A.M. Cenci Nilsson (Sweden), M.B.H. Youdim (Israel)
17.15
Animal models of neurodegeneration in Parkinson’s disease
F. Blandini (Italy)
17.45
Symptomatic models of motor- and non-motor features in Parkinson’s
disease
A.M. Cenci Nilsson (Sweden)
18.15
Huntington animal model
S.M. Hersch (USA)
17.15-18.45
3.42 DIAGNOSTIC CHALLENGES
Chairman: G.K. Wenning (Austria)
38
17.15
Multiple system atrophy vs Parkinson’s disease
G.K. Wenning (Austria)
17.45
Progressive supranuclear palsy subtypes
M. Stamelou (Greece)
18.15
Cortico basal degeneration and cortico basal syndrome
C. Colosimo (Italy)
RED HALL 1
YELLOW HALL 3
Chairmen: D. Calandrella (Italy), A. Merola (Italy), L. Romito (Italy)
OP 3.50.11 Interoceptive awareness in patients with functional motor disorders
B. Demartini, L. Ricciardi*, L. Crucianelli*, C. Krahé*, M.J. Edwards*, A. Photopoulou*
(Italy, *United Kingdom)
OP 3.50.12 Center of pressure velocity and its fast alternating deviations as an objective measure of balance –
normal values and their sensitivity investigated in SCA patients
A. Sobanska, M. Rakowicz, L. Czerwosz, A. Sulek, I. Stepniak, R. Rola (Poland)
OP 3.50.13 Clinical profile of hundred patients with Ataxia Telangiectasia from India
M. Mahadevappa, D.V. Santhosh, M. Netravathi, R. Yadav, P.K. Pal (India)
OP 3.50.14 Altered functional topography of the striatum in resting state FMRI in Parkinson’s disease
S.N. Tan, Y. Zhang, A. Liu, J. Wang, M.J. Mckeown (Canada)
TUESDAY, 8 DECEMBER
17.15-18.45
OP 3.50.15 Is the mechanism of nervous cells death in Parkinson different than in other neurodegenerations
- arguments from MRI study?
A. Friedman, R. Kulinski, J. Galazka-Friedman (Poland)
OP 3.50.16 Putaminal diffusivity changes correlates with motor progression in Parkinson’s disease on 6-year
follow-up
L.L. Chan, K.M. Ng, C.S. Yeoh, H.H. Li, H. Rumpel, E.K. Tan (Singapore)
OP 3.50.17 Fatigue in Parkinson’s disease and striatum dopamine transporter scan (DaTscan) uptake
A. Sauerbier, P. Martinez-Martin*, M. Politis, A. Rizos, N. Trojanovic, N. Mulholland, G. Vivian,
B. Corcoran, D. Trivedi, L. Perkins, R. Inniss, T. Chiwera, R. Barreto, M. Parry, A. Martin,
N. Dimitrov, R. Brown, K. Ray Chaudhuri (United Kingdom, *Spain)
OP 3.50.18 The MIBG scintigraphy and DAT SPECT contribute to the diagnosis of PD and other related disorders,
and evaluations of the course and stage of PD
S. Tada, R. Ando, H. Iwaki, T. Tsujii, Y. Yabe, N. Nishikawa, M. Nagai, M. Nomoto (Japan)
OP 3.50.19 Characteristic metabolic brain pattern in Slovenian Parkinson’s disease patients
P. Tomse, R. Tomaz, Z. Pirtošek , Y. Ma*, D. Eidelberg*, M. Trost (Slovenia, *USA)
OP 3.50.20 Updated long-term safety from ongoing phase 3 trials of levodopa-carbidopa intestinal gel in
patients with advanced Parkinson’s disease
R. Rodriguez, N. Schmulewitz, D. Stein, W. Robieson, C. Hall, S. Eaton, K. Chatamra, J. Benesh,
A. Espay (USA)
OP 3.50.21 Opioid K receptor variant delays the onset of dyskinesias in Parkinson’s disease
R. Cilia, R. Asselta, R. Benfante, E. Cereda, D. Vallauri, L.Marabini, D. Fornasari, S. Goldwurm,
G. Pezzoli (Italy)
OP 3.50.22 Motor effects of phosphodiesterase 9 inhibition in the non-human primate model of Parkinson’s
disease
G. Masilamoni, A. Singh, X. Tang, A. McRiner, L. Leventhal, S. Papa (USA)
39
WEDNESDAY, 9 DECEMBER
8.30-10.00
SILVER HALL
4.10 MOVEMENT DISORDERS DEVELOPMENTS 2014-2015: BEST
PARKINSON RELATED DISEASES ARTICLES
Chairmen: S.M. Calne (Canada), R. Pfeiffer (USA), Z.K. Wszolek (USA)
R. Rodnitzky (USA)
J.H. Friedman (USA)
8.30-10.00
RED HALL 2
4.20 SENSOR AND SLEEP DEFICITS IN PARKINSON’S DISEASE
Chairmen: A. Antonini (Italy), P. Riederer (Germany)
8.30
Vision
I. Bodis-Wollner (USA)
9.00
Auditory
C. Vitale (Italy)
9.30
Sleep
R. Bhidayasiri (Thailand)
8.30-10.00
RED HALL 1
4.40 DIAGNOSIS OF UNCOMMON MOVEMENT DISORDERS
Chairman: V.S. Kostic (Serbia and Montenegro)
40
8.30
Myoclonus
V.S. Kostic (Serbia and Montenegro)
9.00
Chorea and tics
J. Roth (Czech Republic)
9.30
Cerebellar syndromes
A. Dürr (France)
YELLOW HALL 3
Chairman: P. Martinez-Martin (Spain)
OP 4.50.01 Synaptic homeostasis in Parkinson’s disease: an high-density EEG study in different stage of the disease
V. Trendafilov, S. Sarasso*, J. Moeller, C. Staedler, A. Kaelin-Lang, S. Galati (Switzerland, *Italy)
OP 4.50.02 Brain network changes in relation to beginning apathy in PD patients
F. Hatz, A. Meyer, U. Gschwandtner, P. Fuhr (Switzerland)
OP 4.50.03 Functional connectivity underpinnings of fatigue in “drug-naïve” patients with Parkinson’s disease
A. Giordano, A. Tessitore, R. De Micco, G. Caiazzo, A. Russo, M. Cirillo, F. Esposito, G. Tedeschi
(Italy)
OP 4.50.04 Correlation of the EEG frequency with cognitive performance in Parkinson’s disease - six-months
follow-up
V. Cozac, M. Chaturvedi, F. Hatz, A. Meyer, K. Nowak, U. Gschwandtner, P. Fuhr (Switzerland)
OP 4.50.05 Alertness as assessed by clinical testing and alpha reactivity does not correlate with executive
function decline in Parkinson’s disease (PD)
R. Sturzenegger, A. Meyer, M. Chaturvedi, V. Cozac, F. Hatz, U. Gschwandtner, P. Fuhr
(Switzerland)
8.30-10.00
OP 4.50.06 EEG features of dyskinesias, complicated by levodopa therapy in patient with parkinson’s disease
U. Askhonov, B. Gafurov, G. Ashanov (Uzbekistan)
OP 4.50.07 Electromyographic diagnostics of Parkinson’s disease and detection risk groups among relatives of patients
D. Ayupova (Uzbekistan)
OP 4.50.08 Identification of the globus pallidus interna based on time patterns analysis in Parkinson’s disease
D.S. Andres, C. Daniel*, M. Merello* (Switzerland, *Argentina)
OP 4.50.09 Identification of novel PD genes by whole-exome sequencing in Italian families
L. Straniero, G. Soldà, R. Asselta, I. Guella*, G. Pezzoli, M. Farrer*, S. Goldwurm, S. Duga
(Italy, *Canada)
OP 4.50.10 DNAJC6 mutations associated with early-onset Parkinson’s disease
S. Olgiati, M. Quadri, M. Fang, J.P. Rood, J.A. Saute*, H.F. Chien*, C.G. Bouwkamp,
J. Graafland, M. Minneboo, G.J. Breedveld, J. Zhang***, F.W. Verheijen, W. Mandemakers,
A.J. Boon, A.J. Kievit, L.B. Jardim*, E.R. Barbosa*, C.R. Rieder*, K.L. Leenders, J. Wang**,
V. Bonifati (The Netherlands, *Brazil, **China)
OP 4.50.12 Defective glucocerebrosidase in GBA1 mutant Parkinson’s disease fibroblasts is rescued by
chemical chaperone ambroxol through modulation of lysosomal factors
G. Ambrosi, C. Ghezzi, R. Zangaglia, G. Levandis, C. Pacchetti, F. Blandini (Italy)
10.00
Short break
41
10.15-11.45
SILVER HALL
PLENARY SESSION
4.1 COGNITIVE IMPAIRMENT IN PARKINSON’S DISEASE
Chairmen: P. Barone (Italy), A.J. Stoessl (Canada)
10.15
Mild cognitive impairment
10.45
Disrupted functional connectivity and other markers of cognitive decline
in Parkinson’s Disease
O. Monchi (Canada)
11.15
Parkinson’s disease dementia and dementia with Lewy bodies
D. Aarsland (Sweden)
11.45-13.15
SILVER HALL
PLENARY SESSION
4.2 PSYCHOGENIC MOVEMENT DISORDERS
Chairmen: K. Bhatia (United Kingdom), M. Hallett (USA)
11.45
Epidemiology and pathophysiology of psychogenic movement disorders
M. Edwards (United Kingdom)
12.15
Clinical presentations
M. Hallett (USA)
12.45
Electrophysiological evaluation
P. Pal (India)
13.15-13.45
POSTER SESSION III (3.088-6.070)
42
EXHIBITION AREA
SILVER HALL
4.11 DISEASE ASSOCIATIONS IN MOVEMENT DISORDERS:
CONTROVERSIES
Chairmen: U. Bonuccelli (Italy), P. Martinez Martin (Spain),
M. Onofrj (Italy)
13.45
Alzheimer’s disease and Parkinson’s disease
A. Korczyn (Israel)
14.15
Essential tremor and Parkinson’s disease
J. Jankovic (USA)
14.45
Vascular parkinsonism and Parkinson’s disease
I. Rektor (Czech Republic)
13.45-15.15
RED HALL 2
13.45-15.15
4.21 RECENT ADVANCES IN ESSENTIAL TREMOR
Chairmen: E.D. Louis (USA), J. Volkmann (Germany)
13.45
Refining diagnostic criteria
M. Edwards (United Kingdom)
14.15
Genetics
E.K. Tan (Singapore)
14.45
Surgical treatment
A. Fasano (Canada)
13.45-15.15
RED HALL 1
4.41 INSTRUMENTAL HALLMARKS OF PARKINSONISM
Chairman: R. Ceravolo (Italy)
13.45
Neuropathology
W.D.J. van de Berg (The Netherlands)
14.15
Magnetic resonance imaging
A. Tessitore (Italy)
14.45
Position Emission Tomography/Single-Photon Emission Computed
Tomography
R. Ceravolo (Italy)
43
13.45-15.15
YELLOW HALL 3
Chairman: A. Antonini (Italy)
OP 4.50.13 Caffeine intake and genetic susceptibility to Parkinson’s disease
P. Sharan, E.K. Tan (Singapore)
OP 4.50.15 Ameliorative effects of 1,3,4-thiadiazole derivatives on scopolamine induced cognitive deficits in
mice
A. Kulshreshtha, P. Piplani (India)
OP 4.50.16 c-Rel deficient mice, a mouse model of “spreading” PD-like pathology
E. Parrella, A. Bellucci, V. Porrini, A. Lanzillotta, M. Benarese, G. Vegezzi, C. Baiguera,
A. Antonini, P.F. Spano, M. Pizzi (Italy)
OP 4.50.17 Integration of cortical and basal ganglia inputs in motor thalamus of parkinsonian animal models
G. Orban, W. Song, A. Kaelin-Lang, S. Galati (Switzerland)
OP 4.50.20 Role of dopaminergic receptors and post synaptic signaling in arsenic induced neurotoxicity:
ameliorative effect of curcumin
P. Srivastava, Y. Dhuriya, R. Gupta, R. Shukla, A.B. Pant, V.K. Khanna (India)
OP 4.50.21 Antiparkinson and antioxidant effect of pyridylpyrazolinyl substituted heterosteroids in LPS induced
neuroinflammation model of neurodegenerative disorders
R. Singh, R. Bansal (India)
OP 4.50.22 Inhibition of PERK and NFKB pathway can reduce death of stressed dopaminergic neurons
differentiated from human stem cell line
Z.L. Chaudhry, B. Ahmed (United Kingdom)
OP 4.50.23 Oral intake of anti-hangover substance increases aldehyde dehydrogenase activity: new preventive
and therapeutic potentials for oxidative neuronal injury?
C. Bang, B. Kang, S. Choung, K. Choi (South Korea)
15.15-15.30
PLENARY SESSION
CLOSING CEREMONY
44
SILVER HALL
P 1.001
The study of the prevalence of Parkinson disease
K. Karbozova (Kyrgyzstan)
P 1.002
Sex differences in Parkinson’s disease
U. Fiszer, M. Michałowska, T. Szatanowski (Poland)
P 1.003
An unexpected higher prevalence of Parkinson’s disease in females than males in the province of
Trento (Italy): a clues for the etiopathogenesis?
M.C. Malaguti, N. Vanacore, S. Ferrari, S. Piffer, R. Pertile, R. Roni, A. Polverino, M. Gentilini,
F. Cembrani, V. Bertozzi, M. Pellegrini, D. Orrico (Italy)
P 1.004
Parkinson’s disease in Senegal: epidemiologic, clinical and therapeutic aspects
N.M. Gaye, L.B. Seck, N.S. Diagne, A.D. Sow, A.M. Diop, O. Cisse, A.B. Faye, M.S. Diop, K. Toure,
M. Ndiaye, A.G. Diop, M.M. Ndiaye (Senegal)
P 1.006
Birth month and Parkinson’s disease: Is there any relationship?
R. Kurisaki, H. Hori, K. Nakahara, A. Kuratomi, Y. Nishida, K. Uekawa (Japan)
P 1.008
A step forward to the future: UPDRS kinematic measures for telemedicine
G. Albani, C. Azzaro, F. Parisi, C. Ferraris, M. Giuberti, L. Contin, D. Pianu, L.G. Pradotto,
V. Cimolin, M. Galli, R. Nerino, G. Ferrari, A. Mauro (Italy)
P 1.009
Occupational exposure to Organic solvents and welding fumes and risk of Parkinson’s disease
K. Kovendan, R. Chandirasekar, K. Murugan, S. Vincent (India)
P 1.011
An explorative assessment of antioxidant and inflammatory biomarkers for identification of
prodromal Parkinson’s disease (PD)
J. Campolo, R. De Maria, L. Cozzi, M. Parolini, P. Proserpio, L. Nobili, G. Gelosa, I. Piccolo,
P. Marraccini (Italy)
P 1.012
Urinary biomarkers of oxidative stress in early Parkinson’s disease
S. Calzetti, R. Andreoli, A. Negrotti, G. De Palma, E. Marchesi, S. Riccardi, A. Mutti (Italy)
P 1.013
A comparative study of oxidative stress markers between the tremor dominant and akinetic-rigid
subtypes of patients with Parkinson’s disease
R. Naduthota, R. Christopher, R. Yadav, P.K. Pal (India)
P 1.014
The relationship between serum and cerebrospinal fluid inflammatory biomarkers in Parkinson’s disease
I. Miliukhina, A. Kudrevatykh, E. Gracheva, M. Karpenko (Russia)
P 1.015
Level of S100B protein in blood plasma depending on the form Parkinson’s disease
M. Juraev, R. Matmurodov, K. Khalimova (Uzbekistan)
P 1.016
Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in PD
M. Hirayama, S. Hasegawa, T. Minato, T. Asahara, K. Nomoto, H. Tsuji, A. Okamoto, K. Ohno
(Japan)
P 1.017
Changes in serum level of interferon-gamma, alpha tumor necrosis factor and autoantibodies in
E. Giyazitdinova, G. Rakhimbayeva, Y. Musayeva, B. Muinjonov (Uzbekistan)
POSTER SESSION 1 - MONDAY, 7 DECEMBER
POSTER SESSION 1 (1.001-2.036)
45
46
P 1.018
Blood lipid parameters in patients with Parkinson’s disease
E. Giyazitdinova, B. Muinjonov, G. Rakhimbayeva, Y. Musayeva (Uzbekistan)
P 1.019
CSF levels of heart fatty acid binding protein in Parkinson’s and Alzheimer’s disease
D. Chiasserini, L. Biscetti, P. Eusebi, L. Farotti, N. Tambasco, P. Calabresi, L. Parnetti (Italy)
P 1.020
Cancer comorbidity among Parkinson’s Disease patients ; a population based large-scale cohort
study
R. Gurel, N. Giladi, V. Rosani, T. Gurevich, B. El-Ad, B. Hemo, J. Tzamir, C. Peretz (Israel)
P 1.021
Association between cancers and risk of Parkinson disease: a cohort study
R. Piri, M. Naghavi-Behzad (Iran)
P 1.022
Risk of cancer among patients with Parkinson disease
M. Naghavi-Behzad, R. Piri (Iran)
P 1.023
Cancer in Parkinson’s disease
P. Tacik, S. Curry, A. Strongosky, S. Fujioka, M. Heckman, Z.K. Wszolek (USA)
P 1.024
Intraventricular tumour presenting as progressive supranuclear palsy-like phenotype
M. Morelli, F. Fera, F. Bono, A. Fratto, G. Arabia, A. Quattrone (Italy)
P 1.025
A case of premenstrual tremor
S. Khachaturyan, K. Harutyunyan, A. Voskanyan, G. Avagyan, H. Amirjanyan, I. Gabrielyan,
M. Hovhannes* (Armenia)
P 1.026
Motor and cognitive deterioration in advanced young-onset PD: a cautionary tale
N. Zupancic Kriznar, B. Meglic, M. Trost, M. Kramberger Gregoric, L. Ocepek, R. Rajnar,
Z. Pirtošek (Slovenia)
P 1.027
Progression of Parkinson’s disease during the 5-year follow-up
M. Petrovic, E. Stefanova, T. Stojkovic, V. Kostic (Serbia)
P 1.028
Changes of resting state EEG in patients with left-sided and right-sided Parkinson’s disease
N. Kozhemiako, S. Kryzhanovskyi, A. Cherninskyi, I. Karaban, N. Karasevich (Ukraine)
P 1.029
Evaluation of serum amino acid profile in patients with advanced Parkinson’s disease
M. Figura, K. Kusmierska, E. Bucior, S. Szlufik, D. Koziorowski, Z. Jamrozik, A. Friedman,
P. Janik (Poland)
P 1.030
Hospitalisation in early Parkinson’s disease using Hospital Episodes Statistics from the PD MED
trial
S. Muzerengi, R. Woolley, C. Rick, N. Ives, R. Gray, F. Dowling, C.E. Clarke (United Kingdom)
P 1.031
Hospitalisation coding errors in Parkinson’s disease in a large UK teaching hospital
S. Muzerengi, C. Rick, I. Begaj, N. Ives, F. Evison, R. Woolley, C.E. Clarke (United Kingdom)
P 1.032
Hospital-based study on emergency admission in patients with Parkinson’s disease
S. Fujioka, J. Fukae, H. Ogura, T. Mishima, S. Yanamoto, M. Higuchi, G. Umemoto, Y. Tsuboi
(Japan)
P 1.033
Usefulness of Parkinson’s KinetiGraph in a Parkinson’s disease clinic - Survey of 82 patients
L. Klingelhoefer, A. Rizos*, A. Sauerbier*, D. Trivedi*, R. Inniss*, L. Perkins*, H. Reichmann*,
K.R. Chaudhuri* (Germany, *United Kingdom)
Premotor symptoms as predictors of outcome in Parkinson’s disease: a nationwide populationbased and case-control study
M. Chang (Taiwan)
P 1.036
Non motor symptoms impact quality of life (QOL) in de novo Parkinson’s disease (PD)
C. Toyoda, T. Umehara, H. Matsuno, H. Oka (Japan)
P 1.037
Clinical manifestations at stage de novo of Parkinson disease in the neurological clinic of Fann
National Teaching Hospital
O. Cisse, A.M. Basse, E.H.M. Ba, S.M.L. Dadah, N.M. Gaye, M.A. Diop, F.Y. Fogang, A.D. Sow,
M.S. Diop, A. Diatta, M. Ndiaye, A.G. Diop, M.M. Ndiaye (Senegal)
P 1.038
Assessing the non-motor symptom burden progression in a longitudinal study of 411 Parkinson’s
patients, using the non-motor symptom questionnaire
M. Grilo, D. Trivedi, E. Moti, R. Barreto, A. Sauerbier, A. Rizos, L. Perkins, R. Inniss, T. Chiwera,
K.R. Chaudhuri (United Kingdom)
P 1039
Quality of life in patients with Parkinson’s Disease in Uzbekistan
N. Tolibova, M. Khanova, O. Turgunkhujaev (Uzbekistan)
P 1.040
Validation of the Italian Non Motor Symptoms Questionnaire and Non Motor Symptoms Scale for
I. Cova, N. Vanacore, P. Contri, G. Meco, S. Pomati, G. Grande, E. Lacorte, A. Priori, C. Mariani (Italy)
P 1.041
Parkinson’s disease non-motor profile and MAPT haplotypes
M.E. Di Battista, A. Rubino, C. Papi, M. Valente, E. Pascale, C. Purcaro, G. Meco (Italy)
P 1.042
Sleep and mood predict quality of life change in Parkinson’s disease: a longitudinal study
K.M. Prakash, N. Nadkarni, W. Lye, M. Yong, E. Tan (Singapore)
P 1.043
Frequency and sleep stage sequence of SOREM periods in Parkinson’s disease
T. Murer, E. Werth, R. Poryazova, Y. Gavrilov, D. Waldvogel, C. Baumann, P. Valko (Switzerland)
P 1.044
REM sleep behavior disorder and cognitive functions in Parkinson’s disease
E. Lyashenko, O. Levin, M. Poluektov (Russia)
P 1.045
REM Sleep Behavior Disorder (RBD) as a predictor of development of daytime hypersomnia and
nocturia in Parkinson’s disease (PD)
M. Nodel, N. Yakhno, J. Ukraintseva (Russia)
P 1.046
Sleep and motor symptoms in Parkinson’s disease with REM sleep behavior disorder: a
preliminary study
K.H. Park, C. Kim, Y. Sung (South Korea)
P 1.047
Insomnia in Parkinson’s disease
P 1.048
Association between daytime sleepiness and the cholinergic ascending reticular activating system
in Parkinson’s disease
M. Iijima, M. Osawa, K. Kitagawa (Japan)
P 1.049
The painful dimension of Parkinson’s disease – relation between pain, depression and sleep
N. Horia, I. Serbanoiu, C. Panea (Romania)
P 1.034
47
48
P 1.050
The first Parkinson’s Disease Pain Questionnaire (King’s PD Pain Quest) – An interim analysis of a
multicentre study of the patient’s perspective
A. Rizos, P. Martinez-Martin*, S. Pal, C. Carroll, D. Martino, R. Sophia, C. Falup-Pecurariu**,
B. Kessel, A. Sauerbier, A. Martin, M. Parry, R. Inniss, L. Parkins, D. Trivedi, T. Chiwera,
P. Odin***, A. Antonini****, K.R. Chaudhuri
(United Kingdom, *Spain, **Romania, ***Sweden, ****Italy)
P 1.051
ON-OFF fluctuations predict the re-emergence of fatigue in Parkinson’s disease
T. Tamburini, D. Massucco, G. Abbruzzese (Italy)
P 1.052
Visuospatial, visuoconstructive and visuoperceptive functioning in patients with Parkinson`s
disease
M. Rodriguez-Violante, G. Arciniega-Martinez, A. Jorge De Sarachaga, Y. Rodriguez-Agudelo,
A. Cervantes-Arriaga, M. Chavez-Oliveros (Mexico)
P 1.054
The importance of Ishihara Testing in early diagnosing of Parkinson’s disease
S. Mirdedaev (Uzbekistan)
P 1.055
Somatization factor in Parkinson’s disease: a preliminary study
L. Bonanni, D. Carrozzini*, M. Fulchieri, M. Onofrj, S. Delli Pizzi, A. Thomas (Italy, *Denmark)
P 1.056
Autonomic disorders in Parkinson’s disease
J. Toshev, N. Nurmetov, O. Kurbanov, Z. Ibodullaev (Uzbekistan)
P 1.057
The ability of autonomic function tests to detect the possible deterioration of autonomic system in
PD patients - Preliminary results
A. Strasz, W. Niewiadomski, A. Gasiorowska, A. Karbowniczek, M. Zylinski, M. Skupinska,
G. Cybulski, E. Palasz, G. Niewiadomska (Poland)
P 1.058
Autonomic dysfunction in Parkinson’s disease associated with common glucocerebrosidase gene
mutations
F. Del Sorbo, A.E. Elia, L.M. Romito, P. Soliveri, C. Barzaghi, B. Garavaglia, P. Cortelli,
A. Albanese (Italy)
P 1.059
Orthostatic hypotension and cardiac sympathetic denervation in Parkinson disease patients with
REM sleep behavioral disorder
S.H. Lee, J.S. Kim (South Korea)
P 1.060
Longer duration of Parkinson’s disease is associated with reduced prevalence of hypertension
V. Brandi, D. Vetrano, M.S. Pisciotta, M.R. Lo Monaco, A. Laudisio, G. Onder, R. Bernabei,
G. Zuccalà (Italy)
P 1.061
Clinical course of migraine in Parkinson patients
M. Lotfinia (Iran)
P 1.062
Vegetative nervous system status according to cardiointervalogram data of ethnic Kyrgyz people
with Parkinson disease
N. Chekeeva (Kyrgyzstan)
Cardiac sympathetic denervation predicts levodopa-induced dyskinesia in patients with Parkinson’s
disease
S. Kang, J.Y. Ahn, H. Kim (South Korea)
P 1.064
Structural and functional myocardial abnormalities in patients with Parkinson’s disease compared
with control group: an echocardiography study
A. Gonzalez-Martinez, A. Lopez-Garcia, J. Piqueras-Flores, A. Moreno-Reig, J. Vaamonde-Gamo
(Spain)
P 1.065
Relationship S100 Protein levels in blood plasma with a frequency of occurrence of cardiovascular
complications Parkinson’s disease
P 1.067
Colonic volume and gastrointestinal symptoms in Parkinson’s disease
K. Knudsen, T. Fedorova, P. Borghammer (Denmark)
P 1.068
Gastroesophageal dysmotility in advanced Parkinson’s disease
F. Mancini, L. Manfredi, M. Lacerenza, C. Colombo, A. Bestetti (Italy)
P 1.069
Alpha-synuclein immunohistochemistry studies of gastrointestinal tissue from patients with
prodromal Parkinson’s disease
M. Gersel Stokholm, S.J. Hamilton-Dutoit, E.H. Danielsen, P. Borghammer (Denmark)
P 1.071
What can go wrong? Sexual dysfunction in Parkinson’s disease
I. Serbanoiu, H. Nicolae, C. Panea (Romania)
P 1.072
Pulmonary function and clinical characteristics of Parkinson’s disease
S. Cheon, M. Park, J.W. Kin (South Korea)
P 1.073
Character of respiratory disorders in Parkinson’s disease
J. Toshev, N. Nurmetov, O. Nurmetov, Z. Ibodullaev (Uzbekistan)
P 1.074
Dysphagia, pneumonia and hospital admissions in Parkinson’s Disease: a multicentre observational
study
E. Moti, K. Lauckaite*, R. Barreto, C. Bitsara, M. Grilo, S. Diaconu**, T. Chiwera, A. Rizos,
J. Johnson, S. Bostantjopoulou***, C. Falup-Pecurariu***, K. Ray Chaudhuri
(United Kingdom, *Lithuania, **Romania, ***Greece)
P 1.075
Speech disorders and Parkinson’s disease
M. Pettorino, E. Pellegrino, M.G. Busà (Italy)
P 1.076
Positional nystagmus from BPPV in polysomnography of PD patients
E. Werth, C. Baumann, D. Straumann, P. Valko, K. Weber, Y. Valko (Switzerland)
P 1.077
An alternative perspective on interpretation of the secondary motor symptoms of Parkinson’s
disease
L. Vucolova (USA)
P 1.078
An alternative perspective on interpretation of the cardinal motor symptoms of Parkinson’s disease
L. Vucolova (USA)
P 1.079
Prevalence of anxiety in Parkinson’s disease
K. Mengesha (Ethiopia)
P 1.063
49
50
P 1.080
Can arm swing be clinical predictors of postural instability in Parkinson’s disease?
W. Buated, P. Lolekha*, S. Hidaka, N. Kashyap, T. Fujinami (Japan, *Thailand)
P 1.081
Clinical predictors of postural instability in Parkinson’s disease: the Nintendo Wii Balance Board
Posturographic Study
P. Lolekha, W. Buated*, S. Hidaka*, N. Kashyap*, T. Fujinami* (Thailand, * Japan)
P 1.082
Postural instability detected by stabiloplatform examination in the patients with vascular mild
cognitive impairment and Parkinson’s disease patients with mild cognitive impairment
I. Miliukhina, T. Sergeev, A. Kudrevatykh, E. Gracheva, M. Didour (Russia)
P 1.083
Clinical and objective evaluation of turning in floor squares of various sizes in patients with
Parkinson’s disease and healthy controls
L. Stuhlinger, U. Fietzek, A. Plate, C. Hamann, K. Bötzel, A. Ceballos-Baumann (Germany)
P 1.084
Posturography evaluation and balance tests as potential markers of assessment of postural
disability progression in Parkinson’s disease patients after DBS STN implantation
S. Szlufik, M. Kloda, D. Koziorowski, I. Potrzebowska, J. Dutkiewicz, K. Gregier, T. Mandat,
A. Friedman (Poland)
P 1.085
Postural sensory correlates of gait freezing in Parkinson’s disease
Y.E. Huh, J. Youn, Y.S. Kim, M. Hwang, J.W. Cho (South Korea)
P 1.086
Alterations in the dynamic balance level in elderly with Parkinson´s disease
B. Mendez-Rial, J.M. Cancela Carral, C. Ayan, M.H. Vila (Spain)
P 1.087
Evaluation of spatiotemporal parameters in Parkinson’s disease and their correlation with UPDRS
motor score about 32 cases
D. Kadi, N. Ababou, S. Daoudi, M. Aderkichi (Algeria)
P 1.088
Using the “StartReact” paradigm to investigate postural instability in Parkinson’s disease
J. Tan, T. Perera, J. Mcginley, W. Thevathasan (Australia)
P 1.089
Timed up and Go and its application in older adults with Parkinson’s disease. Systematic review
I. Mollinedo-Cardalda, J.M. Cancela Carral, G. Rodriguez-Fuentes (Spain)
P 1.090
Factors influencing the falls in patients with Parkinson`s disease
N. Skripkina, O. Levin (Russia)
P 1.091
Falling direction is important predictors for mechanism of falls in patients with Parkinson’s disease
J. Youn, M. Hwang, D. Kim, J.W. Cho (South Korea)
P 1.092
Frequency and risk of falls in Parkinson’s disease in Ibadan
T. Farombi, M. Owolabi, A. Ogunniyi (Nigeria)
P 1.093
Falls in Parkinson’s disease: effects on health related quality of life
T. Farombi, J. Yaria, M. Owolabi, A. Ogunniyi (Nigeria)
P 1.094
A prospective study of cumulative incidence and course of RLS in de novo PD patients during
chronic dopaminergic therapy
S. Calzetti, E. Marchesi, M. Goldoni, A. Negrotti (Italy)
Semantic and phonemic verbal fluency in patients with Parkinson’s disease (PD)
A.D. Roesch, A. Meyer, K. Nowak, U. Gschwandtner, P. Fuhr (Switzerland)
P 1.096
Facial emotion recognition in Parkinson’s disease
S. Kalampokini, E. Lyros, M. Luley, J. Spiegel, M. Unger (Germany)
P 1.097
Emotion recognition and emotion expression in Parkinson’s disease: an unifying emotional mirror
mechanism?
L. Ricciardi, F. Visco-Comandini, R. Erro, F. Morgante*, M. Bologna*, A. Fasano**,
D. Ricciardi*, M. Edwards, J. Kilner (United Kingdom, *Italy, **Toronto - Canada)
P 1.098
Mentally and emotional disorders of Parkinson’s disease
K. Khasanova (Uzbekistan)
P 1.099
Behavioral and psychological symptoms in Korean patients with early Parkinson’s disease
J. Ahn, H. Kim, J. Heo (South Korea)
P 1.100
Prevalence of depression in Parkinson’s disease patients
A.M. Woldehana (Ethiopia)
P 1.101
Prevalence of depression and dementia in Parkinson’s disease
F. Yunusov, G. Rakhimbaeva (Uzbekistan)
P 1.102
Clinical correlates of depression and anxiety in patients with Parkinson’s disease
H. Hambardzumyan, H. Manvelyan (Armenia)
P 1.103
Suicidal ideation in Parkinson’s disease
M.M. Dumitru (Romania)
P 1.104
Is there any relationship between olfactory dysfunction and depression in Parkinson’s disease?
K. Hasegawa, H. Onuma, S. Nakamura, A. Kumon, E. Horiuchi (Japan)
P 1.105
Association of depressive symptoms with circadian blood pressure alterations in Parkinson’s
disease
M.S. Pisciotta, D.L. Vetrano, V. Brandi, M.R. Lo Monaco, A. Laudisio, D. Fusco, G. Onder,
R. Bernabei, G. Zuccalà (Italy)
P 1.106
Vascular risk factors and depressive symptoms in Parkinson’s disease dementia
M.H. Park, J.Y. Min (South Korea)
P 1.107
Clinical impact of mood disorders on non-motor symptoms in Parkinson’s disease
T. Shinoda, T. Maeda (Japan)
P 1.108
Parkinson’s disease and cognitive reserve
S. Guzzetti, A. Caporali, F. Mancini, L. Manfredi, R. Daini, A. Antonini (Italy)
P 1.109
Is cognitive function influenced to the self-assessment about the psychological symptom in PD?
A. Kumon, Y. Kobayashi, M. Saruwatari, N. Kawashima, K. Hasegawa (Japan)
P 1.110
Theory of the mind in subjects with Parkinson´s disease: a case-control study
G.G. Arciniega-Martinez, A. Jorge De Sarachaga, J.E. Simancas-Ruiz, M.S. Escobar-Barrios,
E.E. Carreon-Bautista, L.F. Balboa-Alegría, A. Cervantes-Arriaga, M. Rodriguez-Violante
(Mexico)
P 1.095
51
52
P 1.111
The heterogeneity of cognitive impairments in Parkinson’s disease
L. Alonso Recio, P. Martín Plasencia, J.M. Serrano Rodríguez (Spain)
P 1.112
Cognitive profile in non-demented GBA-carriers Parkinson’s disease patients
C. Siri, E. Reali, B. Pozzi, A. Colombo, R. Cilia, M. Canesi, C.B. Mariani, N. Meucci, G. Sacilotto,
S. Tesei, A.L. Zecchinelli, M. Zini, G. Pezzoli, S. Goldwurm (Milan)
P 1.113
Description of cognitive disorders of Alzheimer’s disease and Parkinson’s disease
D. Tolibov, G. Rakhimbaeva (Uzbekistan)
P 1.114
Cognitive disorders in Parkinsonism
S. Karakhonova, G. Ishanhodjaeva (Uzbekistan)
P 1.115
Cognitive impairment in Parkinson’s disease is associated with reduced cerebrovascular reactivity
A. Rubino, T. Romeo, M.E. Di Battista, M. Valente, C. Papi, P. Giacomini, G. Meco (Italy)
P 1.116
MoCA vs. MMSE sensitivity as screening instruments of cognitive impairment in PD, MSA and PSP
patients
E. Fiorenzato, L. Weis, C. Falup-Pecurariu*, A. Antonini, R. Biundo (Italy, *Romania)
P 1.117
Blood biomarkers associated with cognitive decline in early stage and drug-naive Parkinson’s
disease patients
J. Santiago, J. Potashkin (USA)
P 1.118
Visual Hallucination Inventory (VHI) and NMS Questionnaire (NMSQ) in identification and
characterisation of visual hallucinations (VH) in elderly patients with Parkinson’s disease (PD)
S. Gangadharan, G. Padmakumar, M. Rees, A. Johnson, A. Withanage, C.P. Padmakumar
(Australia)
P 1.119
Impact of gender on impulse control disorders and other non-motor symptoms among Parkinson’s
disease patients
N. Kovács, G. Deli, Z. Aschermann, A. Makkos, J. Janszky, M. Kovács (Hungary)
P 1.120
Pathological gambling in Parkinson’s disease patients: dopaminergic medication or personality
traits fault?
L. Brusa, V. Pavino, R. Ceravolo, M.C. Massimetti, A. Stefani, P. Stanzione (Italy)
P 1.121
Impulsive-compulsive behaviors in Parkin-associated Parkinson’s disease: a case-control study
F. Morgante, A. Fasano*, M. Ginevrino, S. Petrucci, L. Ricciardi**, F. Bove, C. Criscuolo,
M. Moccia, A.R. Bentivoglio, M.T. Pellecchia, G. Di Michele**, P. Barone, E.M. Valente
(Italy, *Canada, **United Kingdom)
P 1.122
Compulsive eating and olfaction in Parkinson’s disease
A. Gonçalves, A. Mendes, N. Vila-Chã, I. Moreira, J. Fernandes, J. Damásio, S. Cavaco (Portugal)
P 1.123
Effects of Parkinson’s disease on cognitive action control: insights on impulsive response
tendencies using an oclomotor Simon task
J. Duprez, J. Houvenaghel, S. Argaud, M. Vérin, P. Sauleau (France)
P 1.124
Sensory attenuation and Parkinson’s disease: a new pathophysiological framework of bradykinesia
A. Macerollo, J. Chen, P. Korlipara, T. Foltynie, J. Rothwell, M. Edwards, J. Kilner
(United Kingdom)
Fine motor function skills in patients with Parkinson’s disease (PD) with and without mild cognitive
impairment (MCI)
P. Dahdal, A. Meyer, M. Chaturvedi, K. Nowak, A.D. Roesch, U. Gschwandtner, P. Fuhr (Switzerland)
P 1.126
The relationship between impulse control disorders and dyskinesia in Parkinson’s disease: the
ALTHEA study
R.J. Vorovenci, L. Weiss, R. Biundo, A. Antonini (Italy)
P 1.130
Continuous monitoring of PD with an affordable novel computerised motor test based on a tablet
M. Da Lio, M. De Cecco, P. Bosetti, M. Malaguti (Italy)
P 1.131
N30 somatosensory evoked potential is negatively correlated with motor function in Parkinson’s disease
S.Y. Kang, H. Ma, H. Song, Y.H. Soh (South Korea)
P 1.132
Reconsidering diagnosis and prevalence of neuropathy in PD
A. Rubino, M.E. Di Battista, M. Valente, L. De Lipsis, G.O.R. Valente, G. Meco (Italy)
P 1.133
Methylmalonic acid is an important factor that cause peripheral neuropathy in Idiopathic
Parkinson`s disease
J.-S.Park, P.-W. Go, K. Kang, H.-W. Lee (South Korea)
P 1.134
A case series of coexisting Parkinson’s disease and epilepsy
A. Son, D. Kaminski, A. Gurevich, M. Biagioni, B. Stone, R. Gilbert, M. Nirenberg, A. Di Rocco (USA)
P 1.135
Parkinson’s disease with congenital porencephalia
M. Khanova, N. Tolibova, O. Turgunkhujaev, K. Maksudova (Uzbekistan)
P 2.001
Recognition of life-long curiosity in Parkinson’s disease treatment developments
P. Riederer (Germany)
P 2.002
Review of interventions to reduce hospitalisation in Parkinson’s disease
S. Muzerengi, C. Herd, C. Rick, C.E. Clarke (United Kingdom)
P 2.003
Does premorbid educational attainment modify motor compensation in Parkinson’s disease?
Y.H. Sohn, M.K. Sunwoo, P.H. Lee (South Korea)
P 2.004
Relationship between stay-at-home patients’ understanding of nformation regarding their
Parkinson’s disease and the burden of spouse caregivers
H. Takamoto, M. Hori (Japan)
P 2.005
Usefulness of the well being map for the follow-up of Parkinson’s disease patients
B. Schuller, Y. Zouitina, M. Lefranc, O. Godefroy, M. Tir, P. Krystkowiak (France)
P 2.006
Pilates method guidelines for physical therapy in patients with Parkinson’s disease
I. Mollinedo-Cardalda, J.M. Cancela Carral, G. Rodriguez-Fuentes (Spain)
P 2.007
Restoration of tensegrity equilibrium can lead to beneficial modification of Parkinson disease’s
motor symptoms
L. Vucolova (USA)
P 2.008
Impact of the whole body vibration training on the motor symptoms in Parkinson’s disease patients
A. Karbowniczek, W. Niewiadomski, A. Gasiorowska, A. Strasz, G. Cybulski, E. Palasz,
G. Niewiadomska (Poland)
P 1.125
53
54
P 2.009
Impact of the whole body vibration training on activity of daily living and quality of life in
Parkinson’s disease patients
A. Karbowniczek, W. Niewiadomski, A. Gasiorowska, A. Strasz, G. Cybulski, E. Palasz,
G. Niewiadomska (Poland)
P 2.010
Changes in maximum static force of knee extensors caused by prolonged whole body vibration
training in Parkinson’s disease patients
W. Niewiadomski, A. Strasz, A. Karbowniczek, A. Gasiorowska, M. Zylinski, K. Pariaszewska,
G. Cybulski, E. Palasz, G. Niewiadomska (Poland)
P 2.011
Cases of negative effect of chronic whole-body vibration on the dynamics of the flow and the quality
of life in patients with Parkinson’s disease
O. Turgunkhujaev, N. Tolibova, M. Khanova, R. Matmurodov, K. Khalimova (Uzbekistan)
P 2.012
Longitudinal study of the effect of a combined exercise program (land and water) on the physical
condition in elderly with Parkinson´s disease
B. Mendez-Rial, J.M. Cancela Carral, C. Ayan, M.H. Vila, M. Seijo (Spain)
P 2.013
The control of quiet stance in persons with Parkinson’s disease
C. Rigoldi, M. Galli, L. Mainardi, G. Guffanti, A. Maras, G. Riboldazzi (Italy)
P 2.014
Effects of trunk proprioceptive neuromuscular facilitation on dynamic balance, mobility and quality
of life in Parkinson’s disease
B.S. Sneha, S. Karthikbabu, N. Syed*, L.K. Prashanth (India, *Canada)
P 2.015
Use of three-dimensional gait analysis to assess the effectiveness of conventional rehabilitation
protocols in people with Parkinson’s disease
M. Pau, F. Corona, C. Casula, R. Pili, M. Murgia, M. Guicciardi (Italy)
P 2.016
A pilot study: evaluation of a tactile cueing device prototype for patients with Parkinson’s disease
R. Schweinfurther, M. Herold-Nadig, V. Klamroth-Marganska, S. Neumann, S. Brühlmann,
A. Menig, D. Zutter, J.C. Möller, M. Oechsner, R. Riener (Switzerland)
P 2.019
Center of pressure displacements during gait initiation in individuals with Parkinson’s disease
C. Rigoldi, M. Galli, A. Maras, G. Riboldazzi (Italy)
P 2.020
The worse is the clinical status of the patient with Parkinson, the higher is the stride length
percentage of improvement after automated mechanical peripheral stimulation
A. Kleiner, M. Galli, M. Gaglione, D. Hildebrand*, P. Sale, G. Albertini, F. Stocchi, M.F. De Pandis
(Italy, *Brazil)
P 2.021
Neurofeedback in Parkinson’s disease
S. Esmail, D. Linden (United Kingdom)
P 2.022
A pilot randomised controlled trial (RCT) of real-time fMRI neurofeedback and motor training for the
treatment of Parkinson’s disease (PD)
L. Subramanian, M. Busse, M. Brosnan*, D. Turner, H. Morris, D. Linden (United Kingdom, *Ireland)
P 2.023
Effects of virtual reality exercise program on balance in lower parkinsonism patients
G. Lee (South Korea)
Stress Reduction Training in PD Patients - Influence on neuropsychiatric symptoms?
A. Meyer, A. Hadinia, K. Nowak, U. Gschwandtner, P. Fuhr (Switzerland)
P 2.025
Cognitive Behavioral Group Therapy (CBT) for stress reduction in patients with Parkinson’s disease.
A randomized control trial
A. Hadinia, A. Meyer, K. Nowak, U. Gschwandtner, P. Fuhr (Switzerland)
P 2.026
Quality of life measured by PDQ39 and SEIQoL during anti-stress training for Parkinson’s disease
(PD) patients
K. Nowak, A. Meyer, M. Chaturvedi, A. Hadinia, U. Gschwandtner, P. Fuhr (Switzerland)
P 2.027
Cortisol measurements as a laboratory biomarker for stress reduction in Parkinson’s disease (PD)
patients
K. Nowak, A. Meyer, A. Hadinia, M. Chaturvedi, A.D. Roesch, U. Gschwandtner, P. Fuhr
(Switzerland)
P 2.028
Effects of cognitive loading on standing balance and postural stability in Parkinson’s disease
patients with freezing of gait
W. Buated, P. Lolekha*, T. Fujinami, S. Hidaka, N. Kashyap (Japan, *Thailand)
P 2.029
Learning rhythm: an innovative multifunctional neuro-rehabilitative method to improve cognitive
performances in Parkinson’s disease patients
S. Minella, S. Guzzetti, F. Mancini (Italy)
P 2.030
The potential of cognitive-behavioral intervention for anxiety in Parkinson’s disease
G.O. Reynolds, D.H. Barlow, A. Cronin-Golomb (USA)
P 2.031
Short and long term effect of cognitive rehabilitation in mild cognitive impairment subtypes in
M. Diez-Cirarda, N. Ojeda, J. Peña, O. Lucas-Jimenez, M.Á. Gómez-Beldarrain, J.C. GómezEsteban, N. Ibarretxe-Bilbao (Spain)
P 2.032
Treatment and diagnosis with the use of neuropsychological scale in patients with subcortical
parkinsonian dementia
N. Sokhibnazarov, F. Muratov (Uzbekistan)
P 2.033
Theatre is a valid complementary therapeutic interventions for emotional rehabilitation of
G. Mirabella, P. De Vita, S. Rampelli, F. Lena, F. Dilettuso, M. Iacopini, R. D’Avella,
M.C. Borghese, S. Mazzotta, D. Lanni, M. Grano, S. Lubrani, N. Modugno (Italy)
P 2.034
Beneficial role of voice inter-relating process and OM mantra enchanting in Parkinson’s disease
patients in south Delhi metro population
V. Sharma (India)
P 2.035
New opportunities for innovation and internet technologies in rehabilitation of patients with
Parkinson’s disease in the Aral Sea region of the Republic of Uzbekistan
G. Izyumova, D. Izyumov (Uzbekistan)
P 2.036
Zero non-motor symptoms in a martial arts’ expert
L. Jaffe (USA)
P 2.024
55
POSTER SESSION 2 - TUESDAY, 8 DECEMBER
56
P 2.037
Pharmaceutical design in Parkinson’s disease: what do patients prefer?
K. Lefteri, F. Liu, M. Brown (United Kingdom)
P 2.038
Effect of pharmacist-led interventions on motor symptoms in Parkinson’s patients: a pilot study
C. Stuijt, T. Van Laar (The Netherlands)
P 2.039
Unlocking Alzheimers and Parkinsonism - Do you dream for cure?
J. Joy (India)
P 2.040
Protective effects of superoxide dismutation activity in genetic models of Parkinson’s disease
A. Biosa, F. Roberta, V.K. Godena*, A. Sanchez-Martinez*, L. Bubacco, M. Beltramini,
A.J. Whitworth*, M. Bisaglia (Italy, *United Kingdom)
P 2.041
Randomized double-blind, placebo-controlled multi-center trial for determining efficacy of
molecular hydrogen water for Parkinson’s disease, baseline characteristics
A. Yoritaka, N. Hattori, The Hydrogen Water Parkinson Study Group (Japan)
P 2.042
Pharmacogenetics of levodopa: an algorithm for dose prediction
V. Altmann, M. Rieck, A. Schumacher-Schuh, S. Callegari-Jacques, C. de Mello Rieder, M. Hutz
(Brazil)
P 2.043
Gait analysis in Parkinson’s disease assessing the effect of levodopa using a validated electronic
walkway
B. Mondal, S. Choudhury, R. Banerjee, P. Chatterjee, M.U. Kulsum, S. Chatterjee, K. Chatterjee,
S. Sen, A. Ghoshal, S. Shubham, D. Naskar, S.S. Anand, H. Kumar (India)
P 2.044
Treatment with l-dopa normalize learning as measured with CVLT-2 in drug naive patients with
Parkinsons`disease
H.T.J. Sari, O.B. Tysnes, J.P. Larsen, A. Gramstad, G.O. Skeie (Norway)
P 2.045
Dopaminergic therapy: on a number of complications as increasing of libido in patients with
Parkinson’s disease and Parkinson’s syndrome
S. Mirdedaev (Uzbekistan)
P 2.046
Dyskinesia and L-dopa treatment
J. Nunomura, M. Tomiyama, C. Suzuki, A. Arai, H. Nishijima, R. Haga, T. Ueno, T. Kon,
Y. Funamizu (Japan)
P 2.047
Role of striatal projection neurons in the generation of L-DOPA-induced dyskinesia
C. Alcacer, I. Sebastianutto, T. Fieblinger, J. Jakobsson, A. Cenci (Sweden)
P 2.048
The effectiveness of amantadine and dopamine in the treatment of Guillain-Barre syndrome
M. Tadjenov, R. Sadikov, Y. Musaeva, S. Kuranbaeva (Uzbekistan)
P 2.049
Efficacy of rasagiline in PD patients with mild cognitive impairment
D. Weintraub, R.A. Hauser, M. Davis, A. Choudhry (USA)
P 2.050
Symptomatic efficacy of rasagiline in early PD: a meta-analysis
R.A. Hauser, R. Eliaz, E. Eyal, V. Abler, T. Schilling (USA)
H-3 receptor antagonist anD JNK-3 inhibitor: a new therapeutic approach to treat Parkinson’s
disease
N. Ambhore, S. Mohire, R.R. Kalidindi, S. Mulukutala, V. Murthy*, E. Kannan (India, *USA)
P 2.052
Motor effects of phosphodiesterase 9 inhibition in the non-human primate model of Parkinson’s
disease
G. Masilamoni, A. Singh, X. Tang, A. McRiner, L. Leventhal, S. Papa (USA)
P 2.053
Impact of current antipsychotic medications on comparative mortality and adverse events in people
with Parkinson’s disease psychosis (PDP)
R. Mills, C. Ballard*, S. Isaacson, H. Williams, A. Corbett*, B. Coate, R. Pahwa, O. Rascol**,
D. Burn* (USA, *United Kingdom, **France)
P 2.054
Parkinson’s disease with psychosis (PDP): role of 5-HT2A receptors
R. Horowski, P.-A. Loeschmann, P. Riederer (Germany)
P 2.055
Efficacy and tolerability of NUPLAZID™ (pimavanserin) in PD psychosis: analysis of an integrated
phase 3 placebo-controlled dataset
R. Mills, J. Friedman, W. Ondo, R. Pahwa, K. Black, K. Chi-Burris, H. Williams (USA)
P 2.056
Long-term effectiveness of NUPLAZID™ (pimavanserin) in PD psychosis: Data from 2 open-label
studies
R. Mills, S. Isaacson, J. Azulay*, J. Ferreira**, D. Kreitzman, T. Ilic***, K. Chi-Burris,
H. Williams (USA, *France, **Portugal, ***Serbia)
P 2.057
Antiparkinsonian medication adjustments following deep brain stimulation of subthalamic nucleus
in patients with advanced Parkinson’s disease
A. Gamaleya, E. Bril, A. Tomskiy, N. Gubareva, A. Poddubskaya, N. Fedorova, V. Shabalov
(Russia)
P 2.060
Onset and duration of motor effects with IPX066, levodopa-carbidopa extended-release capsules:
comparison with immediate-release levodopa-carbidopa and with levodopa-carbidopa+entacapone
S. Gupta, S. Khanna, R. Rubens, N. Modi (USA)
P 2.061
Outpatient levodopa-carbidopa intestinal gel titration in patients with advanced Parkinson’s disease
R. Rodriguez, M. Lobatz, J. Dubow, S. Eaton, C. Hall, K. Chatamra, J. Benesh (USA)
P 2.062
Evodopa-Carbidopa intestinal gel treatment in patients with < 10 years of Parkinson's disease:
GLORIA Registry interim results
A. Antonini, K.R. Chaudhuri*, L. Bergmann**, A. Yegin**, K. Onuk**, W. Poewe*** (Italy,
*United Kingdom, **USA, ***Austria)
P 2.063
The impact of levodopa-carbidopa intestinal gel on health-related quality of life in Parkinson’s
disease
N. Kovács, G. Deli, Z. Aschermann, P. Ács, A. Makkos, M. Kovács, J. Janszky, S. Komoly
(Hungary)
P 2.064
Effects of levodopa-carbidopa intestinal gel on non-motor symptoms and safety of outpatient
titration: a new phase 3 study in patients with advanced Parkinson’s disease
D. Standaert, J. Slevin, C. Hall, J. Dubow, S. Eaton, K. Chatamra, J. Benesh (USA)
P 2.051
57
58
P 2.065
Telemedicine facilitates efficient and safe home titration of Levodopa/Carbidopa Intestinal Gel
(LCIG) in patients with advanced Parkinson’s disease
T. Willows, N. Dizdar, D. Nyholm, H. Widner, K. Groth, J. Larsson, J. Permert, S. Kjellander
(Sweden)
P 2.066
Determination of minimal important difference thresholds for Parkinson’s Disease Questionnaire-39
in advanced Parkinson’s disease patients
A. Antonini, E. Dansie Bacci*, K. Sail*, Y.J. Jalundhwala*, P.L. Kandukuri*, T. Marshall*,
K. Chatamra*, I. Wiklund**, D. Revicki* (Italy, *USA, **United Kingdom)
P 2.067
Gastrointestinal safety of levodopa-carbidopa intestinal gel in advanced Parkinson’s disease
patients: GLORIA long-term registry interim results
D. Domagk, S. Dam-Larsen*, **A. Antonini, L. Bergmann***, A. Yegin***, W. Poewe****
(Germany, *Denmark, **Italy, ***USA, ****Austria)
P 2.068
Updated long-term safety from ongoing phase 3 trials of levodopa-carbidopa intestinal gel in
patients with advanced Parkinson’s disease
R. Rodriguez, N. Schmulewitz, D. Stein, W. Robieson, C. Hall, S. Eaton, K. Chatamra,
J. Benesh, A. Espay (USA)
P 2.069
Italian survey on intraduodenal levodopa gel treatment in advanced Parkinson disease: state of the
art 10 years after marketing
M. Sensi, G. Cossu, F. Mancini, N. Modugno, M. Pilleri, R. Quatrale, F. Tamma, M. Zibetti,
M. Aguggia, A. Antonini, L. Bartolomei, M. Amboni, D. Calandrella, M. Canesi, M.G. Ceravolo,
R. Ceravolo, P. Cortelli, R. Eleopra, E. Grassi, M. Guido, G. Gusmaroli, M. Coletti, P. Marano,
F. Morgante, C. Pacchetti, G. Riboldazzi, S. Rossi, A. Stefani, G. Meco, A. Tessitore, G. Fabbrini,
M.V. Saddi (Italy)
P 2.070
Comparison of the antiparkinsonian and antidyskinetic effects of hemantane and amantadine
E. Ivanova, I. Kapitsa, E. Valdman, T. Voronina (Russia)
P 2.071
Favourable effect of safinamide on mood over 2-year treatment of fluctuating Parkinson’s disease patients
C. Cattaneo, R. La Ferla, E. Müller*, M. Sardina (Italy, *Germany)
P 2.072
Post-hoc analysis of safinamide studies as add-on therapy to levodopa in mid- to late-stage
fluctuating Parkinson’s Disease patients
C. Cattaneo, R. La Ferla, E. Bonizzoni, M. Sardina (Italy)
P 2.073
Efficacy and safety of istradefylline for the treatment of non-motor symptoms and quality of life
(QOL) in patients with Parkinson’s disease
K. Abe, S. Kitamura, J. Ogura, M. Fujita, H. Yoshikawa (Japan)
P 2.075
Clinical characteristics of Parkinson’s disease patients responsive to Istradefylline treatment
T. Hazama, K. Fukada, Y. Mitani, M. Kinoshita, K. Takata, Y. Kokunai, J. Sawada (Japan)
P 2.076
Efficacy and safety of istradefylline for the treatment of non-motor symptoms and quality of life
(QOL) in patients with Parkinson’s disease and QOL in their caregivers
K. Abe, S. Kitamura, J. Ogura, M. Fujita, H. Yoshikawa (Japan)
One-year follow-up of opicapone’s efficacy and safety in patients with Parkinson’s disease and
motor fluctuations (BIPARK I)
J. Ferreira, A. Lees*, A. Santos, N. Lopes, J. Rocha, P. Soares-da-Silva (Portugal, *United Kingdom)
P 2.078
The 1-Metylxantine affinity for A2A adenosine receptors is similar to caffeine, theobromine,
theophylline and adenosine. The importance of xanthine core
L.C. Jimenez-Botello, R.B. Muñoz-Soto, I. Castilla De Cortazar Larrea, M. Garcia-Magariño
Alonso, M.A. Soriano-Ursua, J. Correa-Basurto (Mexico)
P 2.079
Meta-analysis: donepezil in the treatment of cognitive impairment & dementia in patients with
E. Barcelon, L. Shiong Shu, P.M. Pasco (Philippines)
P 2.080
Pooled efficacy of opicapone as adjunctive therapy to levodopa in patients with Parkinson’s disease
and motor fluctuations
J. Ferreira, A. Lees*, N. Lopes, A. Santos, J. Rocha, P. Soares-da-Silva (Portugal, *United Kingdom)
P 2.081
Pooled safety and tolerability of opicapone in the treatment of Parkinson’s disease and motor
fluctuations
A. Lees, J. Ferreira*, H. Gama*, C. Oliveira*, N. Lopes*, J. Rocha*, P. Soares-da-Silva*
(United Kingdom, *Portugal)
P 2.082
PANDA: prolonged release oxycodone/naloxone (OXN PR) for severe Parkinson’s disease (PD)related pain
K.R. Chaudhuri, P. Martinez-Martin*, O. Rascol**, M. Lomax, J. Decesare, M. Hopp***
(United Kingdom, *Spain, **France, ***Germany)
P 2.083
A study of real life tolerability of rotigotine transdermal patch in Parkinson’s disease across all
motor stages
R. Barreto, A. Sauerbier, A. Rizos, R. Chaudhuri (United Kingdom)
P 2.084
Rotigotine efficacy on sleep disturbances in Parkinson’s Disease patients: evidence from a
polysomnographic study
C. Liguori, M. Pierantozzi, F. Placidi, A. Stefani (Italy)
P 2.085
Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson’s disease: effects
on motor and non motor symptoms with brain metabolism correlations
M. Auffret, A. Maurus, M. Vérin, J. Houvenaghel, F. Le Jeune, S. Drapier (France)
P 2.086
Efficacy of sublingual apomorphine (APL-130277) for the treatment of OFF episodes in patients with
A. Agro, J. Dubow, B. Dzyngel, T. Bilbault, A. Giovinazzo, H. Shill*, R. Hauser* (Canada, *USA)
P 2.087
The effects of sublingual apomorphine (APL-130277) by disease severity on the acute reversal of
OFF episodes in Parkinson’s disease patients
P 2.088
Baseline disease severity not predictive of sublingual apomorphine (APL-130277) dose needed to
convert a PD patient from the OFF to ON state
P 2.077
59
60
P 2.089
Safety of sublingual apomorphine (APL-130277) for the treatment of OFF episodes in patients with
A. Agro, J. Dubow, B. Dzyngel, T. Bilbault, A. Giovinazzo, S. Isaacson* (Canada, *USA)
P 2.090
Minimum MDS-UPDRS part III change needed to convert a Parkinson’s disease patient from the OFF
to full ON state with sublingual apomorphine (APL-130277)
P 2.091
Differences between apomorphine (APO) and lisuride (LIS) in PD therapy
R. Horowski (Germany)
P 2.092
A multicenter epidemiological and clinical study on Deep Brain Stimulation (DBS) for Parkinson’s
disease: the pilot study
E. Scelzo, E. Beghi, M. Rosa, E. Bianchi, C. Pacchetti, A. Antonini, L. Romito, L. Lopiano,
N. Modugno, F. Tamma, A. Priori (Italy)
P 2.093
A comparison of deep brain stimulation and continuous intrajejunal levodopa infusion in advanced
Parkinson’s disease: The INVEST study
D. Van Poppelen, R.M. De Bie, J.M. Dijk (The Netherlands)
P 2.094
Multicenter experience of mixed deep brain stimulation implants for moviment disorders
F. Preda, C. Cavandoli, A. Antonini, R. Eleopra, M. Mondani, S. Sarubbo, A. Martinuzzi,
M. Pilleri, M. Cavallo, A. Landi, M. Sensi (Italy)
P 2.095
Effect of bilateral subthalamic DBS on gait in patients with idiopathic Parkinson’s disease
R. Borgohain, R.M. Kandada, V.P.V. Kagita, A.K. Puligopu, S.A. Jabeen, M.A. Kanikannan (India)
P 2.096
The effect of bilateral sub-thalamic nucleus deep brain stimulation (STN-DBS) on prosody of speech
F. Majdinasab, S.A.H. Habibi, E. Ghorbani, M. Khoddami (Iran)
P 2.097
The effect of deep brain stimulation of subthalamic nucleus on cognitive functions in Parkinson’s
disease - Pilot study
K. Potasz-Kulikowska, K. Kulikowski, A. Górecka-Mazur, W. Pietraszko, J. Polak,
A. Krygowska-Wajs (Poland)
P 2.098
The effect of subthalamic deep brain stimulation on ghrelin levels in Parkinson’s disease
A. Chrobak, A. Furgała, S. Jeziorko, G. Siwek, W. Pietraszko, M. Moskała, K. PotaszKulikowska, U. Fiszer, A. Krygowska-Wajs (Poland)
P 2.099
Can intraoperative clinical testing predict stimulation-induced effects of STN-DBS?
J. Blume, E. Rothenfußer-Korber, A. Janzen, U. Bogdahn, J. Schlaier, M. Lange (Germany)
P 2.100
Subthalamic deep brain stimulation in Parkinson’s disease: does the therapeutic range remain the
same in the absence of clinical intraoperative testing?
Y. Zouitina, M. Lefranc, A. Benoist, P. Merle, D. Montpellier, M. Roussel, J.M. Constans,
J.M. Macron, O. Godefroy, M. Tir, P. Krystkowiak (France)
P 2.101
Deep brain stimulation of STN for advanced Parkinson disease with octopolar leads: programming
electrical parameters guided for a neuroanatomical-3D-image software 12 months follow-up
G. Salazar (Spain)
The impact of microelectrode recording on selecting the most optimal trajectories for electrode implantation
P 2.103
Effect of high versus low frequency subthalamic nucleus deep brain stimulation in freezing of gait
S. Asaadi, Z. Gholizadeh Ghozloujeh, A. Zali, F. Ashrafi, R. Jalili Khoshnood (Iran)
P 2.104
Comparative study of microrecording-based STN location and MRI-based STN location
R. Verhagen, P.R. Schuurman, P. Van Den Munckhof, M.F. Contarino, R.M.A. De Bie, L.J. Bour
(The Netherlands)
P 2.105
Three new techniques for improving DBS therapy: what are we waiting for?
L. Bour, F. Contarino, S. Van Gils (The Netherlands)
P 2.106
Reflex saccades evaluation can estimate long-term symptom progression in DBS STN vs only
medically treated Parkinson’s disease patients
S. Szlufik, A. Przybyszewski, J. Dutkiewicz, P. Habela, T. Mandat, D. Koziorowski (Poland)
P 2.107
High frequency repetitive transcranial magnetic stimulation can improve the quality of life and
depression in Parkinson’s disease: a randomized, double-blind, placebo-controlled study
N. Kovács, G. Deli, Z. Aschermann, A. Makkos, M. Kovács, J. Janszky, E. Pál (Hungary)
P 2.108
The impact of STN DBS on kinetic tremor in Parkinson’s disease patients
S. Szlufik, M. Szumilas, J. Dutkiewicz, D. Koziorowski, T. Mandat, E. Slubowska (Poland)
P 2.109
Weight gain after subthalamic nucleus deep brain stimulation in PD: the role of electrodes position,
hormonal setting and clinical outcome
M. Fichera, D. Baroncini, R. Balestrino, A. Franzin, G. Comi, M.A. Volonté (Italy)
P 2.110
The three-dimensional motion analysis system as an useful tool in evaluation of gait disorders in
Parkinson’s disease patients treated with DBS STN
S. Szlufik, M. Stolarczyk, J. Dutkiewicz, A. Stolarczyk, T. Mandat, A. Friedman,
J.M. Deszczynski, D. Koziorowski (Poland)
P 2.111
Current status of the treatment with Deep Brain Stimulation (DBS) conducted in Ehime, Japan
H. Yabe, K. Tanaka, R. Ando, H. Iwaki, N. Nishikawa, M. Nagai, M. Nomoto (Japan)
P 2.112
The combined depletion of monoamines alters the effectiveness of subthalamic deep brain
stimulation
E. Faggiani, C. Delaville, A. Benazzouz (France)
P 2.113
Unilateral deep brain stimulation of subthalamic nuclei does not affect reactive inhibition in
G. Mirabella, G. Giannini, M. Fragola, M. Santilli, N. Modugno (Italy)
P 2.114
Impact of gait and balance training on advanced Parkinson’s disease patients after bilateral STN-DBS
V.P.V. Kagita, D.R. Borgohain, D.A. Kumar, D.R.M. Kandadai, S.A. Jabeen, M.A. Kanikannan
(India)
P 2.115
Is emotional prosody of speech affected by Quality of life and depression in bilateral sub-thalamic
nucleus deep brain stimulation (STN-DBS) of Parkinson’s disease?
F. Majdinasab, S.A.H. Habibi, E. Ghorbani, S.A. Khatoonabadi, S. Salehi (Iran)
P 2.102
61
62
P 2.116
Impulse control disorders in Parkinson’s disease and effect of bilateral STN DBS on them
R.M. Kandadai, R. Borgohain, S.A. Jabeen, M.A. Kanikannan, A.K. Pulligopu, V.V.P. Kagita (India)
P 2.117
Mortality of advanced Parkinson’s disease patients who received deep brain stimulation surgery
H. Ryu, M. Kim, S. You, M. Kim, Y.J. Kim, J. Kim, K. Kim, S.J. Chung (South Korea)
P 2.118
Infections related to deep brain stimulation in patients with Parkinson’s disease: clinical
characteristics and risk factors
M.S. Kim, J.S. Jeong, H. Ryu, S.J. Chung (South Korea)
P 2.119
Deep brain stimulation babies
E. Scelzo, J. Mehrkens*, K. Bötzel*, P. Krack, A. Mendes**, S. Chabardes, M. Polosan,
E. Seigneuret, E. Moro, V. Fraix (France, *Germany, **Portugal)
P 2.120
Photo-stimulating effect of low reactive level laser can improve overactive bladder in a patient with
Parkinson disease?
T. Uchiyama, T. Yamamoto, Y. Watanabe, T. Kadowaki, K. Suzuki, K. Hashimoto, K. Kaga,
C. Shibata-Yamaguchi, T. Yamanishi, R. Sakakibara, S. Kuwabara, K. Hirata (Japan)
P 2.121
A comparison study for the optimal stimulation site of high-frequency repetitive transcranial
magnetic stimulation in Parkinson’s disease
M. Yokoe, T. Maruo, K. Hosomi, T. Shimokawa, H. Kishima, S. Oshino, S. Morris, Y. Kageyama,
Y. Goto, T. Shimizu, H. Mochizuki, T. Yoshimine, Y. Saitoh (Japan)
P 2.122
Transcranial magnetic stimulation for rehabilitation of axial symptoms in Parkinson’s disease
M. Biagioni, S. Agarwa, K. Sticklor, G. Dacpano, A. Cucca*, A. Son, P. Kumar, D. Kaminski,
A. Gurevich, M. Brys, F. Battenberg, A. Quartarone, A. Di Rocco (USA, *Italy)
P 2.123
Adult neural progenitor cells auto transplantation in a non-human primate model of Parkinson’s
disease: a pre-clinical study
J. Cottet, S. Badoud, S. Borgognon, P. Chatagny, M. Fregosi, V. Moret, J. Bloch, J. Brunet,
E. Rouiller (Switzerland)
P 2.124
Differential induction of dyskinesia and inflammatory responses by intermittent versus continuous
L-DOPA delivery in the 6-OHDA model of Parkinson’s disease
A.R. Carta, G. Mulas, S. Spiga, D. Lecca E. Pillai (Italy)
P 2.125
Association of α-synuclein gene expression with Parkinson’s disease is attenuated with higher
serum urate in the PPMI cohort
M. Schwarzschild, K. Fitzgerald, R. Bakshi, E. Macklin, C. Scherzer, A. Ascherio (USA)
P 2.126
The experience of the Unit of Functional Neurosurgery - Hopital des Specialites Rabat - in the
surgical management of movements desorders
E. Hakkou, A. Melhaoui, Y. Arkha, W. Regragui, M. Jiddane, A. El Khamlichi, A. El Ouahabi
(Morocco)
P 3.001
Clinical and neuropathological features of rapid progressive dementia with lewy bodies
A. Geut, D. Hepp, A. Ingrassia, Y. Galis, E. Foncke, A. Lemstra, A. Rozemuller, W. Van De Berg
(The Netherlands)
P 3.002
Clinical usefulness of F18-FP-CIT PET/CT in possible dementia with Lewy bodies: preliminary study
J. Ahn, J. Heo, H. Kim (South Korea)
The association with cognitive function in Lewy body disease: The study of serum biomarkers
S. Nakashita, Y. Tajiri, K. Wada-Isoe, K. Nakashima (Japan)
P 3.004
Lysosomal enzyme activities in postmortem brain tissue of patients with Lewy Body disease
T. Moors, S. Paciotti*, A. Ingrassia, D. Chiasserini*, P. Eusebi*, L. Parnetti*, T. Beccari*,
W. Van De Berg (The Netherlands, *Italy)
P 3.005
The plasma level of alpha-synuclein in lysosomal storage diseases
P 3.006
Lewy body disease as pure autonomic failure with more than 20 years history: a post mortem study
K. Oiwa, Y. Hasegawa, K. Yasui, Y. Iwasaki, M. Yoshida, A. Takahashi (Japan)
P 3.007
Typical atypical or atypical atypical Parkinsonism?
S.T. Hirschbichler, R. Erro, M. Stamelou*, B. Balint, K. Bhatia (United Kingdom, *Greece)
P 3.008
Gastrointestinal symptom is a significant indicator of nigrostriatal dopaminergic degeneration in
idiopathic REM sleep behavior disorder patients
J. Lee, C.M. Shin, E.J. Yun, Y. Kim, B.S. Jeon (South Korea)
P 3.009
Case study of sporadic multiple system atrophy at a young age
P 3.010
The earliest finding of brain MRI in a case with the Parkinson variant of multiple system atrophy:
clinical usefulness of diffusion-weight imaging
K.Y. Kwon (South Korea)
P 3.011
Anatomical profile of cognitive impairment in MSA
E. Fiorenzato, R. Biundo, L. Weis, K. Seppi*, M. Onofrj, P. Cortelli, H. Kaufmann**,
F. Krismer*°, G. Wenning*, A. Antonini (Italy, *Austria, **USA)
P 3.012
Case report: multiple system atrophy C
L. Fazzi, P.R.J.P. Gianotti, J.R.T. Ponte Junior, I.F.D.S. Massaia, M.A.G.T. Silva, M.L. Gorzoni,
R.A.J. Ocha, W.L. Sanvito, B.G. Dutra (Brazil)
P 3.013
Cognitive function in multiple system atrophy-C (cerebellar type)
Y. Yang (South Korea)
P 3.014
Generation and characterization of iPSC-derived cortical pyramidal neurons from patients affected
by multiple system atrophy
G. Monzio Compagnoni, E. Frattini, S. Salani, F. Fortunato, N. Bresolin, G.P. Comi, S. Corti,
A. Di Fonzo (Italy)
P 3.015
Confocal laser microscopy and 3D reconstruction of Pick-like and ring-like inclusions in atypical
multiple system atrophy
B. Sikorska, G.G. Kovacs*, P.P. Liberski (Poland, *Austria)
P 3.016
Hyposmia in progressive supranuclear palsy
P 3.017
Diagnosis of progressive supranuclear palsy in a memory clinic setting
C. Nilsson, K. Tilderkvist, A. Santillo, M. Landqvist Waldö, K. Nilsson, D. Van Westen,
S. Vestberg, E. Englund (Sweden)
P 3.003
63
64
P 3.018
Japanese Longitudinal Biomarker Study in PSP and CBD (JALPAC): a prospective multicenter PSP/
CBD cohort study in Japan
H. Takigawa, T. Ikeuchi, I. Aiba, M. Morita, O. Onodera, T. Shimohata, T. Tokuda, S. Murayama,
K. Nakashima, JALPAC Study Group (Japan)
P 3.019
Progression of atrophy in brainstem structures for differentiation of progressive supranuclear
palsy–parkinsonism from Parkinson’s Disease
M. Hwang (South Korea)
P 3.020
Regional brain atrophy and cognitive impairment of pure akinesia with gait freezing
J.Y. Hong, H.J. Yun, M.K. Sunwoo, J.H. Ham, J. Lee, Y. Sohn, P.H. Lee (South Korea)
P 3.021
Corpus callosum volumetry as a tool to differentiate subtypes of progressive supranuclear palsy
A. Lenka, S.A. Pasha, S. Mangalore, K. Jhunjhunwala, R. Yadav, J. Saini, P.K. Pal (India)
P 3.022
Parkinson’s disease or symptomatic parkinsonism? Can they be combined?
A. Voskanyan, S. Khachaturyan*, K. Harutyunyan, G. Avagyan, E. Khachatryan, H. Amirjanyan,
I. Gabrielyan, H. Manvelyan (Armenia)
P 3.023
Whether the Parkinson’s disease develops in patients with chronic cerebral ischemia?
D. Izyumov, G. Izyumova (Uzbekistan)
P 3.024
Comparative analysis of cognitive and affective disorders at vascular parinsonism and Parkinson’s
disease
S. Djalilova, Z. Ibodullayev, A. Mamadaliyev, D. Abdullayeva (Uzbekistan)
P 3.025
Vascular parkinsonism as a common manifestation of second stage of CADASIL syndrome
P 3.026
Neuroophthalmic disorders in children with cerebral palsy
I. Abdukadirova, Y. Madjidova (Uzbekistan)
P 3.027
Did Charcot have vascular parkinsonism?
H. Teive, F.M. Branco Germiniani, R. Puppi Munhoz* (Brazil, * Canada)
P 3.028
Movement disorders after stroke in third level hospital Marrakech morocco
A. Chahidi, M. Chraa*, N. Kissani* (France, *Morocco)
P 3.030
Use of the drug choline ALFOSTSERAT in combined treatment of vascular Parkinsonism
O. Kurbanov, N. Nurmetov, Z. Ibodullaev, D. Abdullaeva (Uzbekistan)
P 3.031
Analysis of the effectiveness of CEA and evaluation of factors affecting its long-term results
M. Ataniyazov, G. Rakhimbaeva (Uzbekistan)
P 3.032
Effect of rhythmic auditory stimulation on gait in patients with stroke
M. Fouad, G. Mousa (Egypt)
P 3.033
Acute parkinsonism as a predominant sign of neuroleptic malignant syndrome in a patient with
schizophrenia
P. Koprivnik (Slovenia)
P 3.035
Parkinsonism in acute hepatic encephalopathy: Experimental evidence in rat
O. El Hiba, A. Abbaoui, H. Gamrani (Morocco)
Parkinsonism in patient diagnosed as multiple sclerosis-case report
N. Khizanishvili, M. Beridze, M. Mdivani, E. Devidze, L. Shanidze, N. Kvirkvelia (Georgia)
P 3.037
Implication of CD4 in progression of Parkinsonian syndrome on patients with lupus erythematosus
S. Bebitov, K. Mirzaeva, G. Rakhimbaeva (Uzbekistan)
P 3.038
Enteric fever presenting as catatonia and parkinsonism: an unusual presentation
S.K. Jaiswal (India)
P 3.039
Predictive value of [123I]FP-CIT-SPECT on surgical outcome in idiopathic adult chronic
hydrocephalus: a pilot study
C. Del Gamba, F. Aquila, P. Perrini, D. Volterrani, U. Bonuccelli, N. Benedetto, R. Ceravolo (Italy)
P 3.040
Impulse control disorders and punding in Perry syndrome
T. Mishima, S. Fujioka, R. Kurisaki, S. Yanamoto, M. Higuchi, J. Tsugawa, J. Fukae, R. Neshige,
Y. Tsuboi (Japan)
P 3.042
Parkinsonism and central nervous system disease among lead exposed workers
Y. Ahn (South Korea)
P 3.043
Pesticide exposure and parkinsonism: a systematic review and meta-analysis
M. Chondrogiorgi, I. Tzoulaki, E. Evangelou, G. Ntritsos, X. Tseretopoulou, M. Pappa,
S. Konitsiotis, E. Ntzani (Greece)
P 3.044
Neurotoxic alterations in pesticide exposed population: a preliminary study
R.S. Yadav (India)
P 3.045
The role of the motor cortex in essential tremor
S. Sharifi, F. Luft, T. Heida, W. Mugge, A. Schouten, L. Bour, A. Van Rootselaar (The Netherlands)
P 3.046
Development of a wireless sensor for tremors analysis
D. Alimonti, P. Locatelli, M. Caldara, V. Re (Italy)
P 3.047
Spike shape analysis of electromyography for parkinsonian tremor evaluation
J. Marusiak, R. Andrzejewska, D. wiercz, K. Kisiel-Sajewicz, A. Jaskólska, A. Jaskólski (Poland)
P 3.048
Unrevealing the diagnoses of a sample of cases with hard-to-classify tremor and normal DaT-SPECT
M. Menendez-Gonzalez, T. Alvarez-Avellon, A. López-Muñiz, J. Vega Álvarez (Spain)
P 3.049
Research on neuropsychiatric symptoms in patients with essential tremor and Parkinson’s disease
in Latvian population
L. Smeltere, V. Kuznecovs, R. Smelters (Latvia)
P 3.050
Transcranial direct current stimulation in the treatment of essential tremor
N. Helvaci Yilmaz, B. Polat, L. Hanoglu (Turkey)
Impact of an interdisciplinary deep brain stimulation screening model on post-surgical
complications in essential tremor patients
M. Higuchi, M. Okun, Y. Tsuboi (Japan)
P 3.051
P 3.052
P 3.036
Centrifugal progression of TDP-43 pathology along olfactory pathway in ALS patients in contrast to
centripetal progression of alpha-synuclein pathology in PD patients
T. Takeda, M. Iijima, T. Uchihara, C. Duyckaerts, S. Uchiyama, K. Kitagawa (Japan)
65
66
P 3.053
Clinical profile of Filipino patients with amyotrophic lateral sclerosis seen in a tertiary hospital:
a 5 year-retrospective study
M.A.K.D. Moll, J.P. Reyes (Philippines)
P 3.054
Myokymia revealing multiple sclerosis
H. Tibar, E. Ait Benhaddou, W. Regragui, A. Benomar, M. Yahyaoui, N. Birouk, M. Jiddane
(Morocco)
P 3.055
Pathogenetic mechanisms myoclonic hyperkinesia
O. Kurbanov, N. Nurmetov, Z. Ibodullaev, D. Abdullaeva (Uzbekistan)
P 3.056
Restless legs syndrome presenting as acute form in a patient with Guillain-Barre syndrome
M. Ozmenoglu, V.A. Cakmak, N. Usta, S. Gazioglu (Turkey)
P 3.057
Analysis of weight and BMI among patients with Huntington’s disease
N. Szejko, L. Milanowski, A. Gogol, Z. Jamrozik, P. Janik (Poland)
P 3.059
Hyperkinesia in ancient China: perspectives and prescriptions
J. Liu, L. Wang (China)
P 3.060
Cortical and subcortical neurodegeneration in chorea-acanthocytosis and Huntington’s disease:
more differences than similarities
J. Liu, H. Heinsen*, T. Arzberger*, B. Bader*, C. Schmitz*, M. Kiessling*, A. Danek*
(China, *Germany)
P 3.062
The rise, the fall and the revival of hyperglycemic hemichorea
D. Lee, T. Ahn (South Korea)
P 3.063
Inhaled steroid induced hemichorea-hemiballism
H.J. Kim, H.J. Kang, S. Han (South Korea)
P 3.064
Reversible hemichorea-hemiballism associated with post-thrombolysis reperfusion
H.J. Kim, J.H. Jin, H. Roh, H.J. Kang, H.Y. Kim (South Korea)
P 3.065
Tardive dyskinesia after long-term treatment with topical Prostoglandin F2α analog (latanoprost)
B. Bulut, D. Ince Gunal, K. Agan Yildirim (Turkey)
P 3.066
Neuroleptic Induced Dyskinesia or…?
K. Harutyunyan, I. Gabrielyan, H. Amirjanyan, S. Khachaturyan, G. Avagyan, A. Nazaryan,
A. Voskanyan, H. Manvelyan (Armenia)
P 3.067
Novel GNAL mutation with intra-familial clinical heterogeneity: expanding the phenotype
M. Carecchio, C. Panteghini, C. Reale, C. Barzaghi, V. Monti, L. Romito, F. Sasanelli,
B. Garavaglia (Italy)
P 3.068
Health-related quality of life in primary and secondary dystonia after pallidal deep brain stimulation
P 3.069
DYT16/PRKRA founder mutation causes childhood-onset generalized dystonia in a family from
Southern Italy
M. Quadri, S. Olgiati, M. Sensi*, F. Gualandi*, E. Groppo*, V. Rispoli*, J. Graafland,
G.J. Breedveld, G. Fabbrini*, V. Bonifati (The Netherlands, *Italy)
Affected side is a prognostic factor in typist’s cramp
S.Y. Kang, S.K. Song, J.Y. Hong, J.H. Ham, S.J. Kim, H. Song, P.H. Lee, Y.H. Sohn (South Korea)
P 3.071
A questionnaire survey of musician’s dystonia performed in a music college
K. Konaka, M. Mihara, H. Mochizuki (Japan)
P 3.072
Bias of visuo-spatial attention in cervical dystonia
G. Chillemi, A. Calamuneri, F. Morgante, C. Terranova, V. Rizzo, P. Girlanda, A. Quartarone (Italy)
P 3.073
Frequency of the pain and sleep problems at dystonia patients and influence of deep brain
stimulation
V. Vuletic (Croatia)
P 3.074
A case of hemifacial spasm in young adult
I. Gabrielyan, K. Harutyunyan, H. Amirjanyan, G. Avagyan, H. Hambardzumyan,
S. Khachaturyan, A. Nazaryan, H. Manvelyan (Armenia)
P 3.075
Atypical presentation of psychogenic movement disorder with jaw-opening dystonia: two cases
reports
W.T. Yoon (South Korea)
P 3.076
Tobacco increases dystonia risk but may ameliorate symptoms
C. Hellberg, A. Puschmann (Sweden)
P 3.077
A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for
blepharospasm
D. Truong, J. Fezza, J. Burns, J. Woodward, T. Hedges, A. Verma (USA)
P 3.078
Therapeutic assessment of botulinum toxin in the treatment of hemifacial spasm
H. Teive, J.P. Batisti, N. Galli, A.D. Kleinfelder (Brazil)
P 3.079
Acute allergic reaction following injection of generic, government-provided botulinum toxin A (GGPBTA) for hemifacial spasm
H. Teive, F.M. Branco Germiniani, R.H. Scola, R.N. Brito, G. Ribas, L. Fiuza Parolin, V. Scavasine,
M. Canever, C.M. Borges, K.F. Miska Thölken, S. Zuneda Serafini (Brazil)
P 3.080
Zolpidem in movement disorder after cardiac arrest
H. Teive, W. Arruda, M. Silva, D. Bertholdo (Brazil)
P 3.081
Paradoxical effect of a high frequency stimulation protocol on temporal discrimination in dystonic
patients
R. Erro, M. Tinazzi, J. Rothwell, K.P. Bhatia (United Kingdom)
P 3.082
Dopaminergic medicines are drugs of choice for medicament-resistant facial nerve neuropathy
A. Azimov, R. Sadykov, S. Dadajonov, O. Azizova, R. Ismoilov (Uzbekistan)
P 3.083
Dopaminergic medicines are drugs of choice for medicament-resistant facial nerve neuropathy:
EMG study
A. Azimov, R. Sadykov, S. Dadajonov, O. Azizova, R. Ismoilov, E. Giyazitdinova (Uzbekistan)
P 3.084
Late onset Wilson’s disease with central pontine and extrapontine MRI changes
T. Biller, G. Fatterpekar, M. Nirenberg, M. Brys (USA)
P 3.070
67
68
P 3.085
Wilson disease: acute dystonia during treatment with SSRI or SNRI
L. Wictor, K. Wictorin, H. Widner, A. Puschmann (Sweden)
P 3.086
A clinicoradiologic study of hypertrophic olivary degeneration
T. Konno, A. Strongosky, D. Broderick, Z.K. Wszolek (USA)
P 3.087
Interoceptive awareness in patients with functional motor disorders
B. Demartini, L. Ricciardi*, L. Crucianelli*, C. Krahé*, M.J. Edwards*, A. Photopoulou*
(Italy, *United Kingdom)
P 3.088
The distribution and progression pattern of adult onset cerebellar ataxias: hospital based study
J.S. Kim, J. Cho, J.E. Yoon, J. Youn (South Korea)
P 3.089
Idiopathic very late-onset cerebellar ataxia: a Brazilian case series
H. Teive, A. Moro, M. Moscovich, W. Arruda, R. Munhoz (Brazil)
P 3.090
Anthropometric profile of patients with Spinocerebellar Ataxia
H. Teive, C. Leite, D. Macedo, M.E. Schieferdecker, R. Vilela, A. Moro (Brazil)
P 3.091
Anthropometric equations to assess muscle mass in patients with spinocerebellar ataxia
H. Teive, D. Macedo, C. Leite, M.E. Schieferdecker, R. Vilela, A. Moro, C. Taconeli (Brazil)
P 3.092
Estimation of skeletal muscle mass in patients with spinocerebellar ataxia
H. Teive, C. Leite, D. Macedo, M.E. Schieferdecker, R. Vilela, A. Moro (Brazil)
P 3.093
Comparison of Non-motors symptoms in patients with Spinocerebellar ataxia type 10 and type 3
A. Moro, M. Moscovich, M. Farah, R. Munhoz, W. Arruda, S. Raskin, T. Ashizawa, H. Teive (Brazil)
P 3.094
Sleep architecture observed in the patients with SCA 10
E. London, A.C. Crippa, M. Moscovich, T. Ashizawa, H. Teive (Brazil)
P 3.095
Center of pressure velocity and its fast alternating deviations as an objective measure of balance –
Normal values and their sensitivity investigated in SCA patients
A. Sobanska, M. Rakowicz, L. Czerwosz, A. Sulek, I. Stepniak, R. Rola (Poland)
P 3.096
The importance of the vestibular evaluation in the body balance prognosis and therapy in
spinocerebellar ataxia
B.S. Zeigelboim, H.A.G. Teive, J.H. Faryniuk, G. Santos, M.I. Severiano, V.R. Fonseca (Brazil)
P 3.097
Otoneurological findings prevalent in hereditary ataxias
B.S. Zeigelboim, H.A.G. Teive, G. Santos, M.I. Severiano, V.R. Fonseca, J.H. Faryniuk (Brazil)
P 3.098
Labyrinth diseases in autosomal recessive ataxia
B.S. Zeigelboim, H.A.G. Teive, G. Santos, M.I. Severiano, E. Abdulmassih, J.H. Faryniuk (Brazil)
P 3.099
Non-invasive biomarkers for spinocerebellar ataxias, types 2 &12 patients and their correlation with
cerebellar degeneration
R.R. Moganty, V. Swarup, A.K. Srivastava, M.V. Padma (India)
P 3.100
Clinical profile of hundred patients with Ataxia Telangiectasia from India
M. Mahadevappa, D.V. Santhosh, M. Netravathi, R. Yadav, P.K. Pal (India)
P 3.101
Burden of mitochondrial DNA variations in Friedreich’s Ataxia (FRDA) patients and sharing of
mitochondrial lineage with Caucasians
I. singh, S. Sakhya, M. Behari, M.V.P. Srivastava, G. Shukla, V. Goyal, A.K. Srivastava, M. Faruq
(India)
P 3.102
Distal hereditary motor neuropathy with HSJ1 chaperone mutation, presenting with peripheral
motor neuropathy, associated to parkinsonism, and cerebellar ataxia. Case report
H. Teive, F. Kok, S. Raskin, W. Arruda (Brazil)
POSTER SESSION 3 - WEDNESDAY, 9 DECEMBER
69
70
P 3.103
Sporadic progressive ataxia with palatal tremor
S. Agarwal, A. Son, J. Rucker, M. Brys (USA)
P 3.104
HMG-CoA Reductase Inhibitors-induced cerebellar ataxia. A Brazilian case series
A. Moro, M. Moscovich, W. Arruda, R. Munhoz, H. Teive (Brazil)
P 3.105
Comparison of gait and cognitive function in the elderly with Alzheimer’s disease dementia, mild
cognitive impairment and normal control
S.W. Moon (South Korea)
P 3.106
Movement disorders in Ethiopia
S. Belay (Ethiopia)
P 3.107
The role and significance of neuron specific protein S100B at extrapyramidal disorders
P 4.002
Transcranial B-mode sonography in Parkinson’s disease and parkinsonism: our experience on 403
patients
M. Ravagnani, K. Savio, P. Pastorello, D. Barbagli, M. Mongiovetti, G. Gusmaroli (Italy)
P 4.003
Altered functional topography of the striatum in resting state FMRI in Parkinson’s disease
S.N. Tan, Y. Zhang, A. Liu, J. Wang, M.J. Mckeown (Canada)
P 4.004
Is the mechanism of nervous cells death in Parkinson different than in other neurodegenerations –
Arguments from MRI study?
A. Friedman, R. Kulinski, J. Galazka-Friedman (Poland)
P 4.005
Volumetry of the olfactory bulbs and tracts in the differential diagnosis of Parkinson’s disease from
parkinsonisms
M. Menendez-Gonzalez, A. López-Muñiz, J. Vega Álvarez (Spain)
P 4.006
Apathy is associated to altered resting-state functional connectivity and structural changes in
O. Lucas-Jiménez, N. Ojeda, J. Peña, M. Díez-Cirarda, A. Cabrera, J.C. Gómez-Esteban,
M. Gómez-Beldarrain, N. Ibarretxe-Bilbao (Spain)
P 4.007
Structural changes in basal ganglia-thalamocortical circuits in Parkinson’s disease with cognitive
impairment
A. Son, M. Biagioni, S. Agarwal, Y. Li, M. Brys, A. Di Rocco, J. Galvin (USA)
P 4.008
Magnetic resonance characteristic of Parkinson’s disease based on the presence of cognitive
impairments
N. Okiljonova, Y. Madjidova (Uzbekistan)
P 4.009
White matter changes associated with cognitive impairment in Parkinson’s disease
M. Chondrogiorgi, L. Astrakas, A. Zikou, M. Argyropoulou, S. Konitsiotis (Greece)
P 4.010
Putaminal diffusivity changes correlates with motor progression in Parkinson’s disease on 6-year
follow-up
L.L. Chan, K.M. Ng, C.S. Yeoh, H.H. Li, H. Rumpel, E.K. Tan (Singapore)
Magnetic resonance characteristic of Parkinson’s disease based on the presence of cognitive
impairment
D. Farangis Bonu (Uzbekistan)
P 4.012
The 2D-Medial Temporal lobe Atrophy (2D-MTA) correlates with memory in Parkinson’s disease
T. Alvarez Avellón, M. Menendez Gonzalez, F. Cuetos Vega, R. Ribacoba Montero (Spain)
P 4.013
Changes of cerebral morphometry in patients with cerebrovascular and Parkinson’s diseases
R. Bogdanov, S. Borisova, S. Kotov, G. Stashuk (Russia)
P 4.014
Abnormal white matter integrity in elderly patients with idiopathic normal-pressure hydrocephalus:
a tract-based spatial statistics study
K. Kang, H. Lee, W. Choi, U. Yoon, J. Lee (South Korea)
P 4.015
Exploring the grey matter correlates of Wilson’s disease using voxel based morphometry
A.S. Sunny, L. George, K.R. Jhunjhunwala, A. Lenka, J. Saini, M. Netravathi, P.K. Pal (India)
P 4.016
Arterial spin labeling (ASL) may be useful for diagnosing existence of dementia in Parkinson’s
disease
K. Abe, T. Yamamoto, M. Yamamoto, N. Akiyama, M. Fujita (Japan)
P 4.017
Predictors of normal and abnormal outcome in clinical brain dopamine transporter imaging
E. Jaakkola, J. Joutsa, V. Kaasinen (Finland)
P 4.018
Iodine-123-FP-CIT SPECT in familial parkinsonism
S. Onuma, K. Hasegawa, S. Nakamura, E. Horiuchi (Japan)
P 4.019
Dopaminergic dysfunction and cognitive impairment in Parkinson’s disease: evidence from a SPECT
study in a large cohort of de-novo patients
D. Frosini, M. Giuntini, C. Pagni, E. Del Prete, G. Tognoni, D. Volterrani, U. Bonuccelli,
R. Ceravolo (Italy)
P 4.020
Fatigue in Parkinson’s disease and striatum dopamine transporter scan (DaTscan) uptake
A. Sauerbier, P. Martinez-Martin*, M. Politis, A. Rizos, N. Trojanovic, N. Mulholland, G. Vivian,
B. Corcoran, D. Trivedi, L. Perkins, R. Inniss, T. Chiwera, R. Barreto, M. Parry, A. Martin,
N. Dimitrov, R. Brown, K. Ray Chaudhuri (United Kingdom, *Spain)
P 4.021
The MIBG scintigraphy and DAT SPECT contribute to the diagnosis of PD and other related disorders,
and evaluations of the course and stage of PD
S. Tada, R. Ando, H. Iwaki, T. Tsujii, Y. Yabe, N. Nishikawa, M. Nagai, M. Nomoto (Japan)
P 4.022
Characteristic metabolic brain pattern in Slovenian Parkinson’s disease patients
P. Tomse, R. Tomaz, Z. Pirtošek , Y. Ma*, D. Eidelberg*, M. Trost (Slovenia, *USA)
P 4.023
Features neuroimaging and neurological disorders in Alzheimer’s disease with parkinsonism
D. Tolibov, G. Rakhimbaeva (Uzbekistan)
P 4.025
Can Quantitative EEG (QEEG) differentiate patients with Parkinson’s disease (PD) from healthy
controls?
M. Chaturvedi, F. Hatz, A. Meyer, V. Cozac, U. Gschwandtner, V. Roth, P. Fuhr
P 4.011
71
72
P 4.026
Synaptic homeostasis in Parkinson’s disease: an high-density EEG study in different stage of the
disease
V. Trendafilov, S. Sarasso*, J. Moeller, C. Staedler, A. Kaelin-Lang, S. Galati (Switzerland, *Italy)
P 4.027
Nigrostriatal dopamine-independent resting-state functional networks in Parkinson’s disease
P.H. Lee, J.S. Baik, Y.H. Sohn (South Korea)
P 4.028
Brain network changes in relation to beginning apathy in PD patients
F. Hatz, A. Meyer, U. Gschwandtner, P. Fuhr (Switzerland)
P 4.029
Functional connectivity underpinnings of fatigue in “drug-naïve” patients with Parkinson’s disease
A. Giordano, A. Tessitore, R. De Micco, G. Caiazzo, A. Russo, M. Cirillo, F. Esposito, G. Tedeschi
(Italy)
P 4.030
Classification of early stage Parkinson’s disease in EEG and tremor time-frequency features space
O. Sushkova, Y. Obukhov, I. Kershner, A. Karabanov, A. Gabova (Russia)
P 4.031
Correlation of the EEG frequency with cognitive performance in Parkinson’s disease - Six-months
follow-up
V. Cozac, M. Chaturvedi, F. Hatz, A. Meyer, K. Nowak, U. Gschwandtner, P. Fuhr (Switzerland)
P 4.032
Alertness as assessed by clinical testing and alpha reactivity does not correlate with executive
function decline in Parkinson’s disease (PD)
R. Sturzenegger, A. Meyer, M. Chaturvedi, V. Cozac, F. Hatz, U. Gschwandtner, P. Fuhr
(Switzerland)
P 4.033
EEG features of dyskinesias, complicated by levodopa therapy in patient with Parkinson’s disease
U. Askhonov, B. Gafurov, G. Ashanov (Uzbekistan)
P 4.034
Polysomnographic features of REM sleep behavior disorder with or without Parkinson’s disease
C. Ha, E. Bae (South Korea)
P 4.035
Electromyographic diagnostics of Parkinson’s disease and detection risk groups among relatives of
patients
D. Ayupova (Uzbekistan)
P 4.036
Identification of the globus pallidus interna based on time patterns analysis in Parkinson’s disease
D.S. Andres, C. Daniel*, M. Merello* (Switzerland, *Argentina)
P 5.001
Mayo Clinic Florida Morris K. Udall. Center of excellence for Parkinson’s research
A. Strongosky, R. Rademakers, O. Ross, R. Uitti, J. Van Gerpen, Z.K. Wszolek, D. Dickson (USA)
P 5.002
Epigenetics role in Parkinson’s disease
M. Dehbashi, M. Rouigari (Iran)
P 5.003
Identification of novel PD genes by whole-exome sequencing in Italian families
L. Straniero, G. Soldà, R. Asselta, I. Guella*, G. Pezzoli, M. Farrer*, S. Goldwurm, S. Duga
(Italy, *Canada)
P 5.004
Antioxidant kinase inhibitors for LRRK2 Parkinson’s disease
P. Sharan, D.C. Angeles, P. Ho, B.W. Dymock, K. Lim, E. Tan (Singapore)
LRRK2 and GBA mutation analysis in a cohort of Italian familial and sporadic PD
I. Trezzi, V. Melzi, G. Franco, L. Borellini, E. Monfrini, N. Bresolin, G.P. Comi, A. Di Fonzo (Italy)
P 5.007
I2020T LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation
through the AKT/GSK-3beta signaling pathway
E. Ohta, T. Nihira, A. Uchino, Y. Imaizumi, Y. Okada, W. Akamatsu, K. Takahashi, M. Nagai,
M. Ohyama, M. Ryo, M. Ogino, S. Murayama, A. Takashima, K. Nishiyama, Y. Mizuno,
H. Mochizuki, F. Obata, H. Okano (Japan)
P 5.008
Neuropsychological assessment in patients with Parkinson’s disease associated with PARK2 gene
mutations: a case-control study
P. Amami, C. Bagella, A. Elia, C. Barzaghi, B. Garavaglia, A. Albanese (Italy)
P 5.010
Cytogenetic study and compared with measurements of oxidative stress and PINK1 gene in
Parkinson’s disease (PD) patients
J. Pichai Fenn, D. Shanwaz, S. Keshavarao, B. Vellingiri (India)
P 5.011
DNAJC6 mutations associated with early-onset Parkinson’s disease
S. Olgiati, M. Quadri, M. Fang, J.P. Rood, J.A. Saute*, H.F. Chien*, C.G. Bouwkamp,
J. Graafland, M. Minneboo, G.J. Breedveld, J. Zhang***, F.W. Verheijen, W. Mandemakers,
A.J. Boon, A.J. Kievit, L.B. Jardim*, E.R. Barbosa*, C.R. Rieder*, K.L. Leenders, J. Wang**,
V. Bonifati (The Netherlands, *Brazil, **China)
P 5.012
Novel compound heterozygous mutations of PLA2G6 in a Korean pedigree of young-onset
Parkinson’s disease: a study of whole genome sequencing
E.J. Choi, W. Lee, J. Shin, J. Seo, C.S. Lee (South Korea)
P 5.013
Evaluation of genetic load in early-onset Parkinson’s disease patients by next-generation
sequencing
A. Seresini, T. Brambilla, C. Siri, G. Sacilotto, M. Zini, G. Pezzoli, M. Seia, S. Goldwurm (Italy)
P 5.014
Association of TNF-alpha and IL-1beta genes polymorphism in Parkinson’s disease
M. Subramanium, S. Keshavarao*, I. Kim (South Korea, *India)
P 5.016
Polymorphisms of dopamine receptor genes are associated to increased risk of visual hallucinations
in Italian Parkinson’s disease patients
C. Comi, M. Ferrari, F. Marino, G. Riboldazzi, S. Rosa, R. Cantello, G. Bono, M. Cosentino (Italy)
P 5.017
Evaluation of clinical phenotypes associated with cytogenetic effects and
Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms in Parkinson’s disease in
Coimbatore region, South India
M. Iyer, M. Gomathi, D. Shanawaz, B. Vellingiri, S. Keshavarao (India)
P 5.018
A Molecular And Genetic basis study in POLG mutation of MtDNA in Parkinson’s patients in South
Indian population
K.K. Alagamuthu, M. Shafi Ahammed Khan, Y. Mohd, P. Krishnan, S. Keshvarao, B. Vellingiri
(India)
P 5.006
73
74
P 5.019
Association of mortalin (HSPA9) and other mitochondria-related genes with the risk of Parkinson’s
disease and Alzheimer’s disease
S.J. Chung, M. Kim, H. Ryu, J. Kim, Y.J. Kim, K. Kim, S. You, S.Y. Kim, J. Lee (South Korea)
P 5.020
Screening of spontaneous genomic alterations and p53 gene polymorphism in new onset of
J. Ramalingam, I. Mahalaxmi, M. Subramaniam, L. Thangamani, A. Meyyazhagan, B. Vellingiri
(India)
P 5.021
Identification and verification of novel FBXO7 interacting proteins
W. Mandemakers, R. Masius, M. Minneboo, D. Dekkers, J. Demmers, M. Kros, V. Bonifati (The
Netherlands)
P 5.022
Defective glucocerebrosidase in GBA1 mutant Parkinson’s disease fibroblasts is rescued by
chemical chaperone ambroxol through modulation of lysosomal factors
G. Ambrosi, C. Ghezzi, R. Zangaglia, G. Levandis, C. Pacchetti, F. Blandini (Italy)
P 5.023
“Benign” GBA variants may alter gene splicing in South African Parkinson’s disease cases
M. Barkhuizen, D.G. Anderson, F.H. Van Der Westhuizen, A.F. Grobler (South Africa)
P 5.024
Epigenome-wide DNA methylation analysis in brothers and monozygotic twins discordant for
O. Kaut, I. Schmitt, S. Witt, J. Tost*, U. Wüllner (Germany, *France)
P 5.025
DNA methylation status and LINE-1 expression in rat brain
S. Mukherjee, K. Upadhyaya, D. Sharma (India)
P 5.026
Caffeine intake and genetic susceptibility to Parkinson’s disease
P. Sharan, E.K. Tan (Singapore)
P 5.027
Interaction between a GWAS-linked genetic variant and caffeine intake in Parkinson’s disease
Y.C. Cheng, M.H. Yong, E.K. Tan (Singapore)
P 5.028
Interaction between caffeine intake and N-acetyltransferase 2 genotype in Parkinson’s disease
J.W. Lim, M.H. Yong, J.C.J. Allen, S. Shenolikar, K.M. Prakash, E.K. Tan (Singapore)
P 5.029
Systems biology analysis of the proteomic alterations in Parkinson’s disease: common and diseasespecific pathways
T. Alberio, C. Monti, H. Bondi, I. Colugnat, L. Lopiano, A. Chiò, M. Fasano (Italy)
P 5.030
Two new SCL20A2 mutations identified in two southern Italy families with primary familial brain
calcification
S. Scannapieco, M. Gagliardi, G. Annesi, M. Morelli, G. Iannello, G. Nicoletti, A. Gambardella,
A. Quattrone (Italy)
P 5.031
A novel nonsense CAMTA1 mutation presenting as a tremor predominant phenotype
S. Agarwal, R. Gilbert, H. Lau (USA)
P 5.032
Exome sequencing in a family with autosomal-recessive mental retardation, polyneuropathy, ataxia
and epilepsy
H. Hor, C. Wider (Switzerland)
Vanishing white matter disease and juvenile lateral sclerosis type 4: possibly a novel genetic and
clinical overlap
J. Good, F. Vingerhoets, C. Wider (Switzerland)
P 5.034
Association of Parkinson’s disease (PD) with geterozygous carriers of the Wilson disease (WD) gene
E. Ilyechova, T. Sankova, I. Milyukhina, M. Karpenko, L. Puchkova (Russia)
P 5.035
Polymorphisms of genes of oxidative stress and glutamate excitotoxicity in patients with tardive
dyskinesia in schizophrenia
N. Nurmetov, O. Kurbanov, Z. Ibodullaev, D. Abdullaeva (Uzbekistan)
P 5.036
Cytogenetic, genotypic, gene sequencing and gene expression studies on the stroke patients.
A case control study
R. Chandirasekar, K. Murugan, B. Lakshman Kumar, R. Jayakumar*, K. Sasikala
(India, *Malaysia)
P 5.037
Analysis of GABA and serotonin levels concordance with Vitamin D receptor gene (VDR)
polymorphism in late onset Alzheimer disease (LOAD)
M. Shafi Ahammed Khan, K. Alagamuthu, J. Ramalingam, P. Krishnan, Y. Mohd, B. Vellingiri
(India)
P 5.038
Cytogenetic biomarkers and molecular study of PS1 gene in Alzheimer’s disease in South Indian
population
L. Thangamani, A. Meyyazhagan, S. Keshavarao, B. Vellingiri (India)
P 5.039
Identification of chromosomal alteration and association study of neuroligins and neurexins gene
polymorphisms with Alzheimer’s disease (ad) patients in Coimbatore population, TamilNadu, India
S. Srinivasan, A. Meyyazhagan, D. Shanwaz, B. Vellingiri (India)
P 5.040
NcRNAs, Nutrition and Brain disorders
P 5.041
CREB expression in hippocampus of different age groups of wistar rats
S. Sharma, S. Rajput (India)
P 5.042
Toward a pharmacological control of gene therapy for Parkinson’s disease
M. Humbert-Claude, A. Chtarto* (Switzerland, *Belgium)
P 6.001
Safinamide differentially modulates glutamate release in the basal ganglia nuclei
M. Morari, A. Brugnoli, C. Caccia, E. Melloni, G. Padoani, S. Vailati, M. Sardina (Italy)
P 6.002
Safinamide and glutamate release: new insights
E. Melloni, A. Brugnoli, C. Caccia, M. Morari, G. Padoani, S. Vailati, M. Sardina (Italy)
P 6.003
Restoration of biochemical, behavioral and ultrastructural changes in aging rat brain:
neuroprotective role of 17β -estradiol
P. Kumar, R.K. Kale, N.Z. Baquer (India)
P 6.004
4i (N-(3-Chloro-2-methylphenyl) quinoxalin-2-carboxamide), a novel 5-HT3 receptor antagonist
alleviates depressive behavior evoked in streptozotocin-induced diabetic mice: role of oxidative stress
D. Gupta, M. Radhakrishnan (India)
P 5.033
75
76
P 6.005
Functional connectivity changes in gait related neural network in PD with freezing of gait
M. Mihara, Y. Watanabe, K. Konaka, H. Otomune, H. Fujimoto, H. Mochizuki (Japan)
P 6.006
Neuroprotective effects of Withania Someniferais on mice brain: a therapeutic potential drug
for Parkinson’s disease
V. Sharma, L. Singh (India)
P 6.007
Effect of electroconvulsive therapy on visuospatial memory in rats
N. Lakkappa, P. Thaggikuppe Krishnamurthy (India)
P 6.008
Anti-aging and neuro-protective effects of syzygium cumini (Jambolan) extract on spatial learning
and memory of aging male rats
P. Pandey, S.F. Bashir (India)
P 6.010
Ameliorative effects of 1,3,4-thiadiazole derivatives on scopolamine induced cognitive deficits in mice
A. Kulshreshtha, P. Piplani (India)
P 6.011
Effect of combination therapy of caffeinated coffee and selective 5-HT4 agonist, prucalopride, in an
Alzheimer’s disease mouse model: possible implications on Amyloid Beta formation
N. Al-Shehaby, L. Mahran, K. Abou-Aisha, M. Rady, N. El-Sayed (Egypt)
P 6.012
Possible involvement of janus kinase-signal transducers and activators of transcription (JAK/STAT)
signaling pathway in vitamin e-mediated anti-depressant-like effects in a rat depression model
N. Alrasheed, M. Al-Samhari, S. Al-Rejaie, R. Ahmed, N. Dzimiri (Saudi Arabia)
P 6.013
The mutation causing the motor and behavioral disorders in white mice
O. Turgunkhujaev, R. Matmurodov, N. Tolibova, M. Khanova, Z. Absaitov (Uzbekistan)
P 6.014
Genetic models of Parkinson’s disease
P 6.015
Progressive axonal degeneration of the striatonigral dopaminergic neurons in calcium-independent
phospholipase A2β-knockout mice
G. Beck, K. Shinzawa, H. Sumi-Akamaru, H. Mochizuki (Japan)
P 6.016
c-Rel deficient mice, a mouse model of “spreading” PD-like pathology
E. Parrella, A. Bellucci, V. Porrini, A. Lanzillotta, M. Benarese, G. Vegezzi, C. Baiguera,
A. Antonini, P.F. Spano, M. Pizzi (Italy)
P 6.017
Neurodegeneration of the dopaminergic neurons due to the inhibition of platelet-derived growth
factor receptors (PDGFR) In Zebrafish Larvae
A. Norazit, D. Wong, N. Abdul Halim, S. Mohd Noor (Malaysia)
P 6.018
Integration of cortical and basal ganglia inputs in motor thalamus of parkinsonian animal models
G. Orban, W. Song, A. Kaelin-Lang, S. Galati (Switzerland)
P 6.019
Role of brain neurotransmitters in Parkinson’s induced rats
N. Kumar, R.K. Khanna (India)
P 6.020
Spreading depression susceptibility is reduced in parkinson rat model
M. Lotfinia (Iran)
The hippocampal serotonin system is related with the antidepressant effect of sertraline,
venlafaxine, nortriptyline and L-tryptophan in the 6-OHDA-lesioned rats
M. Vital, Z. Thiago, M. Meira Santos Lima, C. Da Cunha, R. Andreatini, R. Santiago (Brazil)
P 6.022
Weak static magnetic field exposure blocks 6-hydroxydopamine (6-OHDA)-induced neuronal
degeneration
R. Uzan-Gueta, L. Schachter, Y. Loboda, J. Finberg (Israel)
P 6.023
High fat diet feeding exacerbates the toxic effects of 6-hydroxydopamine in rats: Possible
involvement of histone acetylation
S. Sharma, R. Taliyan (India)
P 6.024
Unprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as
observed in the 6-OHDA lesioned rat model of Parkinson’s disease
A. Michel, P. Downey, J. Nicolas, D. Scheller (Belgium)
P 6.025
Opioid K receptor variant delays the onset of dyskinesias in Parkinson’s disease
R. Cilia, R. Asselta, R. Benfante, E. Cereda, D. Vallauri, L. Marabini, D. Fornasari, S. Goldwurm,
G. Pezzoli (Italy)
P 6.027
Symptomatic and biochemical assessments using microdialysis method of an antidyskinetic
compound in a L-DOPA induced dyskinesias rat model
S. Robelet, V. Girod, D. Revy, B. Audrey, B. Adeline (France)
P 6.028
Increased serotonin innervation of the sensorimotor striatum in a primate model of Parkinson’s
disease
D. Gagnon, T. Di Paolo, M. Parent (Canada)
P 6.029
Design and synthesis of coumarin based dual binding acetylcholinesterase inhibitors for the
treatment of cognitive dysfunction
S. Shaffali, P.P. Piplani (India)
P 6.030
Increased density of large calretinin expressing interneurons in the striatum of parkinsonian monkeys
S. Petryszyn, M. Parent (Canada)
P 6.032
Phosphorylation by okadaic acid enhances MPP+ induced hydroxyl radical generation in rat striatum
T. Obata, M. Nakajima (Japan)
P 6.033
Studying pain-related manifestations in an MPTP-induced rat model of Parkinson’s disease
M. Padurariu, A. Ciobica, R. Lefter, E. Anton (Romania)
P 6.034
Exercising is reducing anxiety, depression and memory deficits induced by a MPTP-induced rat
model of Parkinson’s disease
A. Ciobica, M. Padurariu, R. Lefter, E. Anton (Romania)
P 6.035
Computer aided movement analysis of MPTP mouse on inverted horizontal grid
W. Niewiadomski, E. Palasz, M. Skupinska, M. Zylinski, M. Steczkowska, A. Gasiorowska,
G. Niewiadomska, G. Riedel* (Poland, *United Kingdom)
P 6.036
Rolipram, a PDE-IV inhibitor protects against experimental Parkinsonism in mice
N. Kumar, R.K. Khanna (India)
P 6.021
77
78
P 6.037
Crossbreeding two mice strains with differential susceptibility to 1-Methyl-4-Phenyl-1,2,3,6Tetrahydropyridine (MPTP) positively modulates nigral dopaminergic phenotype
D.J. Vidyadhara, H. Yarreiphang, T.R. Raju, P. Anand Alladi (India)
P 6.038
Nigrostriatal degeneration dictates a top-down genetic program for neuroplasticity and neurorepair:
focus on the hippocampus and Wnt/GSK-3β/β-catenin signaling cascade
B. Marchetti, F. L’Episcopo, C. Tirolo, N. Testa, M.F. Serapide (Italy)
P 6.039
Distribution, metabolism and elimination of opicapone in the rat and non-human primates
A.I. Loureiro, C. Fernandes-Lopes, P. Soares-da-Silva (Portugal)
P 6.040
Pharmacokinetics of opicapone, a novel catechol-O-methyltransferase inhibitor, in the Wistar rat
D. Gonçalves, G. Alves, A. Fortuna, P. Soares-da-Silva, A. Falcão (Portugal)
P 6.041
Opicapone improved the effect of L-DOPA on the MPTP-induced Parkinson’s-like syndrome in
cynomolgus monkeys
M.J. Bonifacio, F. Sousa, S. Medakkar*, J. Vivian*, P. Soares-da-Silva (Portugal, *Singapore)
P 6.042
Opicapone improves the levodopa induced rotational behavior in 6-OHDA hemiparkinsonian rats
E. Moura, M.J. Bonifacio, P. Soares-da-Silva (Portugal)
P 6.043
Perinatal arsenic exposure alters central dopaminergic system of rats
L.P. Chandravanshi, R. Gupta*, R.K. Shukla, V.K. Khanna, S.K. Trigun (India)
P 6.044
Role of dopaminergic receptors and post synaptic signaling in arsenic induced neurotoxicity:
ameliorative effect of curcumin
P. Srivastava, Y. Dhuriya, R. Gupta, R. Shukla, A.B. Pant, V.K. Khanna (India)
P 6.045
Evidence of heavy metals implication in Parkinson’s disease: involvement of serotonin and the
beneficial therapeutic role of curcumin
H. Benammi, O. El Hiba, H. Gamrani (Morocco)
P 6.046
Experimental model of extrapyramidal disorders caused by reserpine
D. Tursunov (Uzbekistan)
P 6.047
Exogenous salsolinol influences gut-brain axis
M. Kurnik, K. Gil, M. Białas, V. Aleksandrovych, A. Bugajski, P. Thor (Poland)
P 6.048
Characterization of the lipopolysaccharide induced model of Parkinson’s disease: role of oxidative
stress and neuroinflammation
N. Sharma, B. Nehru (India)
P 6.049
Antiparkinson and antioxidant effect of pyridylpyrazolinyl substituted heterosteroids in LPS induced
neuroinflammation model of neurodegenerative disorders
R. Singh, R. Bansal (India)
P 6.050
Apocyanin, a microglial NADPH oxidase inhibitor prevents dopaminergic neuronal degeneration in
lipopolysaccharide induced Parkinson’s disease model
N. Sharma, B. Nehru (India)
P 6.051
Bacopa monnieri supplements offset motor and co-morbid behavioral pathology, oxidative impairments
and neurotoxicity in an chronic environmental toxin model of Parkinson’s disease in mice
G. Krishna, R. Hosamani*, M. Muralidhara (India, *USA)
Neuroprotective effect of ethanolic extract of Pandanus odoratissimus Ln. to Paraquat mice model
E.C. Sitepu, R. Adji, A.K. Tedja, S. Simanjaya (Indonesia)
P 6.053
Alteration of striatal tetrahydrobiopterin in iron-induced unilateral model of Parkinson’s disease
B. Aryal (Nepal)
P 6.054
Copper poisoning induces neurobehavioral features of Parkinson’s disease in rat: alters
dopaminergic system and locomotor performance
A. Abbaoui, O. El Hiba, H. Gamrani (Morocco)
P 6.055
Deciphering the mechanism of cadmium induced brain dopaminergic dysfunctions and assess the
protective potential of quercetin in rats
R. Gupta, R.K. Shukla, L.P. Chandravanshi, P. Srivastava, Y. Dhuriya, A.V. Pant, V.K. Khanna
(India)
P 6.056
The protective effect of curcumin on dopaminergic system after chronic aluminum intoxication:
possible link with Parkinson’s disease
W. Laabbar, A. Elgot, H. Gamrani (Morocco)
P 6.057
Origin of α-mannosidase in CSF
A. Tasegian, S. Paciotti, M.R. Ceccarini, M. Codini, T. Moors, D. Chiasserini, E. Albi, W.D. Van De
Berg*, L. Parnetti, T. Beccari (Italy, *The Netherlands)
P 6.058
Synapsin III alterations in Parkinson’s disease
A. Bellucci, M. Zaltieri, F. Longhena, G. Faustini, J. Grigoletto, G. Favero, S. Castrezzati,
R. Rezzani, M. Pizzi, F. Benfenati, M.G. Spillantini*, C. Missale, P. Spano (Italy, *United Kingdom)
P 6.059
Understanding the differential regulation of GBA and GBAP1 expression
V. Rimoldi, G. Rovaris, L. Straniero, G. Pezzoli, S. Goldwurm, G. Soldà, R. Asselta, S. Duga (Italy)
P 6.060
Astrocytes and microglia: new insights in oxidative metabolism of dopamine
A. De Iuliis, L. Facci, S. Skaper, G. Arrigoni, M. Plebani, P. Giusti, A. Antonini (Italy)
P 6.061
Structural analysis of alpha-synuclein oligomers via antibody fingerprinting
L. Nilsson, T. Islam, I. Iakovleva, K. Brännström, A. Olofsson (Sweden)
P 6.062
Deregulation of miRNAs 103a, 30b and 29a in peripheral blood of L-dopa treated Parkinson’s patients
A. Serafin*, L. Foco*, S. Zanigni*, H. Blankenburg*, A. Picard*, A. Zanon*, G. Giannini*,
I. Pichler*, M.F. Facheris*, P. Cortelli*, P.P. Pramstaller*,°, A.A. Hicks*, F.S. Domingues*,
C. Schwienbacher* (*Italy, °Germany)
P 6.063
An experimental study of transplantation of human amniotic epithelial cells in the corpus striatum
of Parkinson’s induced wistar albino rats
P. Ravisankar (India)
P 6.064
Inhibition of PERK and NFKB pathway can reduce death of stressed dopaminergic neurons
differentiated from human stem cell line
Z.L. Chaudhry, B. Ahmed (United Kingdom)
P 6.065
Oral intake of anti-hangover substance increases aldehyde dehydrogenase activity: new preventive
and therapeutic potentials for oxidative neuronal injury?
C. Bang, B. Kang, S. Choung, K. Choi (South Korea)
P 6.052
79
80
P 6.066
Blocking mitochondrial fission is protective in dopaminergic neuronal cells with inducible
α-synuclein expression
R.Z. Fan, K. Tieu (United Kingdom)
P 6.067
A novel histone deacetylase 1 and 2 isoform-specific inhibitor alleviates experimental Parkinson’s
disease
C. Choong, T. Sasaki, T. Yasuda, H. Hayakawa, K. Baba, Y. Hirata, S. Uesato, H. Mochizuki (Japan)
P 6.068
IL-1beta induces MMP-9 expression associated with cell migration via NOX2-derived ROS signals in
rat brain astrocytes
C. Yang, P. Yu (Taiwan)
P 6.069
Effect of metal ions on aggregation of amyloid beta peptide
Z. Abbaskhani (Iran)
P 6.070
Presenilins mutations within moroccan cases with Alzheimer disease
N. El Kadmiri (Morocco)
Alonso Recio L., 52
Alrasheed N., 76
Altmann V., 29, 56
Alvarez-Avellon T., 65, 71
Alves G., 78
Amami P., 73
Ambhore N., 57
Amboni M., 58
Ambrosi G., 41, 74
Amirjanyan H., 46, 64, 66, 67
Anand S.S., 56
Anand Alladi P., 78
Anderson D.G., 74
Ando R., 39, 61, 71
Andreatini R., 77
Andreoli R., 45
Andres D.S., 41, 72
Andrzejewska R., 65
Angeles D.C., 72
Annesi G., 74
Anton E., 77
Antonini A., 26, 30, 33, 40, 44,
48, 51, 52, 53, 57, 58, 60,
63, 76, 79
Aquila F., 65
Arabia G., 46
Arai A., 56
Arciniega-Martinez G., 48
Arciniega-Martinez G.G., 51
Argaud S., 22, 52
Argyropoulou M., 70
Arkha Y., 62
Arrigoni G., 79
Arruda W., 67, 69, 70
Aryal B., 79
Arzberger T., 34, 66
Asaadi S., 61
Asahara T., 45
Ascherio A., 62
Aschermann Z., 22, 32, 52,
57, 61, 66
Ashanov G., 41, 72
Ashizawa T., 69
Ashrafi F., 61
Askhonov U., 41, 72
Asselta R., 36, 39, 41, 72,
77, 79
Astrakas L., 70
Ataniyazov M., 64
Audrey B., 77
Auffret M., 35, 59
Avagyan G., 46, 64, 66, 67
Ayan C., 50, 54
Ayupova D., 41, 72
Azimov A., 67
Azizova O., 67
Azulay J.-P., 30
Azulay J., 27, 57
Azzaro C., 20, 45
B
Ba E.H.M., 47
Baba K., 80
Bader B., 34, 66
Badoud S., 62
Bae E., 72
Bagella C., 73
Baiguera C., 44, 76
Baik J.S., 72
Bakshi R., 62
Balás I., 32, 61, 66
Balboa-Alegría L.F., 51
Balestrino R., 61
Balint B., 63
Ballard C., 57
Banerjee R., 56
Bang C., 44, 79
Bansal R., 44, 78
Baquer N.Z., 75
Barbagli D., 70
Barbosa E.R., 41, 73
Barcelon E., 59
Barkhuizen M., 74
Barlow D.H., 55
Baroncini D., 61
Barone P., 21, 27, 42, 52, 96
Barreto R., 30, 39, 47, 49,
59, 71
Bartolomei L., 58
Barzaghi C., 27, 34, 48, 66, 73
Bashir S.F., 76
Basse A.M., 47
Bassetti C., 28
Batisti J.P., 67
Battacharyya K.B., 30
Battenberg F., 62
Baumann C., 28, 47, 49
Bebitov S., 65
Beccari T., 63, 79
Beck G., 76
Begaj I., 46
Beghi E., 60
Behari M., 69
Belay S., 70
Bellucci A., 44, 76, 79
Beltramini M., 56
Benammi H., 78
Benarese M., 44, 76
Benazzouz A., 32, 61
Benedetto N., 65
Benesh J., 29, 39, 57, 58
Benfante R., 39, 77
Benfenati F., 79
Benoist A., 60
Benomar A., 66
Bentivoglio A.R., 27, 52
Berardelli A., 28, 36
Bergmann L., 30, 57, 58
Beridze M., 65
Bernabei R., 20, 22, 48, 51
Bertholdo D., 67
Bertozzi V., 20, 45
Bestetti A., 20, 49
Bhatia K., 33, 42 , 63
Bhatia K.P., 67
Bhattacharyya K.B., 30
Bhidayasiri R., 40
Biagioni M., 53, 62, 70
Białas M., 78
Bianchi E., 60
Bilbault T., 32, 59, 60
Biller T., 67
Biosa A., 56
Birouk N., 66
Bisaglia M., 56
Biscetti L., 46
Bitsara C., 49
Biundo R., 33, 52, 53, 63
Bjorklund A., 23
Black K., 57
Blandini F., 38, 41, 74
Blankenburg H., 79
Bloch J., 62
Bloem B.R., 30
Blume J., 32, 60
Bodis-Wollner I., 40
Bogdahn U., 32, 60
NAME INDEX
A
Aarsland D., 24, 42
Ababou N., 50
Abbaoui A., 64, 79
Abbaskhani Z., 80
Abbruzzese G., 26, 30, 48
Abdukadirova I., 64
Abdul Halim N., 76
Abdullaeva D., 64, 66, 75
Abdullayeva D., 64
Abdulmassih E., 69
Abe K., 58, 71
Abler V., 56
Abou-Aisha K., 76
Absaitov Z., 76
Ács P., 57
Adeline B., 77
Aderkichi M., 50
Adji R., 79
Adler C., 29, 35, 36
Agan Yildirim K., 66
Agarwa S., 62
Agarwal S., 70, 74
Agro A., 32, 59, 60
Aguggia M., 58
Ahmed B., 44, 79
Ahmed R., 76
Ahn J., 51, 62
Ahn J.Y., 49
Ahn T., 66
Ahn Y., 65
Aiba I., 64
Ait Benhaddou E., 66
Akamatsu W., 73
Akiyama N., 71
Al-Rejaie S., 76
Al-Samhari M., 76
Al-Shehaby N., 76
Alagamuthu K., 75
Alagamuthu K.K., 73
Albanese A., 27, 36, 37, 48, 73
Albani G., 20, 45
Alberio T., 74
Albertini G., 25, 54
Albi E., 79
Alcacer C., 56
Aleksandrovych V., 78
Alimonti D., 65
Allen J.C.J., 74
81
NAME INDEX
82
Bogdanov R., 71
Bologna M., 22, 51
Bonanni L., 48
Bondi H., 74
Bonifacio M.J., 78
Bonifati V., 18, 25, 34, 41,
66, 73, 74
Bonizzoni E., 58
Bono F., 46
Bono G., 73
Bonuccelli U., 24, 43, 65, 71
Boon A.J., 41, 73
Borellini L., 73
Borges C.M., 67
Borghammer P., 49
Borghese M.C., 26, 55
Borgognon S., 62
Borgohain D.R., 61
Borgohain R., 60, 62
Borisova S., 71
Bosetti P., 22, 53
Bostantjopoulou S., 49
Bötzel K., 50, 62
Bour L., 61, 65
Bour L.J., 61
Bouwkamp C.G., 41, 73
Bove F., 27, 52
Brambilla T., 73
Branco Germiniani F.M.,
64, 67
Brandi V., 20, 22, 48, 51
Brännström K., 79
Breedveld G.J., 34, 41, 66, 73
Bresolin N., 63, 73
Bril E., 30, 57
Brito R.N., 67
Broderick D., 68
Brooks D.J., 21
Brosnan M., 54
Brown M., 26, 56
Brown P., 38
Brown R., 39, 71
Brücke T., 18
Brugnoli A., 75
Brühlmann S., 54
Brunet J., 62
Brusa L., 52
Brys M., 62, 67, 70
Buated W., 26 , 50, 55
Bubacco L., 56
Bucior E., 46
Bugajski A., 78
Bulut B., 66
Burn D., 57
Burns J., 67
Busà M.G., 20, 49
Busse M., 54
C
Cabrera A., 70
Caccia C., 75
Caiazzo G., 41, 72
Cakmak V.A., 66
Calabresi P., 28, 46
Calamuneri A., 67
Calandrella D., 35, 39, 58
Caldara M., 65
Callegari-Jacques S., 29, 56
Calne S.M., 40
Calzetti S., 22, 45, 50
Campolo J., 27, 45
Cancela Carral J.M., 50,
53, 54
Canesi M., 52 , 58
Canever M., 67
Cantello R., 73
Caporali A., 51
Cardoso F., 21, 24, 33
Carecchio M., 34, 66
Carreon-Bautista E.E., 51
Carroll C., 48
Carrozzini D., 48
Carta A.R., 35, 62
Castilla De Cortazar Larrea I.,
59
Castrezzati S., 79
Casula C., 25, 54
Cattaneo C., 58
Cavaco S.
Cavallo M., 60
Cavandoli C., 60
Ceballos-Baumann A., 50
Ceccarini M.R., 79
Cembrani F., 20, 45
Cenci A., 56
Cenci Nilsson A.M., 28, 38
Ceravolo M.G., 58
Ceravolo R., 44, 52, 58, 65, 71
Cereda E., 39, 77
Cervantes-Arriaga A., 48, 51
Chabardes S., 62
Chahidi A., 64
Chan L.L., 39, 70
Chandirasekar R., 45, 75
Chandravanshi L.P., 78, 79
Chang M., 47
Chatagny P., 62
Chatamra K., 29, 30, 39,
57, 58
Chatterjee K., 56
Chatterjee P., 56
Chatterjee S., 56
Chaturvedi M., 22, 25, 26, 41,
53, 55, 71, 72
Chaudhry Z.L., 44, 79
Chaudhuri K.R., 35, 46, 47,
49, 57, 59
Chaudhuri R., 30, 59
Chavez-Oliveros M., 48
Chekeeva N., 48
Chen J., 22, 52
Cheng Y.C., 74
Cheon S., 49
Cherninskyi A., 46
Chi-Burris K., 27, 57
Chiasserini D., 46, 63, 79
Chien H.F., 41, 73
Chillemi G., 67
Chiò A., 74
Chiwera T., 39, 47, 48, 49, 71
Cho J., 69
Cho J.W., 20, 50
Choi W., 71
Choi E.J., 73
Choi K., 44, 79
Chondrogiorgi M., 65, 70
Choong C., 80
Choudhry A., 56
Choudhury S., 56
Choung S., 44, 79
Chraa M., 64
Christopher R., 45
Chrobak A., 60
Chung S.J., 62, 74
Cilia R., 29, 32, 34, 39, 52, 77
Cimolin V., 20, 45
Ciobica A., 77
Cirillo M., 41, 72
Cisse O., 20, 45, 47
Clarke C.E., 46, 53
Coate B., 57
Codini M., 79
Coletti M., 58
Colombo A., 52
Colombo C., 20, 49
Colosimo C., 21, 33, 37, 38
Colugnat I., 74
Comi C., 73
Comi G., 61
Comi G.P., 63, 73
Constans J.M., 60
Contarino F., 38, 61
Contarino M.F., 61
Contin L., 20, 45
Contri P., 47
Corbett A., 57
Corcoran B., 39, 71
Corona F., 25, 54
Correa-Basurto J., 59
Cortelli P., 27, 28, 31, 48,
58, 63, 79
Corti S., 63
Cosentino M., 73
Cossu G., 58
Costa R.M., 28
Cottet J., 62
Cova I., 47
Cozac V., 41, 71, 72
Cozzi L., 27, 45
Crippa A.C., 69
Criscuolo C., 27, 52
Cronin-Golomb A., 55
Crucianelli L., 39, 68
Cucca A., 62
Cuetos Vega F., 71
Curry S., 46
Cybulski G., 48, 53, 54
Czerwosz L., 39, 69
D
D’Avella R., 26, 55
Da Cunha C., 77
Da Lio M., 22, 53
Dacpano G., 62
Dadah S.M.L., 47
Dadajonov S., 67
Dimitrov N., 39, 71
Diop A.G., 20, 45, 47
Diop A.M., 20, 45, 47
Diop M.S., 20, 45, 47
Dizdar N., 58
Djalilova S., 64
Domagk D., 30, 58
Domingues F.S., 79
Dowling F., 46
Downey P., 36, 77
Drapier S., 35, 59
Dressler D., 37
Dubow J., 29, 32, 57, 59, 60
Duga S., 36, 41, 79, 72
Dumitru M.M., 51
Duprez J., 22, 52
Dürr A., 21, 40
Dutkiewicz J., 32, 50, 61
Dutra B.G., 63
Duyckaerts C., 65
Dymock B.W., 72
Dzimiri N., 76
Dzyngel B., 32, 59, 60
E
Eaton S., 29, 39, 57, 58
Edwards M., 22, 42, 43, 51, 52
Edwards M.J., 39, 68
Eidelberg D., 39, 71
El Hiba O., 64, 78, 79
El Kadmiri N., 80
El Khamlichi A., 62
El Ouahabi A., 62
El-Ad B., 46
El-Sayed N., 76
Eleopra R., 58, 60
Elgot A., 79
Elia A., 20, 22, 25, 27, 73
Elia A.E., 27, 48
Eliaz R., 56
Englund E., 63
Erro R., 22, 51, 63, 67
Escobar-Barrios M.S., 51
Esmail S., 54
Espay A., 39, 58
Espay A.J., 28, 33
Esposito F., 41, 72
Eusebi P., 46, 63
Evangelou E., 65
Evison F., 46
Eyal E., 56
F
Fabbrini G., 34, 58, 66
Facci L., 79
Facheris M.F., 79
Faggiani E., 32, 61
Falcão A., 78
Falup-Pecurariu C., 48, 49, 52
Fan R.Z., 80
Fang M., 41, 73
Farah M., 69
Farangis Bonu D., 71
Farombi T., 20, 50
Farotti L., 46
Farrer M., 41, 72
Faruq M., 69
Faryniuk J.H., 69
Fasano A., 22, 27, 37, 38, 43,
51, 52
Fasano M., 74
Fatterpekar G., 67
Faustini G., 79
Favero G., 79
Faye A.B., 20, 45
Fazzi L., 63
Fedorova N., 30, 57
Fedorova T., 49
Fera F., 46
Ferini-Strambi L., 28
Fernandes J., 52
Fernandes-Lopes C., 78
Ferrari G., 20, 45
Ferrari M., 73
Ferrari S., 20, 45
Ferraris C., 20, 45
Ferreira J., 27, 57, 59
Fezza J., 67
Fichera M., 61
Fieblinger T., 56
Fietzek U., 50
Figura M., 46
Finberg J., 77
Fiorenzato E., 20, 52, 63
Fiszer U., 45, 60
Fitzgerald K., 62
Fiuza Parolin L., 67
Foco L., 79
Fogang F.Y., 47
Foltynie T., 22, 52
Foncke E., 35, 62
Fonseca V.R., 69
Fornasari D., 39, 77
Fortuna A., 78
Fortunato F., 63
Fouad M., 64
Fragola M., 32, 61
Fraix V., 62
Franco G., 73
Franzin A., 61
Frattini E., 63
Fratto A., 46
Fregosi M., 62
Friedman A., 34, 39, 46, 50,
61, 70
Friedman J., 57
Friedman J.H., 40
Frosini D., 71
Fuhr P., 22, 22, 25, 26, 41, 51,
53, 55, 71, 72
Fujimoto H., 76
Fujinami T., 26, 50, 55
Fujioka S., 46, 65
Fujita M., 58, 71
Fukada K., 58
Fukae J., 46, 65
Fulchieri M., 48
Funamizu Y., 56
Furgała A., 60
Fusco D., 22, 51
NAME INDEX
Dahdal P., 22, 53
Daini R., 51
Dam-Larsen S., 30, 58
Damásio J., 52
Danek A., 34, 66
Daniel C., 41, 72
Danielsen E.H., 49
Dansie Bacci E., 30, 58
Daoudi S., 50
Davis M., 56
De Bie R.M., 60
De Bie R.M.A., 61
De Cecco M., 22, 53
De Iuliis A., 79
De Lipsis L., 53
De Maria R., 27, 45
de Mello Rieder C., 29, 56
De Micco R., 41, 72
De Palma G., 45
De Pandis M.F., 25, 54
De Vita P., 26, 55
Decesare J., 35, 59
Dehbashi M., 72, 75, 76
Dekkers D., 74
Del Gamba C., 65
Del Prete E., 71
Del Sorbo F., 27, 48
Delaville C., 32, 61
Deli G., 22, 32, 52, 57, 61, 66
Delli Pizzi S., 48
Demartini B., 39, 68
Demmers J., 74
Deszczynski J.M., 61
Devidze E., 65
Dhuriya Y., 44, 78, 79
Di Battista M.E., 47, 52, 53
Di Fonzo A., 63, 73
Di Michele G., 27, 52
Di Paolo T., 77
Di Rocco A., 53, 62, 70
Diaconu S., 49
Diagne N.S., 20, 45
Diatta A., 47
Dickson D., 72
Didour M., 50
Dietrichs E., 31
Diez-Cirarda M., 55, 70
Dijk J.M., 60
Dilettuso F., 26, 55
G
Gabova A., 72
Gabrielyan I., 46, 64, 66, 67
Gafurov B., 41, 72
Gaglione M., 25, 54, 74
Gagnon D., 77
Galati S., 41, 44, 72, 76
Galazka-Friedman J., 39, 70
Galis Y., 35, 62
Galli M., 20, 25, 45, 54
Galli N., 67
Galvin J., 70
Gama H., 59
Gamaleya A., 30, 57
Gambardella A., 74
Gamrani H., 64, 78, 79
83
NAME INDEX
84
Gangadharan S., 52
Garavaglia B., 27, 34, 48, 66,
73
Garcia-Magariño Alonso M.,
59
Gasiorowska A., 48, 53, 54, 77
Gavrilov Y., 47
Gaye N.M., 20, 45, 47
Gazioglu S., 66
Gelosa G., 27, 45
Gentilini M., 20, 45
George L., 71
Gersel Stokholm M., 49
Geut A., 35, 62
Ghezzi C., 41, 74
Gholizadeh Ghozloujeh Z., 61
Ghorbani E., 32, 60, 61
Ghoshal A., 56
Giacomini P., 52
Giannini G., 32, 61, 79
Gianotti P.R.J.P., 63
Gil K., 78
Giladi N., 46
Gilbert R., 53, 74
Ginevrino M., 27, 52
Giordano A., 41, 72
Giovinazzo A., 32, 59, 60
Girlanda P., 67
Girod V., 77
Giuberti M., 20, 45
Giuntini M., 71
Giusti P., 79
Giyazitdinova E., 34, 45, 46,
47, 63, 64, 67
Go P.-W., 53
Godefroy O., 53, 60
Godena V.K., 56
Gogol A., 66
Goldoni M., 22, 50
Goldwurm S., 18, 36, 39, 41,
52, 72, 73, 77, 79
Gomathi M., 73
Gómez-Beldarrain M., 70
Gómez-Beldarrain M.Á., 55
Gómez-Esteban J.C., 55, 70
Gonçalves A., 52
Gonçalves D., 78
Gonzalez-Martinez A., 49
Good J., 75
Górecka-Mazur A., 60
Gorzoni M.L., 63
Goto Y., 62
Goyal V., 69
Graafland J., 34, 41, 66, 73
Gracheva E., 45, 50
Gramstad A., 29, 56
Grande G., 47
Grano M., 26, 55
Grassi E., 58
Gray R., 46
Gregier K., 50
Grigoletto J., 79
Grilo M., 47, 49
Grobler A.F., 74
Groppo E., 34, 66
Groth K., 58
Gschwandtner U., 22, 25, 26,
41, 51, 53, 55, 71, 72
Gualandi F., 34, 66
Gubareva N., 30, 57
Guella I., 41, 72
Guffanti G., 54
Guicciardi M., 25, 54
Guido M., 58
Gupta D., 75
Gupta R., 44, 78, 79
Gupta S., 29, 57
Gurel R., 46
Gurevich A., 53, 62
Gurevich T., 46
Gusmaroli G., 58, 70
Guzzetti S., 51, 55
H
Ha C., 72
Habela P., 32, 61
Habibi S.A.H., 32, 60, 61
Hadinia A., 25, 26, 55
Haga R., 56
Hakkou E., 62
Hall C., 29, 39, 57, 58
Hallett M., 28, 36, 42
Ham J.H., 64, 67
Hamann C., 50
Hambardzumyan H., 51, 67
Hamilton-Dutoit S.J., 49
Han S., 66
Hanoglu L., 65
Harutyunyan K., 46, 64, 66, 67
Hasegawa K., 51, 71
Hasegawa S., 45
Hasegawa Y., 63
Hashimoto K., 62
Hattori N., 18, 29, 35, 56
Hatz F., 41, 71, 72
Hauser R., 32, 59
Hauser R.A., 56
Hayakawa H., 80
Hazama T., 58
Heckman M., 46
Hedges T., 67
Heida T., 65
Heinsen H., 34, 66
Hellberg C., 34, 67
Helmich R., 34
Helvaci Yilmaz N., 65
Hemo B., 46
Heo J., 51, 62
Hepp D., 35, 62
Herd C., 53
Herold-Nadig M., 54
Hersch S.M., 38
Hicks A.A., 79
Hidaka S., 26, 50, 55
Higuchi M., 46, 65
Hildebrand D., 25, 54
Hirata K., 62
Hirata Y., 80
Hirayama M., 45
Hirsch M., 30
Hirschbichler S.T., 63
Ho P., 72
Höglinger G., 21, 33
Hong J.Y., 64, 67
Hopp M., 35, 59
Hori H., 45, 74
Hori M., 25, 53
Horia N., 47, 49
Horiuchi E., 51, 71
Horowski R., 18, 32, 57, 60
Hosamani R., 78
Hosomi K., 62
Houvenaghel J., 22, 35, 52, 59
Hovhannes M., 46
Huh Y.E., 50
Hutz M., 29, 56
Hwang M., 20, 50, 64
I
Iacopini M., 26, 55
Iakovleva I., 79
Iannello G., 74
Ibarretxe-Bilbao N., 55, 70
Ibodullaev Z., 48, 49, 64,
66, 75
Ibodullayev Z., 64
Iijima M., 47, 65
Ikeuchi T., 64
Ilic T., 27, 57
Ilyechova E., 75
Imaizumi Y., 73
Ince Gunal D., 66
Ingrassia A., 35, 62, 63
Inniss R., 39, 46, 47, 48, 71
Iranzo A., 19, 28
Irwin D., 21
Isaacson S., 27, 57, 60
Isaias I., 25, 34
Ishanhodjaeva G., 52
Islam T., 79
Ismoilov R., 67
Ivanova E., 30, 58
Ives N., 46
Iwaki H., 39, 61, 71
Iwasaki Y., 63
Iyer M., 73
Izyumov D., 55, 64
Izyumova G., 55, 64
J
Jaakkola E., 71
Jabeen S.A., 60, 61, 62
Jaffe L., 55
Jaiswal S.K., 65
Jakobsson J., 56
Jalili Khoshnood R., 61
JALPAC Study Group,
Jalundhwala Y.J., 30, 58
Jamrozik Z., 46, 66
Janik P., 46, 66
Jankovic J., 36, 37, 43
Janszky J., 22, 32, 52, 57, 61
Janzen A., 32, 60
Jardim L.B., 41, 73
Jaskólski A., 65
Jayakumar R., 75
Jeon B.S., 21, 63
K
Kaasinen V., 71
Kadi D., 50
Kadowaki T., 62
Kaelin-Lang A., 41, 44, 72, 76
Kaga K., 62
Kageyama Y., 62
Kagita V.P.V., 60, 61, 62
Kalampokini S., 51
Kale R.K., 75
Kalidindi R.R., 57
Kaminski D., 53, 62
Kandada R.M., 60
Kandadai D.R.M., 61
Kandadai R.M., 62
Kandukuri P.L., 30, 58
Kang K., 71
Kang B., 44, 79
Kang H.J., 66
Kang K., 53
Kang S., 49
Kang S.Y., 53, 67
Kanikannan M.A., 60, 61, 62
Kannan E., 57
Kapitsa I., 30, 58
Karaban I., 46
Karabanov A., 72
Karakhonova S., 52
Karasevich N., 46
Karbowniczek A., 48, 53, 54
Karbozova K., 45
Karpenko M., 45, 75
Karthikbabu S., 54
Kashyap N., 26, 50, 55
Kaufmann H., 31, 63
Kaut O., 35, 74
Kawashima N., 51
Kershner I., 72
Keshavarao S., 73, 75
Keshvarao S., 73
Kessel B., 48
Khachatryan E., 64
Khachaturyan S., 46, 64,
66, 67
Khalimova K., 45, 49, 54, 70
Khanna R.K., 76, 77
Khanna S., 29, 57
Khanna V.K., 44, 78, 79
Khanova M., 47, 53, 54, 76
Khasanova K., 51
Khatoonabadi S.A., 61
Katzenschlager R., 96
Khizanishvili N., 65
Khoddami M., 32, 60
Kiessling M., 34, 66
Kievit A.J., 41, 73
Kilner J., 22, 51, 52
Kim C., 47
Kim D., 20, 50
Kim H., 49, 51, 62
Kim H.J., 66
Kim H.-J., 19
Kim H.Y., 66
Kim I., 73
Kim J., 62, 74
Kim J.S., 48, 69
Kim K., 62, 74
Kim M., 62, 74
Kim M.S., 62
Kim S.J., 67
Kim S.Y., 74
Kim Y., 63
Kim Y.J., 62, 74
Kim Y.S., 50
Kin J.W., 49
Kinoshita M., 58
Kishima H., 62
Kisiel-Sajewicz K., 65
Kissani N., 64
Kitagawa K., 47, 65
Kitamura S., 58
Kjellander S., 58
Klamroth-Marganska V., 54
Kleiner A., 25, 54
Kleinfelder A.D., 67
Klingelhoefer L., 46
Kloda M., 50
Knudsen K., 49
Kobayashi Y., 51
Kok F., 69
Kokunai Y., 58
Komoly S., 57
Kon T., 56
Konaka K., 67, 76
Konitsiotis S., 65, 70
Konno T., 68, 68
Koprivnik P., 64
Korczyn A., 43
Korlipara P., 22, 52
Kostic V., 46
Kostic V.S., 40
Kotov S., 71
Kovacs G.G., 63
Kovács M., 22, 32, 52, 57, 61
Kovács N., 22, 32, 52, 57,
61, 66
Kovendan K., 45
Kozhemiako N., 46
Koziorowski D., 32, 46, 50, 61
Krack P., 62
Krahé C., 39, 68
Kramberger Gregoric M., 46
Kreitzman D., 27, 57
Krishna G., 78
Krishnan P., 73, 75
Krismer F., 63
Kros M., 74
Krygowska-Wajs A., 60
Krystkowiak P., 53, 60
Kryzhanovskyi S., 46
Kudrevatykh A., 45, 50
Kulikowski K., 60
Kulinski R., 39, 70
Kulisevsky J., 21, 24, 42, 96
Kulshreshtha A., 44, 76
Kulsum M.U., 56
Kumar D.A., 61
Kumar H., 56
Kumar N., 76, 77
Kumar P., 62, 75
Kumon A., 51
Kuranbaeva S., 56
Kuratomi A., 45
Kurbanov O., 48, 64, 66, 75
Kurisaki R., 45, 65
Kurnik M., 78
Kusmierska K., 46
Kuwabara S., 62
Kuzņecovs V., 65
Kvirkvelia N., 65
Kwon K.Y., 63
L
L’Episcopo F., 78
La Ferla R., 58
Laabbar W., 79
Lacerenza M., 20, 49
Lacorte E., 47
Lakkappa N., 76
Lakshman Kumar B., 75
Landi A., 60
Landqvist Waldö M., 63
Landwehrmeyer G.B., 21
Lange M., 32, 60
Lanni D., 26, 55
Lanzillotta A., 44, 76
Larsen J.P., 29, 56
Larsson J., 58
Lau H., 74
Lauckaite K., 49
Laudisio A., 20, 22, 48, 51
Le Jeune F., 35, 59
Lecca D., 35, 62
Lee C.S., 73
Lee D., 66
Lee G., 54
Lee H., 71
Lee H.-W., 53
Lee J., 63, 64, 71, 74
Lee P.H., 53, 64, 67, 72
Lee S.H., 48
Lee W., 73
Leenders K.L., 41, 73
Lees A., 59
Lefranc M., 53, 60
Lefter R., 77
Lefteri K., 26, 56
Leite C., 69
Lemstra A., 35, 62
Lena F., 26, 55
Lenka A., 64, 71
Levandis G., 41, 74
NAME INDEX
Jeong J.S., 62
Jeziorko S., 60
Jhunjhunwala K.R., 71
Jhunjhunwala K., 64
Jiddane M., 62, 66
Jimenez-Botello L.C., 59
Jin J.H., 66
Johnson A., 52
Johnson J., 49
Jorge De Sarachaga A., 48, 51
Joutsa J., 71
Joy J., 26, 56
Juraev M., 45, 49, 70
85
NAME INDEX
Leventhal L., 39, 57
Levin O., 47, 50
LeWitt P.A., 23
Li H.H., 39, 70
Li Y., 70
Liberski P.P., 63
Liguori C., 32, 59
Lim J.W., 74
Lim K., 72
Linden D., 54
Liu A., 39, 70
Liu F., 26, 56
Liu J., 34, 66
Lo Monaco M.R., 20, 22, 48,
51
Lobatz M., 29, 57
Locatelli P., 65
Loeschmann P.-A., 57
Lolekha P., 26, 50, 55
Lomax M., 35, 59
London E., 69
Longhena F., 79
Lopes N., 59
Lopez-Garcia A., 49
López-Muñiz A., 65, 70
Lopiano L., 31, 60, 74
Lotfinia M., 48, 76
Louis E.D., 34, 36, 43
Loureiro A.I., 78
Lubrani S., 26, 55
Lucas-Jimenez O., 55, 70
Luft F., 65
Luley M., 51
Lyashenko E., 47
Lye W., 47
Lyros E., 51
M
Ma H., 53
Ma Y., 39, 71
Macedo D., 69
Macerollo A., 22, 52
Macklin E., 62
Macron J.M., 60
Madjidova Y., 64, 70
Maeda T., 51
Mahadevappa M., 39, 69
Mahalaxmi I., 74
Mahran L., 76
86
Mainardi L., 54
Majdinasab F., 32, 60, 61
Makkos A., 22, 32, 52, 57, 61
Maksudova K., 53
Malaguti M., 22, 53
Malaguti M.C., 20, 45
Mamadaliyev A., 64
Mancini F., 20, 22, 49, 51,
55, 58
Mandat T., 32, 50, 61
Mandemakers W., 41, 73, 74
Manfredi L., 20, 49, 51
Mangalore S., 64
Manvelyan H., 51, 64, 66, 67
Marabini L., 39, 77
Marano P., 58
Maras A., 54
Marchesi E., 22, 45, 50
Marchetti B., 78
Mariani C., 47
Mariani C.B., 52
Marino F., 73
Marraccini P., 27, 45
Marshall T., 30, 58
Martin A., 39, 48, 71
Martín Plasencia P., 52
Martinez-Martin P., 32, 35,
39, 41, 43, 48, 59, 71
Martino D., 48
Martinuzzi A., 60
Maruo T., 62
Marusiak J., 65
Masilamoni G., 39, 57
Masius R., 74
Massaia I.F.D.S., 63
Massimetti M.C., 52
Massucco D., 48
Matmurodov R., 45, 49, 54,
70, 76
Matsuno H., 47
Mauro A., 20, 45
Maurus A., 35, 59
Mazzotta S., 26, 55
Mcginley J., 50
Mckeown M.J., 39, 70
McRiner A., 39, 57
Mdivani M., 65
Meco G., 47, 52, 53, 58
Medakkar S., 78
Meglic B., 46
Mehrkens J., 62
Meira Santos Lima M., 77
Melamed E. †, 19, 25
Melhaoui A., 62
Melloni E., 75
Melzi V., 73
Mendes A., 52, 62
Mendez-Rial B., 50, 54
Menendez-Gonzalez M., 65,
70, 71
Mengesha K., 49
Menig A., 54
Merello M., 41, 72
Merle P., 60
Merola A., 35, 39
Meucci N., 52
Meyer A., 22, 25, 26, 41, 51,
55, 71, 72
Meyyazhagan A., 73, 74, 75
Michałowska M., 45
Michel A., 36, 77
Mihara M., 67, 76
Milanowski L., 66
Miliukhina I., 45, 50
Mills R., 27, 57
Milyukhina I., 75
Min J.Y., 51
Minato T., 45
Minella S., 55
Minneboo M., 41, 73, 74
Mirabella G., 26, 32, 55, 61
Mirdedaev S., 48, 56
Mirzaeva K., 65
Mishima T., 46, 65
Miska Thölken K.F., 67
Missale C., 79
Mitani Y., 58
Mizuno Y., 73
Moccia M., 27, 52
Mochizuki H., 62, 67, 73,
76, 80
Modi N., 29, 57
Modugno N., 26, 32, 55, 58,
60, 61
Moeller J., 41, 72
Moganty R.R., 69
Mohd Noor S., 76
Mohd Y., 73, 75
Mohire S., 57
Moll M.A.K.D., 66
Möller J.C., 54
Mollinedo-Cardalda I., 50, 53
Monchi O.
Mondal B., 56
Mondani M., 60
Monfrini E., 73
Mongiovetti M., 70
Monti C., 74
Monti V., 34, 66
Montpellier D., 60
Monzio Compagnoni G., 63
Moon S.W., 70
Moors T., 63, 79
Morari M., 75
Moreira I., 52
Morelli M., 46, 74
Moreno-Reig A., 49
Moret V., 62
Morgante F., 22, 24, 27, 28, 51,
52, 58, 67
Morita M., 64
Moro A., 69, 70
Moro E., 24, 38, 62
Morris H., 54
Morris S., 62
Moscovich M., 69, 70
Moskała M., 60
Moti E., 47, 49
Mousa G., 64
Mugge W., 65
Muinjonov B., 34, 45, 46, 47,
63, 64, 74
Mulas G., 35, 62
Mulholland N., 39, 71
Müller E., 58
Mulukutala S., 57
Munhoz R., 69, 70
Muñoz-Soto R.B., 59
Muralidhara M., 78
Muratov F., 55
Murayama S., 64, 73
Murer T., 47
Murgia M., 25, 54
Murthy V., 57
Murugan K., 45, 75
Musaeva Y., 56
Musayeva Y., 45, 46
N
Nadkarni N., 47
Naduthota R., 45
Nagai M., 39, 61, 71, 73
Naghavi-Behzad M., 46
Nagy M., 32, 61, 66
Nakahara K., 45
Nakajima M., 77
Nakamura S., 51, 71
Nakashima K., 63, 64
Nakashita S., 63
Naskar D., 56
Nazaryan A., 66, 67
Ndiaye M., 20, 45, 47
Ndiaye M.M., 20, 45, 47
Negrotti A., 22, 45, 50
Nehru B., 78
Nerino R., 20, 45
Neshige R., 65
Netravathi M., 39, 69, 71
Neumann S., 54
Ng K.M., 39, 70
Nicolas J., 36, 77
Nicoletti G., 74
Niewiadomska G., 48, 53, 54,
77
Niewiadomski W., 48, 53, 54,
77
Nihira T., 73
Nilsson L., 79
Nilsson C., 63
Nilsson K., 63
Nirenberg M., 53, 67
Nishida Y., 45
Nishijima H., 56
Nishikawa N., 39, 61, 71, 73
Nobili L., 27, 45
Nodel M., 47
Nomoto K., 45
Nomoto M., 39, 61, 71
Norazit A., 76
Nowak K., 22, 25, 26, 41, 51,
53, 55, 72
Ntritsos G., 65
Ntzani E., 65
Nunomura J., 56
Nurmetov N., 48, 49, 64, 66,
75
Nurmetov O., 49
Nyholm D., 58
O
Obata F., 73
Obata T., 77
Obeso J., 97
Obukhov Y., 72
Ocepek L., 46
Ocha R.A.J., 63
Odin P., 29, 31, 48
Oechsner M., 54
Ogino M., 73
Ogunniyi A., 20, 50
Ogura J., 58
Ogura H., 46
Ohno K., 45
Ohta E., 73
Ohyama M., 73
Oiwa K., 63
Ojeda N., 55, 70
Oka H., 47
Okada Y., 73
Okamoto A., 45
Okano H., 73
Okiljonova N., 70
Okun M., 65
Olanow C.W., 97
Olgiati S., 34, 41, 66, 73
Oliveira C., 59
Olofsson A., 79
Onder G., 20, 22, 48, 51
Ondo W., 57
Onodera O., 64
Onofrj M., 24, 43, 48, 63
Onuk K., 57
Onuma S., 71
Onuma H., 51
Orban G., 44, 76
Orrico D., 20, 45
Osawa M., 47
Oshino S., 62
Otomune H., 76
Owolabi M., 20, 50
Ozmenoglu M., 66
P
Pacchetti C., 41, 58, 60, 74
Paciotti S., 63, 79
Padma M.V., 69
Padmakumar C.P., 52
Padmakumar G., 52
Padoani G., 75
Padurariu M., 77
Pagni C., 71
Pahwa R., 57
Pál E., 32, 61
Pal P., 42
Pal P.K., 39, 45, 64, 69, 71
Pal S., 48
Palasz E., 48, 53, 54, 77
Pandey P., 76
Panea C., 47, 49
Pant A.V., 79
Pant A.B., 44., 78
Panteghini C., 34, 66
Papa S., 39, 57, 96
Papi C., 47, 52
Pappa M., 65
Parent M., 77
Pariaszewska K., 54
Parisi F., 20, 45
Park J.-S., 53
Park K.H., 47
Park M., 49
Park M.H., 51
Parkins L., 48
Parnetti L., 46, 63, 79
Parolini M., 27, 45
Parrella E., 44, 76
Parry M., 39, 48, 71
Pascale E., 47
Pasco P.M., 59
Pasha S.A., 64
Pastorello P., 70
Pau M., 25, 54
Pavino V., 52
Pellecchia M.T., 27, 52
Pellegrini M., 20, 45
Pellegrino E., 20, 49
Peña J., 55, 70
Perera T., 50
Peretz C., 46
Perkins L., 39, 46, 47, 71
Permert J., 58
Perrini P., 65
Pertile R., 20, 45
Petrovic M., 46
Petrucci S., 27, 52
Petryszyn S., 77
Pettorino M., 20, 49
Pezzoli G., 26, 36, 39, 41, 52,
72, 73, 77, 79
Pfeiffer R., 36, 40
Photopoulou A., 39, 68
Pianu D., 20, 45
Picard A., 79
Piccolo I., 27, 45
Pichai Fenn J., 73
Pichler I., 79
Pierantozzi M., 32, 59
Pietraszko W., 60
Piffer S., 20, 45
Pili R., 25, 54
Pillai E., 35, 62
Pilleri M., 58, 60
Piplani P., 44, 76, 77
Piqueras-Flores J., 49
Piri R., 46
Pirtošek Z., 39, 46, 71, 96
Pisciotta M.S., 20, 22, 48, 51
Pizzi M., 44, 76, 79
Placidi F., 32, 59
Plate A., 50
Plebani M., 79
Poddubskaya A., 30, 57
Poewe W., 30, 57, 58, 97
Polak J., 60
Polat B., 65
Politis M., 39, 71
Polosan M., 62
Poluektov M., 47
Polverino A., 20, 45
Pomati S., 47
Ponte Junior J.R.T., 63
Porrini V., 44, 76
Poryazova R., 47
Potashkin J., 22, 52
Potasz-Kulikowska K., 60
Potrzebowska I., 50
Pozzi B., 52
Pradotto L.G., 20, 45
Prakash K.M., 47, 74
Pramstaller P.P., 79
NAME INDEX
Mutti A., 45
Muzerengi S., 46, 53
87
NAME INDEX
Prashanth L.K., 54
Preda F., 60
Priori A., 26, 38, 47, 60
Proserpio P., 27, 45
Przybyszewski A., 32, 61
Puchkova L., 75
Puligopu A.K., 60
Pulligopu A.K., 62
Puppi Munhoz R., 64
Purcaro C., 47
Puschmann A., 34, 35, 67, 68
Q
Quadri M., 34, 41, 66, 73
Quartarone A., 62, 67
Quatrale R., 58
Quattrone A., 46, 74
R
Rademakers R., 72
Radhakrishnan M., 75
Rady M., 76
Rajnar R., 46
Rajput S.
Raju T.R., 78
Rakhimbaeva G., 51, 52, 64,
65, 71
Rakhimbayeva G., 45, 46
Rakowicz M., 39, 69
Ramalingam J., 74, 75
Rampelli S., 26, 55
Rascol O., 35, 57, 59, 96
Raskin S., 69
Ravagnani M., 70
Ravisankar P., 79
Ray Chaudhuri K., 19, 23,
39, 71
Re V., 65
Reale C., 34, 66
Reali E., 52
Rees M., 52
Regragui W., 62, 66
Reichmann H., 35, 37, 46
Rektor I., 43
Rektorova I., 24, 33
Revicki D., 30, 58
Revy D., 77
Rey N.L., 19
Reyes J.P., 66
88
Reynolds G.O., 55
Rezzani R., 79
Ribacoba Montero R., 71
Ribas G., 67
Riboldazzi G., 32, 54, 58, 73
Riccardi S., 45
Ricciardi D., 22, 51
Ricciardi L., 22, 27, 39, 51, 52,
68
Rick C., 46, 53
Rieck M., 29, 56
Riedel G., 77
Rieder C.R., 41., 73
Riederer P., 18, 19, 27, 37, 40,
53, 57
Riener R., 54
Rigoldi C., 54
Rimoldi V., 36, 79
Rispoli V., 34, 66
Rizos A., 30, 39, 46, 47, 48,
49, 59, 71
Rizzo V., 67
Robelet S., 77
Roberta F., 56
Robieson W., 39, 58
Rocha J., 59
Rodnitzky R., 40
Rodriguez R., 29, 39, 57, 58
Rodriguez-Agudelo Y., 48
Rodriguez-Fuentes G., 50, 53
Rodriguez-Oroz M.C., 29, 37
Rodriguez-Violante M., 48, 51
Roesch A.D., 22, 26, 51, 53, 55
Roh H., 66
Rola R., 39, 69
Romeo T., 52
Romito L., 34, 35, 39, 60, 66
Romito L.M., 27, 48
Roni R., 20, 45
Rood J.P., 41, 73
Rosa M., 60
Rosa S., 73
Rosani V., 46
Ross O., 18, 25, 72
Rossi S., 58
Roth J., 40
Roth V., 71
Rothenfußer-Korber E.,
32, 60
Rothwell J., 22, 52, 67
Rouigari M., 72, 75, 76
Rouiller E., 62
Roussel M., 60
Rovaris G., 36, 79
Rozemuller A., 35, 62
Rubens R., 29, 57
Rubino A., 47, 52, 53
Rucker J., 70
Rumpel H., 39, 70
Russo A., 41, 72
Ryo M., 73
Ryu H., 62, 74
S
Sacilotto G., 52, 73
Saddi M.V., 58
Sadikov R., 56, 67
Saiki S., 35
Sail K., 30, 58
Saini J., 64, 71
Saitoh Y., 62
Sakakibara R., 62
Sakhya S., 69
Salani S., 63
Salazar G., 60
Sale P., 25, 54
Salehi S., 61
Samuel M., 24, 33
Sanchez-Martinez A., 56
Sankova T., 75
Santhosh D.V., 39, 69
Santiago R., 77
Santiago J., 22, 52
Santilli M., 32, 61
Santillo A., 63
Santos A., 59
Santos G., 69
Sanvito W.L., 63
Sarasso S., 41, 72
Sardina M., 58, 75
Sari H.T.J., 29, 56
Sarubbo S., 60
Saruwatari M., 51
Sasaki T., 80
Sasanelli F., 34, 66
Sasikala K., 75
Sauerbier A., 30, 39, 46, 47,
48, 59, 71
Sauleau P., 22, 52
Saute J.A., 41, 73
Savio K., 70
Sawada J., 58
Scannapieco S., 74
Scavasine V., 67
Scelzo E., 60, 62
Schachter L., 77
Schapira A., 37
Scheller D., 36, 77
Scherzer C., 62
Schieferdecker M.E., 69
Schilling T., 56
Schlaier J., 32, 60
Schmitt I., 35, 74
Schmitz C., 34, 66
Schmulewitz N., 39 58
Schneider S.A., 21
Schouten A., 65
Schuller B., 53
Schumacher-Schuh A., 29, 56
Schuurman P.R., 61
Schwarzschild M., 62
Schwarzschild M.A., 26
Schweinfurther R., 54
Schwienbacher C., 79
Scola R.H., 67
Sebastianutto I., 56
Seck L.B., 20, 45
Seia M., 73
Seigneuret E., 62
Seijo M., 54
Sen S., 56
Sensi M., 34, 58, 60, 66
Seo J., 73
Seppi K., 63
Serafin A., 79
Serapide M.F., 78
Serbanoiu I., 47, 49
Seresini A., 73
Sergeev T., 50
Serrano Rodríguez J.M., 52
Severiano M.I., 69
Shabalov V., 30, 57
Shaffali S., 77
Shafi Ahammed Khan M.,
73, 75
Shanawaz D., 73, 75
Shanidze L., 65
Soliveri P., 27, 48
Son A., 53, 62, 70
Song W., 76
Song H., 53, 67
Song S.K., 67
Song W., 44
Sophia R., 48
Soriano-Ursua M.A., 59
Sousa F., 78
Sow A.D., 20, 45, 47
Spano P., 79
Spano P.F., 44, 76
Spiegel J., 51
Spiga S., 35, 62
Spillantini M.G., 79
Srinivasan S., 75
Srivastava A.K., 69
Srivastava M.V.P., 69
Srivastava P., 44, 78, 79
Staedler C., 41, 72
Stamelou M., 24, 28, 33, 38, 63
Standaert D., 29, 57
Stanzione P., 52
Stashuk G., 71
Steczkowska M., 77
Stefani A., 32, 52, 58, 59
Stefanova E., 46
Stein D., 39, 58
Stepniak I., 39, 69
Sticklor K., 62
Stocchi F., 23, 25, 31, 54,
96, 97
Stoessl A.J., 24, 42
Stojkovic T., 46
Stolarczyk A., 61
Stolarczyk M., 61
Stone B., 53
Storch A., 29
Strafella A., 24, 33
Straniero L., 36, 41, 72, 79
Strasz A., 48, 53, 54
Straumann D., 49
Strongosky A., 46, 68, 72
Stuhlinger L., 50
Stuijt C., 27, 56
Sturzenegger R., 41, 72
Subramaniam M., 74
Subramanian L., 54
Subramanium M., 73
Sulek A., 39, 69
Sumi-Akamaru H., 76
Sung Y., 47
Sunny A.S., 71
Sunwoo M.K., 53, 64
Sushkova O., 72
Suzuki C., 56
Suzuki K., 62
Swarup V., 69
Świercz D., 65
Syed N., 54
Szatanowski T., 45
Szejko N., 66
Szlufik S., 32, 46, 50, 61
Szumilas M., 32, 61
T
Tacik P., 46
Taconeli C., 69
Tada S., 39, 71
Tadjenov M., 56
Tajiri Y., 63
Takahashi A., 63
Takahashi K., 73
Takamoto H., 25, 53
Takashima A., 73
Takata K., 58
Takeda T., 65
Takigawa H., 64
Taliyan R., 77
Tambasco N., 46
Tamburini T., 48
Tamma F., 58, 60
Tan E., 47, 72
Tan E.K., 18, 39, 43, 44, 70, 74
Tan J., 50
Tan S.N., 39, 70
Tanaka K., 61
Tang X., 39, 57
Tasegian A., 79
Tedeschi G., 41, 72
Tedja A.K., 79
Teive H., 64, 67, 69, 70
Teive H.A.G., 69
Terranova C., 67
Tesei S., 52
Tessitore A., 24, 44, 58, 72
Testa N., 78
Thaggikuppe Krishnamurthy
P., 76
Thangamani L., 74, 75
The Hydrogen Water
Parkinson Study Group, 56
Thevathasan W., 50
Thiago Z., 77
Thomas A., 48
Thor P., 78
Tibar H., 66
Tieu K., 80
Tilderkvist K., 63
Tinazzi M., 28, 67
Tir M., 53, 60
Tirolo C., 78
Tognoni G., 71
Tokuda T., 64
Tolibov D., 52, 71
Tolibova N., 47, 53, 54, 76
Tomaz R., 39, 71
Tomiyama M., 56
Tomse P., 39, 71
Tomskiy A., 30, 57
Toshev J., 48, 49
Tost J., 35, 74
Toure K., 20, 45
Toyoda C., 47
Trendafilov V., 41, 72
Trezzi I., 73
Trigun S.K., 78
Trivedi D., 39, 46, 47, 48, 71
Trojanovic N., 39, 71
Trost M., 39, 46, 71
Truong D., 36, 37, 67
Tseretopoulou X., 65
Tsuboi Y., 46, 65
Tsugawa J., 65
Tsuji H., 45
Tsujii T., 39, 71
Turgunkhujaev O., 47, 53, 54, 76
Turner D., 54
Tursunov D., 78
Tysnes O.B., 29, 56
Tzamir J., 46
Tzoulaki I., 65
U
Uchihara T., 65
Uchino A., 73
NAME INDEX
Sharan P., 44, 72, 74
Sharifi S., 65
Sharma D., 74
Sharma N., 78
Sharma S., 75, 77
Sharma V., 55, 76,
Shenolikar S., 74
Shibata-Yamaguchi C., 62
Shill H., 32, 59
Shimizu T., 62
Shimohata T., 64
Shimokawa T., 62
Shin C.M., 63
Shin J., 73
Shinoda T., 51
Shinzawa K., 76
Shiong Shu L., 59
Shubham S., 56
Shukla G., 69
Shukla R., 44., 78
Shukla R.K., 78, 79
Sikorska B., 63
Silva M., 67
Silva M.A.G.T., 63
Simancas-Ruiz J.E., 51
Simanjaya S., 79
Singh A., 39, 57
Singh I., 69
Singh L., 76
Singh R., 44, 78
Siri C., 52, 73
Sitepu E.C., 79
Siwek G., 60
Skaper S., 79
Skeie G.O., 29, 56
Skripkina N., 50
Skupinska M., 48, 77
Slevin J., 29, 57
Slubowska E., 32, 61
Smeltere L., 65
Smelters R., 65
Sneha B.S., 54
Soares-da-Silva P., 59, 78
Sobanska A., 39, 69
Soh Y.H., 53
Sohn Y., 64
Sohn Y.H., 53, 67, 72
Sokhibnazarov N., 55
Soldà G., 36, 41, 72, 79
89
NAME INDEX
Uchiyama S., 65
Uchiyama T., 62
Uekawa K., 45
Ueno T., 56
Uesato S., 80
Uitti R., 35, 72
Ukraintseva J., 47
Umehara T., 47
Umemoto G., 46
Unger M., 51
Upadhyaya K., 74
Usta N., 66
Uzan-Gueta R., 77
V
Vaamonde-Gamo J., 49
Vailati S., 75
Valdman E., 30, 58
Valente E.M., 19, 27, 52
Valente G.O.R., 53
Valente M., 47, 52, 53
Valko P., 47, 49
Vallauri D., 39, 77
Valldeoriola F., 31
Van De Berg W., 35, 62, 63
Van De Berg W.D., 79
van de Berg W.D.J., 29, 44
Van Den Munckhof P., 61
Van Der Westhuizen F.H., 74
Van Gerpen J., 72
Van Gils S., 61
van Laar T., 21, 27, 31, 56
Van Poppelen D., 60
Van Rootselaar A., 65
Van Westen D., 63
Vanacore N., 20, 45, 47
Vega Álvarez J., 65, 70
Vegezzi G., 44, 76
Vellingiri B., 73, 74, 75
90
Verhagen R., 61
Verheijen F.W., 41, 73
Vérin M., 22, 35, 52, 59
Verma A., 67
Vestberg S., 63
Vetrano D., 20, 48
Vetrano D.L., 22, 51
Vidyadhara D.J., 78
Vila M.H., 50, 54
Vila-Chã N., 52
Vilela R., 69
Vincent S., 45
Vingerhoets F., 34, 75
Visco-Comandini F., 22, 51
Vital M., 77
Vitale C., 40
Vivian G., 39, 71
Vivian J., 78
Volkmann J., 36, 43
Volonté M.A., 61
Volterrani D., 65, 71
Voronina T., 30, 58
Vorovenci R.J., 53
Voskanyan A., 46, 64, 66
Vucolova L., 20, 25, 49, 53
Vuletic V., 34, 67
W
Wada-Isoe K., 63
Waldvogel D., 47
Wang J., 39, 41, 70, 73
Wang L., 34, 66
Watanabe Y., 62, 76
Weber K., 49
Weintraub D., 56
Weis L., 52, 63
Weiss L., 53
Wenning G., 63
Wenning G.K., 19, 33, 38
Werth E., 47, 49
Whitworth A.J., 56
Wictor L., 35, 68
Wictorin K., 35, 68
Wider C., 74, 75
Widner H., 35, 58, 68
Wiklund I., 30, 58
William H., 57
Williams H., 27, 57
Willows T., 58
Withanage A., 52
Witt S., 35, 74
Woldehana A.M., 51
Wolters E.Ch., 18, 19, 23
Wong D., 76
Woodward J., 67
Woolley R., 46
Wszolek Z.K., 18, 25, 40, 46,
68, 72
Wüllner U., 35, 74
Y
Yabe H., 61
Yabe Y., 39, 71
Yadav R., 39, 45, 64, 69
Yadav R.S., 65
Yahyaoui M., 66
Yakhno N., 47
Yamamoto M., 71
Yamanishi T., 62, 71
Yanamoto S., 46, 65
Yang C., 80
Yang Y., 63
Yaria J., 20, 50
Yarreiphang H., 78
Yasuda T., 80
Yasui K., 63
Yegin A., 30, 57, 58
Yeoh C.S., 39, 70
Yokoe M., 62
Yong M., 47
Yong M.H., 74
Yoon U., 71
Yoon J.E., 69
Yoon W.T., 67
Yoritaka A., 56
Yoshida M., 63
Yoshikawa H., 58
Yoshimine T., 62
You S., 62, 74
Youdim M.B.H., 18, 37, 38
Youn J., 20, 50, 69
Yu P., 80
Yun E.J., 63
Yun H.J., 64
Yunusov F., 51
Z
Zali A., 61
Zaltieri M., 79
Zangaglia R., 41, 74
Zanigni S., 79
Zanon A., 79
Zecchinelli A.L., 52
Zeigelboim B.S., 69
Zhang J., 41, 73
Zhang Y., 39, 70
Zibetti M., 58
Zikou A., 70
Zimprich A., 18
Zini M., 52, 73
Zouitina Y., 53, 60
Zuccalà G., 20, 22, 48, 51
Zuneda Serafini S., 67
Zupancic Kriznar N., 46
Zutter D., 54
Zylinski M., 48, 54, 77
CONGRESS VENUE
MiCo – Milano Congressi Congress Centre (Fiera Milano)
Via Gattamelata (Entrance Gate 14) - MiCo North Wing
20149 Milano - Italy
Tel. +39 02 4997 6275
Fax +39 02 4801 0265
Website: www.micomilano.it
ORGANIZING SECRETARIAT
GENERAL INFORMATION
GENERAL INFORMATION
OIC s.r.l.
Viale G. Matteotti 7
50121 Florence - Italy
Tel. +39 055 50351
Fax +39 055 5001912
[email protected]
www.oic.it/iaprd2015
REGISTRATION DESK
The Registration Desk will be situated on level +1 of the MiCo Congress
Centre North Wing and will be open for registration and information
according to the following time schedule:
Sunday, December 6
Monday, December 7
Tuesday, December 8
Wednesday, December 9
8.00-21.00
8.00-19.00
8.00-19.00
8.00-15.30
Please collect the conference kit at the Registration Desk and wear your
personal name badge during the scientific sessions and social activities.
91
GENERAL INFORMATION
REGISTRATION FEES – ON SITE
Fees are in Euro and include VAT
REGISTRATION FEES
Full Participants
Students/Trainees/ Post-Docs/Fellows and Residents*
Allied health professionals*
Emerging Countries**
Exhibitors
Congress Dinner
ON-SITE
€ 750,00
€ 400,00
€ 400,00
€ 400,00
€ 400,00
Educational Sessions***
€ 25,00
€ 95,00
* In order to benefit from the reduced fee, the registration form must be accompanied by a letter from the
head of the department confirming this status and/or a valid student card.
** Emerging countries are defined according to the World Bank Country Classification of Low income and
Lower-middle income economies.
*** The fee includes the participation in all Educational Sessions indicated in the scientific program and
the textbook “PD and Other Movement Disorders” for free.
REGISTRATION FEES FOR ALL CONGRESS PARTICIPANTS INCLUDE:
− Free access to the Welcome Reception
− Participation in scientific sessions
− Entrance to the exhibition area
− Final program book and other printed material of the Congress
− Certificate of Attendance
− Access to CME certificate after the Congress
− Lunches and refreshments according to the program
− Free Associate Membership of IAPRD with free electronic subscription
to its journal “Parkinsonism and Related Disorders”
BADGES
Participants are kindly requested to wear the name badge when entering
the Congress venue and to access any offered services.
Badge color coding is as follows:
No color = Delegates
Blue = Faculty
Gold = IAPRD Executive Scientific Board
Red = Exhibitors
Yellow = Press
92
CERTIFICATE OF ATTENDANCE
The certificate of attendance will be obtainable on site.
CLOAKROOM AND LUGGAGE DEPOSIT
A cloakroom and luggage deposit located on level +1 will be available
during the official Congress time schedule. MiCo Congress Centre and
the organisers are not responsible for any items lost or left behind.
EXHIBITION
An exhibition of the latest pharmaceutical products, electromedical
devices and scientific publications is located on level +1 of the MiCo North
Wing.
Opening hours will be corresponding to the congress activities as follows:
Sunday, December 6
9.00-21.00
Monday, December 7
8.00-18.45
Tuesday, December 8
8.00-18.45
Wednesday, December 9
8.00-15.30
GENERAL INFORMATION
REFRESHMENTS
Coffee and tea, refreshments and lunch will be offered to all registered
participants in the Exhibition Area at the times indicated in the timetable.
Delegates will have the chance to visit the Poster Area as well as the
Technical Exhibition on level +1 of the MiCo North Wing.
FREE WI-FI
Free wi-fi Internet connection is available in all meeting rooms and
common spaces.
LOST AND FOUND
For lost and found items, please refer to the cloakroom on site.
MOBILE PHONES
The use of mobile phones is not allowed during all scientific sessions.
Mobile phones must be switched off or muted.
SMOKING POLICY
Smoking is strictly prohibited during all meetings and sessions and in
exhibition halls at all times. Your compliance is appreciated.
93
SOCIAL EVENTS
SOCIAL EVENTS
OPENING CEREMONY
Sunday, December 6 -hrs 18.30
Silver Hall – MiCo Congress Centre (Congress venue)
WELCOME RECEPTION
Sunday, December 6 - hrs 20.00
Exhibition Area – MiCo Congress Centre (Congress venue)
CONGRESS DINNER
Tuesday, December 8 – hrs 20.00
Gessi Milano Showroom – Via A. Manzoni 16/A - Milan
The Congress Dinner of the XXI World Congress on Parkinson’s Disease
and Related Disorders will be held in a very unique venue, set right in
the core of the fashion and design district of Milan city centre which represents its true soul.
Gessi brand is acknowledged worldwide for its fashionable designs in all
types of living environments. With its creations, Gessi has created a new
style of living: a “design to be experienced, to be worn and breathed”.
On March 2013 Gessi opened the brand new Gessi Milano Showroom inside a historic building in the upscale fashion district. The area, a former
movie theater, was radically reinterpreted creating an actual plunge into
nature in a “secret garden”, unexpected, inspired by the Parco Trivulzio
on which the Space stands.
A special evening in a special location! Tickets for the Dinner at € 95,00
are available at the registration desk.
94
Oregon Convention Center
September 20 – 23, 2016
ATTENDEES
WILL INCLUDE
Movement Disorder Specialists
Neurologists & Neuroscientists
Geriatricians & Family Physicians
Nurses & Social Workers
Physical, Occupational &
Speech Therapists
People with Parkinson’s disease
Care partners & Family
Representatives of industry
The 4th World Parkinson Congress is a unique
international event designed to bring
together the full spectrum of people who
live with Parkinson’s disease and those
who serve the Parkinson community. We
hope this cross-pollination helps in finding
a cure as well as identifying the best treatment
practices for people living with Parkinson’s.
www.WPC2016.org
The official language of the WPC 2016 is English.
IMPORTANT
DATES
DECEMBER 7, 2015
Abstract Submission opens
JANUARY 11, 2016
Registration and Housing open
APRIL 25, 2016
Abstract Submission & Travel
Grant Application deadline
JULY 5, 2016
Early Registration deadline
SPONSORED SYMPOSIA
MONDAY, 7 DECEMBER - 11.45-12.45
RED HALL 1
ZAMBON SYMPOSIUM
SAFINAMIDE FOR THE MANAGEMENT OF MID- TO LATE-PD PATIENT:
A CASE-BASED REVIEW
11.45
New treatment options for mid- to late-PD stage - the clinical
development of safinamide
F. Stocchi (Italy)
12.00
Beyond the dopaminergic pathway in mid- to late-PD stage - the
mechanism of action of safinamide
S. Papa (USA)
12.15
New approaches for managing motor complications
O. Rascol (France)
12.30
Advances in the management of non-motor symptoms in PD
P. Barone (Italy)
MONDAY, 7 DECEMBER - 12.45-13.45
BLUE HALL
ABBVIE SYMPOSIUM
ADVANCED PARKINSON DISEASE: FROM SCIENCE TO CLINICAL
APPLICATION
Chairman: J. Kulisevsky (Spain)
96
12.45
Welcome and Introduction
12.50
Advanced PD: incidence, definition, and patient considerations
13.05
Optimizing treatment strategies: changing the mode of delivery
R. Katzenschlager (Austria)
13.20
Translating scientific and clinical data into real world setting
R. Katzenschlager (Austria)
13.35
Multidisciplinary care and aftercare: establishing best practices for
patients and caregivers
SILVER HALL
CYNAPSUS SYMPOSIUM
Chairmen: C.W. Olanow (USA), F. Stocchi (Italy)
12.00
Motor complications - Phenomenology and mechanisms
J. Obeso (Spain)
12.20
Current therapy for motor complications in PD
W. Poewe (Austria)
12.40
Rescue therapies - A new direction in the treatment of OFF episodes
C. Warren Olanow (USA)
13.00
KOL Panel Discussion
J. Obeso (Spain), C.W. Olanow (USA), W. Poewe (Austria),
F. Stocchi (Italy)
SPONSORED SYMPOSIA
TUESDAY, 8 DECEMBER - 12.00-13.30
97
WHITE
ROOM 2
WHITE
ROOM 1
TO LEVEL +1
CONGRESS VENUE LAYOUT
Level +2
SILVER HALL
FROM LEVEL +1
98
YELLOW HALL 1
Faculty Lounge
SLIDE CENTRE
RED HALL 1
BLUE HALL
1,2
RED HALL 2
TO LEVEL +2
FROM LEVEL 0
YELLOW HALL 3
FROM LEVEL +2
Buffet
Lunch
5
4
3
Buffet
Lunch
2
CONGRESS VENUE LAYOUT
Level +1
6
9
REGISTRATION
AREA
8
7
SELECTED TOPIC
SESSIONS AREA
10
11
POSTER AREA
ENTRANCE
TO EXHIBITION
12
BAR
REGISTRATION
AREA
HISTORY OF PD
EXHIBITION
17/18
POSTER AREA
16
CLOAKROOM
Buffet Lunch
COMPANY NAME
ABBVIE
BRITANNIA PHARMACEUTICALS
CANÈ MEDICAL TECHNOLOGY
EVER NEURO PHARMA
GONDOLA MEDICAL TECHNOLOGIES
IAPRD 2017 DESK
IAPRD SOCIETY DESK
MEDTRONIC
MERKUR DESK
MERZ
ST. JUDE MEDICAL
WISEPRESS MEDICAL BOOKSHOP
ZAMBON
BOOTH CODE
10
9
11
6
12
4
5
17-18
3
2
7
8
16
99
Restoring Movement with Ease
ǇŶĂƉƐƵƐŝƐƉƌŽƵĚƚŽďĞĂƐƵƉƉŽƌƚĞƌŽĨƚŚĞ
yy/tŽƌůĚŽŶŐƌĞƐƐŽŶWĂƌŬŝŶƐŽŶ͛Ɛ
ŝƐĞĂƐĞĂŶĚDŽǀĞŵĞŶƚŝƐŽƌĚĞƌƐ͘
ǇŶĂƉƐƵƐŝƐĂƐƉĞĐŝĂůƚǇƉŚĂƌŵĂĐĞƵƚŝĐĂůĐŽŵƉĂŶǇƚŚĂƚŝƐ
ĨŽĐƵƐĞĚŽŶƚŚĞĐůŝŶŝĐĂůĂŶĚƌĞŐƵůĂƚŽƌǇĚĞǀĞůŽƉŵĞŶƚŽĨĂ
ƐƵďůŝŶŐƵĂůĂƉŽŵŽƌƉŚŝŶĞĨŝůŵƐƚƌŝƉ;W>ͲϭϯϬϮϳϳͿ͘
ǇŶĂƉƐƵƐΖĚƌƵŐĐĂŶĚŝĚĂƚĞ͕W>ͲϭϯϬϮϳϳ͕ŝƐĂƐƵďůŝŶŐƵĂů
ĨŽƌŵŽĨĂƉŽŵŽƌƉŚŝŶĞƚŚĂƚŝƐĐƵƌƌĞŶƚůǇĞŶƌŽůůŝŶŐƉĂƚŝĞŶƚƐ
ŝŶWŚĂƐĞ///ĐůŝŶŝĐĂůƐƚƵĚŝĞƐ;ĐůŝŶŝĐĂůƚƌŝĂůƐ͘ŐŽǀ͗
EdϬϮϰϲϵϬϵϬĂŶĚEdϬϮϱϰϮϲϵϲͿ͘
ƉŽŵŽƌƉŚŝŶĞ͕ǀŝĂŝŶũĞĐƚŝŽŶ͕ŝƐĐƵƌƌĞŶƚůǇƚŚĞŽŶůǇĂƉƉƌŽǀĞĚ
ĚƌƵŐĂŶĚƌŽƵƚĞŽĨĂĚŵŝŶŝƐƚƌĂƚŝŽŶ;ŝŶƚŚĞhŶŝƚĞĚ^ƚĂƚĞƐ͕
ƵƌŽƉĞ͕:ĂƉĂŶĂŶĚŽƚŚĞƌĐŽƵŶƚƌŝĞƐͿĨŽƌƚŚĞĂĐƵƚĞ͕
ŝŶƚĞƌŵŝƚƚĞŶƚƚƌĞĂƚŵĞŶƚŽĨΗK&&ΗĞƉŝƐŽĚĞƐŝŶƉĂƚŝĞŶƚƐǁŝƚŚ
WĂƌŬŝŶƐŽŶΖƐĚŝƐĞĂƐĞ͘
549$5)/"4%"2$:/"
XXXDZOBQTVTDB
PLATINUM SUPPORTER
GOLD SUPPORTER
SILVER SUPPORTERS
ACKNOWLEDGEMENTS
The XXI World Congress on Parkinson’s Disease and Related Disorders
would like to acknowledge the support of the following companies:
SUPPORTERS
abcd
101
COMPANY PROFILES
Abbvie
1 North Waukegan Road
North Chicago - USA
www.abbvie.com
AbbVie is a global, research-based biopharmaceutical company formed
in 2013 following separation from Abbott Laboratories. At AbbVie, we
have the expertise of a proven pharmaceutical leader and the focus and
passion of an entrepreneur and innovator. As a result, AbbVie is a leading
company with the stability, resources, expertise and passion to discover,
develop and bring to market groundbreaking science to solve the biggest
health problems that face the world today and tomorrow. AbbVie employs
approximately 25,000 people worldwide and markets medicines in more
than 170 countries.
Adamas Pharmaceuticals
Suite 750, 1900 Powell Street
94608 Emeryville - USA
Tel. +1.510.450.3500
Fax +1.510.428.0519
[email protected]
www.adamaspharma
Adamas Pharmaceuticals, Inc. focuses on the development and
commercialization of therapeutics for chronic disorders of the central
nervous system. ADS-5102, the company’s lead product candidate,
is in Phase 3 trials for the treatment of levodopa-induced dyskinesia
associated with Parkinson’s disease and a Phase 2 trial for the treatment
of major symptoms associated with multiple sclerosis, including walking
impairment. The company’s portfolio includes Namzaric™ and Namenda
XR®, two FDA-approved products with Forest Laboratories Holdings
Limited, an indirect wholly-owned subsidiary of Allergan plc. Please visit
www.adamaspharma.com to learn more.
102
Av. da Siderurgia Nacional
4745-457 Coronado (S. Romão e S. Mamede)
Trofa - Porto - Portugal
Tel. +351.22.986.6100
Fax +351.22.986.6190
[email protected]
www.bial.com
BIAL is an international pharmaceutical company strongly committed
to innovation with the mission to discover, develop and provide new
therapeutic solutions. Consistently investing more than 20% of its turnover
in Research and Development (R&D), BIAL has established an ambitious
R&D program centred on the central nervous, cardiovascular system
and allergy immunotherapy. The company has developed an antiepileptic
drug, (Zebinix - eslicarbazepine acetate) already commercialized in the
US market and in several European countries. A second compound from
its R&D pipeline for the treatment of Parkinson’s disease, Opicapone, is
under review by the European Medicines Agency.
BOEHRINGER INGELHEIM ITALIA
Via Lorenzini, 8
20139 Milan - Italy
Tel. +39.02.5355.1
Fax +39.02.5355.222
[email protected]
www.boehringer-ingelheim.it
COMPANY PROFILES
BIAL
abcd
The Boehringer Ingelheim group is one of the world’s 20 leading
pharmaceutical companies. Headquartered in Ingelheim, Germany, it
operates globally with 146 affiliates and more than 47,700 employees.
The focus of the family-owned company, founded in 1885, is on
researching, developing, manufacturing and marketing new medications
of high therapeutic value for human and veterinary medicine. Social
responsibility, caring for the employees, environmental protection and
sustainability are important elements of the corporate culture. In 2014
company achieved net sales of about 13.3 billion euros. R&D expenditure
corresponds to 19.9% of its net sales.
103
COMPANY PROFILES
Britannia Pharmaceuticals
Longwater Avenue, 200
RG2 6GP Reading - United Kingdom
+44.118.920.9500
[email protected]
www.britannia-pharm.com
Britannia Pharmaceuticals Limited is a UK based pharmaceutical
company specializing in niche innovative products for chronic and serious
medical conditions, and in particular, the treatment of patients with
Parkinson’s disease. The need for apomorphine as a treatment option
for Parkinson’s disease has led to the development of APO-go and other
associated brands around the globe, which are available in many countries
through our Distribution or Licensing Partners.
Canè Medical Technology
Via Cuorgnè, 42/a
10098 Rivoli (TO) - Italy
Tel. +39.011.957.4872
Fax +39. 011.959.8880
[email protected]
www.canespa.it
Canè was founded in 1978 as manufacturer of ambulatory infusion
pumps. Starting from the first syringe-drivers, Canè’s products have
evolved into the CRONO line of miniature pumps which may be worn
without impacting patients’ normal daily routine. Canè’s CRONO series
includes the ambulatory infusion pumps and the dedicated syringes
which are used with them. Depending upon the therapy, the syringes
may have volumes of 10, 20, 30 or 50 ml. All pump R&D and design work
is done in-house, as are final assembly and testing. Canè works with
pharmaceutical companies and other medical device manufacturers to
provide customized solutions where required.
104
Rep.: Rhea Rebello
Richmond Street West, 828
M6J 1C9 Toronto - Canada
Tel. +1.416.703.2449
Fax +1.416.703.8752
[email protected]
www.cynapsus.ca
Cynapsus is a specialty pharmaceutical company that is focused on
the clinical and regulatory development of a sublingual apomorphine
film strip (APL-130277), for the on-demand turning ON of debilitating
OFF episodes associated with Parkinson’s disease (PD). The Company
recently completed a Phase 2 clinical trial for APL-130277. Apomorphine
is the only molecule approved for acute, intermittent treatment of OFF
episodes for advanced PD patients, but is currently only approved as a
subcutaneous injection in the United States, Europe, Japan and other
countries. Cynapsus’ drug candidate, APL-130277, is a sublingual form
of apomorphine that is currently enrolling patients in Phase III clinical
studies (clinicaltrials.gov: NCT02469090 and NCT02542696). Cynapsus
intends to submit a new drug application in 2016.
COMPANY PROFILES
Cynapsus Therapeutics
ELSEVIER
Radarweg, 29
1043 Amsterdam - The Netherlands
Tel. + 44.01865.84.3670
[email protected]
www.elsevier.com
Elsevier is a world-leading provider of information solutions that enhance
the performance of science, health, and technology professionals,
empowering them to make better decisions, deliver better care,
and sometimes make groundbreaking discoveries that advance the
boundaries of knowledge. Elsevier provides web-based, digital solutions
-among them ScienceDirect, Scopus, and Elsevier Research Intelligence.
105
COMPANY PROFILES
Ever Neuro Pharma
Rep.: Marie-Kristin Schoeppl
Oberburgau, 3
4866 Unterach - Austria
Tel. +43.766.520.5550
Fax +43.766.520.555910
offi[email protected]
www.everpharma.com
EVER Neuro Pharma is an Austrian pharmaceutical company focused on
the field of neuroscience. Based on our experience and proprietary R&D
technology platform we develop innovative therapies for neurological
disorders. Among other agents our product portfolio is strengthened with
Dacepton® (apomorphine hydrochloride) for the treatment of disabling motor
symptoms in the advanced stage of Parkinson´s disease. We focus on the
complete Package of Care including Medical Devices for the intermittent and
continuous drug delivery. Recognizing current trends we keep to our endeavor
for further and constant improvement of our patient oriented services.
Global Kinetics Corporation
Rep.: Stefan Asberg
Collins Street
Level 15/440
3000 Melbourne – Australia
Tel. +46.766.316.112
[email protected]
www.globalkineticscorporation.com
Global Kinetics Corporation (GKC) along with the Florey Neuroscience
Institute (Australia) has developed the Parkinson’s KinetiGraph™ (PKG™)
for objective, ambulatory assessment of movement disorder symptoms in
Parkinson’s disease. The PKG™ records a patient’s movement continuously
over 7-10 days and reports correlations of fluctuation severity with respect
to dosage. The PKG™ provides clinicians with an assessment of a patient’s
clinical state which is objective, includes scaled measures of bradykinesia
and dyskinesia with repeat reliability, links fluctuations with the timing of
medication, is comparable over time and allows assessment during the
activities of daily living.
106
Rep.: Francesco Cecchini
Vicolo Nassetta, 2
CH-6900 Lugano - Switzerland
Tel. +41.91.921.3838
Fax +41.91.921.3939
[email protected]
www.gondola-parkinson.com
Gondola Medical Technologies SA specializes in restorative therapies for
neurological conditions. It has developed the proprietary GONDOLA™ medical
device to deliver the AMPS stimulation, an effective treatment for motor
symptoms in intermediate and advanced stages of Parkinson’s disease. AMPS
is a non-invasive, automated, pressure-based stimulation that allows to:
- reduce Freezing of Gait,
- improve walking skills,
- reduce slowness of movement,
- improve balance.
The treatment requires less than 2 minutes, its benefits are perceived
immediately and last 3 to 5 days after use of the device; regular home use
allows to maintain benefits overtime.
COMPANY PROFILES
Gondola Medical Technologies
Medtronic
Rep.: Cathy Persidis
Route du Molliau, 31
1131 Tolochenaz - Switzerland
Tel. +41.21.802.7000
[email protected]
www.medtronic.com
As a global leader in medical technology, services and solutions, Medtronic
improves the health and lives of millions of people each year. We believe our
deep clinical, therapeutic and economic expertise can help address the complex
challenges - such as rising costs, aging populations, and the burden of chronic
disease - faced by families and healthcare systems today. But, we can’t do it alone.
That’s why we’re committed to partnering in new ways and developing powerful
solutions that deliver better patient outcomes. Founded in 1949 as a medical repair
company, we’re now among the world’s largest medical technology, services and
solutions companies, employing more than 85,000 people worldwide, serving
physicians, hospitals and patients in more than 160 countries. Join us in our
commitment to take healthcare Further, Together. Learn more at Medtronic.com.
107
COMPANY PROFILES
Melvin Yahr International Parkinson’s
Diesease Foundation
Rep.: Alessandro Di Rocco
Larkin Dr, 290
10957 Monroe - USA
Tel. +1.718.541.3566
Fax +1877.786.5759
This organization, founded by Melvin D. Yahr M.D., strives to support
excellence in neurologic training, patient care, and scientific
advancement related to Parkinson’s disease and associated motor
disorders. Travel grants are offered to neurology residents, fellows and
junior researchers enabling them to attend and participate in scientific
meetings, thus increasing their understanding of the basic neuroscience
underlying Parkinson’s disease. Applications for such financial aid from
young physicians and scientists from minority groups, underprivileged
communities and developing countries are particularly welcome. The
foundation also provides seed money for the start up of innovative
laboratory and clinical research projects, and for meetings dedicated to
the study of Parkinson’s disease throughout the world.
Mundipharma International
Rep.: Sara Dickerson
Unit 194 Cambridge Science Park
Milton Road
CB4 0AB Cambridge - United Kingdom
Tel. +44(0)1223.424444
[email protected]
www.mundipharma.com
108
The Mundipharma network of independent associated companies
consists of privately owned companies and joint ventures covering the
world’s pharmaceutical markets. The Mundipharma network has a
presence in 51 countries with more than 7,800 employees across the
world. These companies are committed to bringing to patients the
benefits of pioneering treatment options in the core therapy areas of
pain management, oncology, respiratory and inflammatory conditions.
Through innovation, design and acquisition, the Mundipharma network
of independent associated companies delivers important treatments to
meet the most pressing needs of patients, healthcare professionals and
health systems worldwide.
Centro Direzionale Colleoni
Palazzo Andromeda, 20/3
20864 Agrate Brianza (MB) - Italy
+39039607471
[email protected]
www.sjm.com
What if a company could invent breakthrough technologies that transform
the treatment of some of the world’s most expensive epidemic diseases?
At St. Jude Medical we are turning what if into why not by partnering
with physicians, hospitals and insurers to save and improve millions
of lives worldwide – while reducing health care costs for all. St. Jude
Medical is committed to meeting or exceeding the high quality and safety
expectations of our patients, customers and regulators. Headquartered
in St. Paul, USA, St. Jude Medical is focused on six key treatment areas:
Heart Failure, Arrhythmias, Vascular Disease, Structural Heart, Chronic
Pain, Neurological Diseases.
COMPANY PROFILES
St. Jude Medical
US WorldMeds
Ste L07
4010 Dupont Circle
40207 Louisville - USA
Tel. +1.866.750.8796
Fax +1. 502.815.8001
[email protected]
www.usworldmeds.com
At US WorldMeds, we hold a fundamental belief that our science has the
potential to improve the lives of Parkinson’s patients. US WorldMeds’
commitment to Parkinson’s patients is reflected in all that we do. Our
pipeline of development projects, along with our currently available PD
treatment, reflects our resolve to bring innovative solutions to Parkinson’s
patients. US WorldMeds is proud to be a Sponsor at the XXI World
Congress on Parkinson’s disease and Related Disorders. US WorldMeds
is committed to supporting patients and care partners to increase
Parkinson’s disease awareness and help improve the quality of care.
109
COMPANY PROFILES
Wisepress Medical Bookshop
High Path, 25
SW19 2JL London - United Kingdom
Tel. +44.208.715.1812
[email protected]
www.wisepress.com
Wisepress.com, Europe’s leading conference bookseller, has a range of
books and journals relevant to the themes of the meeting. In addition
to attending 200 conferences per year, Wisepress has a comprehensive
medical and scientific bookshop online with great offers. Follow us on
Twitter for the latest news @WisepressBooks.
ZAMBON
Rep.: Maria Grazia Papini
Via Lillo del Duca, 10
20091 Bresso
Tel. +39.02.66524.1
[email protected]
www.zambonpharma.com
Zambon is a leading Italian family company that has operated for 109
years in the chemical and pharmaceutical industries. The company is
well-established in 3 therapeutic areas: respiratory, pain and woman
care. Zambon is also focusing on strengthening the respiratory area
with the treatment of severe diseases such as chronic obstructive
pulmonary disease (COPD) and cystic fibrosis (CF), with the acquisition of
Pharma Profile from Philips. Zambon is carrying on the 132 million Euro
investments plan for the years 2013 – 2017 in supporting research and
development. The Group entered into a new important therapeutic area,
the Central Nervous System (CNS), with the molecule Safinamide for the
treatment of Parkinson’s disease. The Respiratory Business and CNS
are the two main drivers of the development strategy of the company.
Zambon, headquartered in Milan, is present in 84 countries with more
than 2,600 employees and 19 operating subsidiaries.
110
...........................................................................................................................................................................
NOTES
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
111
NOTES
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
...........................................................................................................................................................................
112
...........................................................................................................................................................................
XXII World Congress on
Parkinson’s Disease
and Related Disorders
Ho Chi Minh City, Vietnam
12-15 November 2017
Organizing Secretariat
Viale Matteotti, 7
50121 Florence, Italy
Tel. +39 055 50351
[email protected]

XXI World Congress on Parkinson`s Disease and Related Disorders

Transcription

Similar documents

Malattia di Parkinson

Malattia di Pompe Inquadramento clinico

scarica pdf qui

Modelli animali_4_13_C File

Attività Motoria - Università degli Studi di Ferrara

n°2, 2014 - Jaka Congressi Srl

Genetica 7 - Università degli Studi di Verona

Presentazione di PowerPoint

Programma - Società italiana di neurologia

50° Congresso Nazionale della Società Italiana di Reumatologia

Diapositiva 1 - Terapia Intensiva dell`età Pediatrica (0

SCHEDA INFOR Inglese 2016

Évaluation de la conscience aux soins intensifs